Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 1 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
CLINICAL PROTOCOL  
Protocol No.  MRX 4-201 
Title:  A Phase 2, Multicenter, Randomized, Double -Blind Study to Evaluate 
the Safety and Efficacy of Contezolid Acefosamil Compared to 
Linezolid  Administered Intravenously and Orally to Adult s with 
Acute Bacterial Skin and Skin Structure Infection  
Study Phase:  2 
Product Name:  Contezolid acefosamil  
Indication:  Treatment of patients with acute bacterial skin and skin structure 
infection (ABSSSI)  
Investigators:  Multicenter Study  
Sponsor:  MicuRx Pharmaceuticals, Inc.  
3916 Trust Way Hayward , CA 94545 
Phone: 1- 510-782-2021  
Sponsor Contact : Edward Fang, MD  
SVP, Clinical Development  
MicuRx Pharmaceuticals, Inc  
Phone: 415- 710-5481 
Email: efang@micurx.com  
Current Version  Amendment 2 
Date  Final , 19 October  2018  
Prior Versions:  Original : 16 August 2018  
Amendment 1: 27 September 2018  
 
 
CONFIDENTIAL  
This document contains proprietary and confidential information of MicuRx Pharmaceuticals, Inc. Acceptance of 
this document constitutes agreement by the recipient that no previously unpublished information contained herein 
will be published or disclosed without the prior written approval of MicuRx Pharmaceuticals, Inc. with the 
exception that th is document may be disclosed to study personnel under your supervision who need to know the 
contents for conducting the study and to appropriate Institutional Review Boards (IRBs) under the condition that 
the personnel have agreed to keep this information confidential. The foregoing shall not apply to disclosure required 
by governmental regulations or laws; however, MicuRx Pharmaceuticals, Inc. shall be promptly notified of any 
such disclosure.  
  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 2 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
PROTOCOL APPROVAL PAGE 
Protocol No.  MRX 4-201 
Title:  A Phase 2, Multicenter, Randomized, Double -Blind Study to 
Evaluate the Safety and Efficac y of Contezolid Acefosamil 
Compared to Linezolid Administered Intravenously and Orally to 
Adult Subject s With Acute Bacterial Skin and Skin Structure 
Infection  
Version  Amendment 2  
Date:  Final, 19 October 2018  
 
 
Personnel Approving Protocol Signature 
Edward Fang, MD 
SVP, Clinical Development MicuRx Pharmaceuticals , Inc.   
Barry Hafkin, MD EVP, Chief Medical Officer  
MicuRx Pharmaceuticals , Inc.   
 

Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 3 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
INVESTIGATOR AGREEMENT PAGE  
Protocol No.  MRX 4-201 
Title:  A Phase 2, Multicenter, Randomized, Double -Blind Study to 
Evaluate the Safety and Efficacy of Contezolid Acefosamil 
Compared to Linezolid Administered Intravenously and Orally to 
Adult Subject s With  Acute Bacterial Skin and Skin Structure 
Infection  
Version:  Amendment 2 
Date:  Final, 19 October 2018  
I have read and I understand protocol MRX 4-201 and the Investigator’s Brochure. I agree to the 
following:  
1. To conduct the clinical study in compliance with Good Clinical Practice (GCP) and with 
all applicable regulatory requirement(s), according to the latest version of the protocol 
agreed to by the Sponsor and given approval/favorable opinion by the IRB  
2. To comply with procedures for data recording/repor ting 
3. To permit monitoring, auditing, and inspection by the Sponsor, its designated 
representatives, and regulatory authorities  
4. To retain the essential documents in the Investigator/institution files until the Sponsor 
informs me or the institution that thes e documents are no longer needed  
5. To provide copies of the protocol, any subsequent protocol amendments , and all 
information provided by the Sponsor to the study personnel under my supervision. I will 
discuss these materials with them in the detail required  to ensure that they are fully 
informed about the investigational drug and the study protocol as appropriate for their 
study -related responsibilities.  
   
Investigator Signature   Date  
  
 
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 4 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
  TABLE OF CONTENTS  
CLINICAL PROTOCOL  ..................................................................................................1  
PROTOCOL APPROVAL PA GE ...................................................................................2  
INVESTIGATOR AGREEME NT PAGE  .......................................................................3  
TABLE OF CONTENTS  ..................................................................................................4  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................8  
List of Abbreviations  .........................................................................................................8  
Definitions of Terms  ........................................................................................................10  
1 STUDY SYNOPSIS  ..................................................................................................11  
2 INTRODUCTION ....................................................................................................25  
2.1 Background  ..........................................................................................................25  
2.2 Descriptio n of Contezolid and Contezolid Acefosamil  .....................................26  
2.3 Summary of Relevant Nonclinical Experience ..................................................27  
2.3.1  Pharmacology, Microbiology, Toxicology, and Safety ...............................27  
2.4 Summary of Relevant Clinical Experience ........................................................28  
2.5 Safety and Tolerability of Contezolid Acefosamil .............................................29  
2.6 Pharmacokinetics of Contezolid Acefosamil  .....................................................30  
2.7 Summary and Rationale for Study  .....................................................................31  
2.8 Rationale for Dose Regimens  ..............................................................................33  
3 STUDY DESIGN ......................................................................................................34  
3.1 Study Objectives ...................................................................................................34  
3.2 Study Design Details  ............................................................................................35  
3.3 Number of Subjects ..............................................................................................37  
3.4 Randomization & Blinding  .................................................................................37  
3.5 Study Treatment  ..................................................................................................38  
3.6 Duration  ................................................................................................................39  
4 SELECTION AND WITHDRAWAL OF SUBJECTS  .........................................40  
4.1 Inclusion Criteria  .................................................................................................40  
4.2 Exclusion Criteria  ................................................................................................41  
4.3 Subject Withdrawal from the Study  ..................................................................44  
4.4 Replacement of Subjects ......................................................................................45  
4.5 Study Termination by Sponsor and Termination Criteria  ..............................45  
4.6 Follow -up of Subjects Prematurely Discontinued from Study Drug or 
Withdrawn from Study  .......................................................................................45  
5 TREATMENT OF SUBJECTS  ...............................................................................46  
5.1 Study Drug  ............................................................................................................46  
5.1.1  Contezolid Acefosamil Study Drug  ..............................................................46  
5.1.2  Linezolid Study Drug  .....................................................................................46  
5.1.3  Adjunctive Therapy  .......................................................................................47  
5.1.4  Dose Adjustment  ............................................................................................47  
5.1.5  Study Drug Compliance  ................................................................................47  
5.1.6  Study Drug Storage ........................................................................................48  
5.1.7  Study Drug Accountability ............................................................................49  
5.1.8  Study Drug Handling and Disposal  ..............................................................49  
5.2 Prior & Concomitant Therapy  ...........................................................................49  
6 SUBJECT RESTRICTIONS  ...................................................................................51  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 5 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
7 STUDY PROCEDURES  ..........................................................................................53  
7.1 Screen ing/Baseline  ...............................................................................................53  
7.2 Day 1 ......................................................................................................................55  
7.3 Day 2 ......................................................................................................................56  
7.4 Early Assessment  .................................................................................................56  
7.5 Early Assessment to Day 6 ..................................................................................57  
7.6 Day 7 ......................................................................................................................58  
7.7 End of Therapy  ....................................................................................................59  
7.8 Post T herapy Evaluation  .....................................................................................60  
7.9 Late Follow -up .....................................................................................................61  
8 ASSESSMENT OF THE AC UTE BACTERIAL SKIN AND SKIN 
STRUCTURE INFECTION ....................................................................................62  
8.1 Clinical Assessments  ............................................................................................62  
8.2 Microbiological Assessments ...............................................................................62  
8.3 Digital Photography  .............................................................................................64  
9 ASSESSMENT OF EFFICACY  ..............................................................................65  
9.1 Clinical Response Definitions ..............................................................................65  
9.1.1  Early Clinical Response  .................................................................................65  
9.1.2  Investigator’s Assessment of Clinical Response  ..........................................65  
9.2 Microbiological Response Definitions  ................................................................67  
9.2.1  Per-Pathogen Microbiological Response  .....................................................67  
9.2.2  Per-Subject Microbiological Response ........................................................67  
9.2.3  Emergent Infections  .......................................................................................67  
10 ASSESSMENT OF SAFETY ...................................................................................69  
10.1  Adverse Events  .....................................................................................................70  
10.1.1  Definition  ........................................................................................................70  
10.1.2  Assessment of Severity  ...................................................................................70  
10.1.3  Relationship to Study Drug  ...........................................................................71  
10.1.4  Serious Adverse Events  .................................................................................72  
10.1.5  Treatment -emergent Adverse Event  ............................................................74  
10.1.6  Life-threatening Adverse Event ....................................................................74  
10.1.7  Unexpected Adverse Event ............................................................................74  
10.2  Reporting Laboratory and Electrocardiogram Abnormalities  .......................75  
10.3  Risks for Women of Childbearing Potential  .....................................................75  
10.4  Adverse Event Follow -up ....................................................................................76  
10.5  Study Termination or Temporary Suspension ..................................................76  
10.6  Data Monitoring Committee  ...............................................................................77  
11 ASSESSMENT OF PHARMACOKINETICS  .......................................................78  
12 STATISTICAL METHODS  ....................................................................................80  
12.1  Determination of Study Sample Size  ..................................................................80  
12.2  Analysis Populations  ............................................................................................80  
12.3  Determination of Inclusion in Populations  ........................................................82  
12.4  Analysis of Study Populations and Subject Characteristics  ............................83  
12.5  Study Drug Exposure  ..........................................................................................83  
12.6  Efficacy Analyses  .................................................................................................83  
12.6.1  Primary Efficacy Evaluation  ........................................................................84  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 6 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
12.6.2  Secondary and Additional Efficacy Evaluations  .........................................85  
12.7  Safety Analyses  .....................................................................................................87  
12.8  Pharmacokinetic Analyses  ..................................................................................87  
12.9  Handling of Dropouts, Missing, Unused and Spurious Data  ...........................87  
13 ADMINISTRATIVE CONSI DERATIONS  ...........................................................88  
13.1  Ethical Conduct of Study  ....................................................................................88  
13.2  Informed Consent  ................................................................................................88  
13.3  Institutional Review Board Approval  ................................................................88  
13.4  Investigator Requirements  ..................................................................................88  
13.5  Electronic Case Report Forms and Data Capture System  ...............................89  
13.6  Source Data & Document Maintenance ............................................................89  
13.7  Study Monitoring Requirements  ........................................................................90  
13.8  Study Completion.................................................................................................90  
13.9  Quality Control and Quality Assurance  ............................................................90  
13.10  Retention of Records ............................................................................................91  
13.11  Finance and Insurance  ........................................................................................91  
13.12  Publication Policy .................................................................................................92  
14 REFERENCES  .........................................................................................................93  
APPENDIX 1.  ALLOWED PRIOR ANTIBI OTICS  ...............................................96  
APPENDIX 2.  AVOIDANCE OF HIGH -TYRAMINE FOODS AND DRI NKS  ..98 
APPENDIX 3.  RESTRICTED MEDICATIO NS .....................................................99  
APPENDIX 4.  SAFETY LABORATORY TE STS .................................................100  
APPENDIX 5.  INSTRUCTIONS FOR PRI MARY ABSSSI SITE 
MEASUREMENT  ..................................................................................................101  
APPENDIX 6.  LOCAL SIGNS AND SYMP TOMS OF ABSSSI  .........................103  
APPENDIX 7.  RECOMMENDED INSTRUCT IONS FOR PRIMA RY ABSSSI 
SITE DIGITAL PHOTOGR APHY  ......................................................................104  
 
LIST OF TABLES  
Table 1:  Schedule of Events  ...................................................................................22  
Table 2:  Clinical Response Definitions – Early Clinical Response  .....................65  
Table 3:  Clinical Response Definitions – Investigator’s Assessment  .................66  
Table 4:  Microbiological Outcome Categories  .....................................................67  
Table 5:  Emergent Infections  .................................................................................68  
Table 6:  Guidelines for Severity Assessments  ......................................................71  
Table 7:  Analysis Populations  ................................................................................80  
Table 8:  Summary of Primary and Secondary Efficacy Evaluations  by Analysis 
Population  .................................................................................................84  
Table 9:  Composite Assessment of Clinical Outcome  ..........................................86  
Table 10:  Allowed and Disallowed Prior Antibiotics in Study MRX4 -201 .........96  
Table 11:  Foods and Beverages to Avoida During Study Drug Administrationb 98 
 
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 7 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
LIST OF FIGURES  
Figure 1:  Contezolid Acefosamil Metabolites  ........................................................27  
Figure 2:  Overview of Analysis Populations  ..........................................................82  
Figure 3:  Primary ABSSSI Site Measurement – Example  .................................101  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 8 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
LIST OF ABBREVIATIONS  AND DEFINITIONS OF TERMS  
List of Abbreviations  
Abbreviation  Definition  
ABSSSI  Acute bacterial skin and skin structure infection  
AE Adverse event  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
AUC 0-t/0-12h/0-24h/0-∞  Area under the curve vs. time from time zero to last timepoint (e.g., 12 h, 24 h, infinity)  
BCS  Biopharmaceutics classification system  
β-HCG  Beta-human chorionic gonadotropin  
BID Twice daily  
CACO  Composite assessment of clinical outcome  
CE Clinically evaluable  
CI Confidence interval  
Cmax Maximum concentration  
CNS  Central nervous system  
CrCl  Creatinine clearance  
CRO  Clinical Research Organization  
CRP  C-reactive protein  
CTCAE  Common Terminology for Adverse Events  
D5W 5% dextrose in water  
DEHP  diethylhexyl phthalate  
DMC  Data Monitoring Committee  
ECG  Electrocardiogram  
eCRF  Electronic case report form 
FDA  Food and Drug Administration 
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus  
ICF Informed consent form  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 9 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Abbreviation  Definition  
ICH International Council for Harmonisation  
IM Intramuscular  
IRB Institutional Review Board  
ITT Intent -to-treat 
IV Intravenous  
IWRS  Interactive web response system  
MAOI  Monoamine oxidase inhibitor  
MDR  Multidrug -resistant  
ME Microbiologically evaluable  
MITT  Modified  intent -to-treat 
micro -ITT Microbiological intent -to-treat 
MRSA  Methicillin -resistant Staphylococcus aureus  
MSSA  Methicillin -sensitive Staphylococcus aureus  
NCI National Cancer Institute  
NOAEL  No observed adverse effect level  
NS Normal saline  
PD Pharmacodynamic  
PK Pharmacokinetic  
PO Oral  
PT Preferred term 
QC Quality control  
QD Once daily  
QTc Corrected QT interval  
QTcF  Corrected QT interval using the Fridericia correction formula  
SAE  Serious adverse event  
SAER  Serious adverse event report  
SAP Statistical analysis plan  
SAR  Suspected adverse reaction  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 10 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Abbreviation  Definition  
SOC  System Organ Class  
SSRI  Selective serotonin reuptake inhibitor  
TEAE  Treatment -emergent adverse event  
Tmax Time to maximum concentration  
UA Urinalysis  
ULN  Upper limit of normal  
US United States  
UV Ultraviolet  
VRE  Vancomycin -resistant  enterococci  
WBC  White blood cell count 
 
Definitions of Terms  
Term  Definition  
CACO  Combined outcome of early response at EA and Investigator’s assessment of clinical 
outcome at PTE  
Contezolid  The active metabolite of contezolid acefosamil moiety ( formerly  known as MRX -1) 
Contezolid acefosamil  The investigational medicinal product in this study  (formerly known as MRX -4); a 
prodrug that undergoes a 2- step conversion process to contezolid  (active moiety) by 
means of MRX -1352 (an intermediate metabolite)  
EA Early assessment (48 to 72 hours after the start of the first dose of IV study drug)  
EOT  End of therapy (last day of study drug)  
LFU  Late follow -up (21- 28 days after EOT)  
MRX -1320  A primary metabolite of contezolid; MRX -1320 is also known as “M2” in other 
documents  
MRX -1352  Intermediate metabolite in the 2 -step process by which prodrug (contezolid acefosamil) 
is converted into contezolid (active moiety)  
PTE Post therapy evaluation (7 to 14 days after EOT)  
Subject  An individual who participates in a clinical trial, either as a recipient of the 
investigational product(s) or as a control 
 
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 11 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
1 STUDY SYNOPSIS  
Sponsor:  MicuRx Pharmaceuticals, Inc.  Protocol Number:  MRX4 -201 
Study Drug:  Contezolid acefosamil for intravenous (IV) and oral (PO) administration  
Title:  A Phase 2, Multicenter, Randomized, Double -Blind Study to Evaluate the Safety and Efficacy of 
Contezolid Acefosamil  Compared to Linezolid Administered Intravenously and Orally to Adult s with 
Acute Bacterial Skin and Skin Structure Infection  
Phase of Development : 2 
Study Site:  Approximately 5 to 10 sites in the United States (US)  
Indication:  Acute bacterial skin and skin structure infection (ABSSSI)  
Rationale:  There is an unmet need for additional antibiotic  choices to treat Gram -positive bacterial 
infections caused by organisms such as methicillin -resistant Staphylococcus  aureus  (MRSA)  and 
vancomycin -resistant enterococci (VRE).  
Contezolid acefosamil  (previous ly referred to as MRX -4), a sodium salt of a contezolid (previously 
referred to as MRX -1) prodrug, is a synthetic antibiotic in the oxazolidinone class of antimicrobials. 
Due to the low solubility of contezolid and inability to produce a practical IV formulation using 
contezolid, an orally bioavailable and water soluble new molecular entity ( contezolid acefosamil ) was 
developed, a full battery of preclinical studies was performed , and a successful P hase 1 program was 
completed . 
Contezolid is a novel oxazolidinone with potent in  vitro activity against aerobic and anaerobic 
Gram -positive pathogens , with demonstration of clinical efficacy in ABSSSI in 2 previous Phase  2 
studies. Contezolid acefosamil , which rapidly converts to contezolid, is e xpected to offer similar or 
more consistent (i.e., improved) pharmacokinetic (PK) properties  than other drugs in its class . 
Contezolid acefosamil  will be available in  both IV  and PO formulations . Therefore, contezolid 
acefosamil  may provide an attractive option to overcome the safety and tolerability challenges with 
current antibiotic choices in both the hospital and community settings. 
Both contezolid and contezolid acefosamil  have proven to be highly efficacious in various mode ls of 
animal infections caused by Gram -positive bacteria, including drug- resistant strains of S. aureus, 
Streptococcus pneumoniae , and enterococci. The animal models used for evaluation included murine 
sepsis and thigh infection.  
This study is designed to evaluate the safety and efficacy of IV and PO administered contezolid 
acefosamil  compared to linezolid  in adults with ABSSSI . The primary efficacy endpoint of clinical 
response at early assessment aligns with the current F ood and Drug Administration Guidance for 
Industry, ABSSSI: Developing Drugs for Treatment ( FDA, October  2013 ). 
Study Objectives:  
Primary : 
• Evaluate early clinical response of contezolid acefosamil compared to linezolid at early assessment 
(EA; 48 to 72 hours after the start of the first dose of IV study drug)  in the intent -to-treat (ITT) 
population  
• Evaluate safety and tolerability of both contezolid acefosamil IV and PO formulations compared 
with linezolid  
Secondary : 
• Evaluate early clinical response at:  
- EA in the modified intent -to-treat ( MITT ) population  
- EA (overall and by baseline pathogen) in the microbiological intent -to-treat (micro -ITT) 
population  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 12 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
• Evaluate percent reduction in lesion size from baseline in ABSSSI lesions at Day 7 in the ITT and 
MITT popula tions  
• Evaluate the Investigator’s assessment of clinical response in the ITT, MITT, and clinically 
evaluable (CE) populations at each timepoint:  
- End of therapy (EOT; last day of study drug) in the ITT, MITT, and CE -EOT populations  
- Post therapy evaluation ( PTE; 7 to 14 days after EOT) in the ITT, MITT, and CE -PTE 
populations  
- Late follow -up (LFU; 21- 28 days after EOT) in the ITT, MITT, and CE -PTE populations  
• Evaluate per -subject microbiological response at:  
- PTE in the micro -ITT population  
- PTE in ME population  
• Evaluate per -pathogen microbiological response at:  
- PTE in the micro -ITT population  
- PTE in the ME population  
• Evaluate Investigator’s assessment of clinical response in the micro -ITT and ME populations at:  
- PTE (overall and by baseline pathogen)  
- LFU (overall  and by baseline pathogen)  
• Characterize the  PK of 3 contezolid acefosamil metabolites (MRX -1352, contezolid, and 
MRX -1320) using sparse PK sampling in adult subjects with ABSSSI  
• Evaluate composite assessment of clinical outcome (CACO) in the ITT, micro -ITT, and CE -PTE 
populations  
Study Design:  
This is a Phase 2, multicenter, randomized, double -blind safety and efficacy study of contezolid 
acefosamil 1500 IV x 1 dose , followed by 1000 mg IV every 12 hours (q12h) (±  2 hours) , for at least 
3 total IV  doses , followed by 1300 mg  PO q12h (±  2 hours) compared with linezolid 600 mg IV q12h 
(± 2 hours) , for at least 3 total IV doses,  followed by 600 mg PO q12h (±  2 hours) in adult subjects with 
ABSSSI . Subjects will receive study drug for a total of 10 to 1 4 days . 
Up to 200 subjects will be enrolled to achieve approximately 150 clinically evaluable subjects in the 
CE-PTE population with ABSSSI from approximately 5 to 10 sites in the US . Randomization will have 
a 2:1 ( contezolid acefosamil : linezolid)  allocation ratio ; therefore, up to 133 subjects will be randomized 
to receive contezolid acefosamil  and up to 67 subjects will be randomized to receive linezolid. Efforts 
will be made to enroll a mixture of ABSSSI types (cellulitis/erysipelas, wound infection, and major 
cutaneous abscess); however, subject s with major cutaneous abscess should not comprise >  30% of 
randomized subjects . Subject s will be randomized to treatment provided they meet all inclusion and no 
exclusion criteria. Randomization will be stratified by ABSSSI type to better ensure proper balance  
between the treatment groups.  
Screening/baseline  assessments for study eligibility will be performed  within 24 -hours prior  to the start 
of the first dose of study drug. Subject s who provide informed consent , are willing and able to 
collaborate and cooperate with study  protocol requirements  and meet all study eligibility criteria will  be 
enrolled and randomized in the study.  
Gram stain and culture specimens of the  ABSSSI site must be collected from all subject s for 
microbiologic evaluation at screening/baseline. ABSSSI site specimens (purulent discharge, skin 
biopsy, or aspiration at the leading edge of the cellulitic area) in addition to blood cultures from 
2 separate venipuncture sites, will be obtained from all subject s prior to administration of antibacteria l 
therapy whenever possible. All ABSSSI site specimens will be processed for Gram stain and culture at 
the local laboratory, and all blood cultures will be processed at the local laboratory. All bacterial isolates 
that are identified from an ABSSSI site sp ecimen or blood culture at the local facilities collaborating 
laboratory will be sent to a designated central laboratory for confirmation of species identification and 
antimicrobial susceptibility testing. Microbiological methods will be detailed in the La boratory Manual.  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 13 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Subjects may receive adjunctive antimicrobial therapy with parenteral aztreonam (1 to 2 g IV/ 
intramuscular [IM] q8h, not to exceed 6 g/day) if the Investigator suspects or has confirmed the 
presence of aerobic Gram -negative pathogens, wh ich, in addition to Gram -positive aerobic bacteria, are 
also associated with the pathogenic process.  
Subjects  with only Gram -negative pathogens are not eligible for  continued  treatment under this protocol 
and will be discontinued from study  drug as soon as  Gram stain and culture confirm s that the subject ’s 
infection has no Gram -positive  pathogen contributing to the subject ’s disease. If no Gram -negative  
pathogens  are isolated from the screening/baseline cultures by  Day  3, aztreonam will be discontinued. 
Subject s with suspected infections primarily due to anaerobic organisms as the cause for ABSSSI or 
subject s requiring empiric adjunctive anaerobic antimicrobial coverage are  excluded from  treatment 
under this protocol . 
Prompt enrollment procedures are encouraged to allow for prompt administration of study drug. 
Subject s who received prior systemic antibacterial therapy with Gram -positive activity within 96  hours 
prior to randomization will be excluded from the study unless clear clinical evidence of prior treatment 
failure within the prior 96 hours is available. However, one exception to this criterion is the receipt of a 
single dose of a short -acting, non -oxazolidinone antibiotic (as provided in the study exclusion criteria 
and list of allowable antibiotics). Subject s who received a single dose of a short -acting non-
oxazolidinone Gram -positive  active antibiotic within 96  hours prior to randomization will not  comprise 
> 25% of randomized subjects . 
Randomized subject s will receive at least 3 doses  of treatment with IV study drug followed by PO 
dosing, however subject s may receive the IV formulation for the entire treatment duration . Study 
treatment will be as follows:  
• Subject s randomized to contezolid acefosamil  treatment will receive IV infusion s of contezolid 
acefosamil  q12h (±  2 hours) for a minimum of 3 infusions  followed by 2 PO contezolid 
acefosamil capsules q12h (±  2 hours)  for a total of 10  to 14 days of treatment . The IV dose of 
contezolid acefosamil  will be 1500 mg infused over 60 minutes (±  5 minutes) for 1 dose 
followed by  1000 mg infused over 60 minutes (±  5 min utes); the PO dose of contezolid 
acefosamil will be 13 00 mg  (2 capsules each with 650 mg of contezolid acefosamil) . 
• Subject s randomized to linezolid treatment will receive  IV infusions of linezolid q12h 
(± 2 hours)  for a minimum of 3 infusions  followed by 2 PO linezolid  capsules q12h (±  2 hours)  
for a total of 10 to 14 days of treatment . The IV dose of linezolid will be 600 mg infused over 
60 minutes (±  5 minutes); the PO dose of linezolid will be 600  mg (2 capsules each with 
300 mg of linezolid) . 
It is expected that most subject s will remain in the hospital or clinic while receiving IV treatment with 
study drug for a minimum of 3 total IV doses ; however , subject s who are clinically stable and have 
adequate home support with reliable transportation to/from the hospital or clinic may leave and return to 
the hospital or clinic for IV infusions . Study drug IV infusions are not  to be administered at home . 
Subjects may  receive the IV formulation for the entire treatment duration. If the primary ABSSSI lesion 
has not increased in area from the screening/baseline assessment and the Investigator determines that 
the subject has sufficient PO intake of food and drink to safe ly support the administration of PO doses 
of antibiotics, the subject may be switched to the PO formulation. Subject s who are switched from the 
IV to the PO formulation must remain in the hospital or clinic for observation for at least 90 minutes 
after the first PO dose  and demonstrate  good tolera bility with  the initial dose of PO treatment . Subject s 
will undergo follow -up visits as described in Table 1 in an outpatient setting to assess the safety, 
tolerability , and efficacy of the investigational products . 
Day 1 is the first day of study drug administration; su bsequent study days are consecutive calendar day s. 
For purposes of analysis, EA will be performed 48 to 72 hours after the start of  the first dose of IV study 
drug, EOT will occur on the last calendar day of study drug  (+ 1 day) , PTE will occur 7 to 14 days after 
EOT , and LFU will occur 21 to 28 days after EOT .  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 14 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
The overall study design is as follows (see Table 1) : 
Screening/  
Baseline  Study Treatment Period  (Day 1 to EOT)  PTE  LFU  
Within 
24 hours 
prior to first 
dose Day 1 EA  
(48-72 
hours ) Day 7  
(± 1 day) EOT  
(+ 1 day ) 7-14 days 
after EOT  21-28 days 
after EOT  
Confirm 
eligibility ; 
Baseline 
clinical, 
laboratory, 
and safety 
assessments  Randomize 
to treatment  
First dose of 
study drug  
Safety 
assessments  
PK sample s 
(Days 1 -2)a Clinical, 
laboratory, 
and safety 
assessments  
 Clinical, 
laboratory, 
and safety 
assessments  Last dose of 
study drug  
Clinical, 
laboratory, 
and safety 
assessments  
PK samplesa Clinical, 
laboratory, 
and safety 
assessments  Investigator’s 
assessment of  
clinical 
relapse/fai lure 
and AE 
assessment  
EA = early assessment; EOT  = end of therapy; IV  = intravenous; LFU  = late follow -up; 
PK = pharmacokinetic; PTE = post therapy evaluation 
a PK sampling will be sparse . Samples will be collected after the first IV dose  and prior to and after the third 
IV dose (i.e. on Day 1 and Day 2) and at completion of therapy  (IV or PO), as described in the 
Pharmacokinetic Assessments section  (Section 11). 
 
 
Subject s must be evaluated directly by the Investigator (i.e., return to clinic for required assessments if 
being managed in the outpatient setting) from screening/baseline through  PTE. If  the subject  has 
improved to the point that they have returned to their usual premorbid activity (work/school) , and if the 
primary ABSSSI site has little or no pain, swelling, redness , or purulent/seropurulent  drainage at the 
PTE visit, the n the  LFU visit, designed to provide an assessment of durability of response , may be 
performed over the telephone.  
In addition, documentation of the primary ABSSSI lesion by digital photography will occur at 
screening /baseline , EA, Day 7, and EOT. All subject s will have their primary ABSSSI site evaluated by 
the Investigator, including primary ABSSSI site measurements, as  described below. 
When conducting a clinical examination of the primary ABSSSI site, the Investigator will perform and 
record the following:  
• Extent of the infection (area in cm2) as measured by the area of redness, edema, or induration using 
manual measurement of the longest length multiplied by the greatest perpendicular width, with a 
ruler provided by the Sponsor. Note that only measurement of the longest length and the greatest 
perpendicular width (and not calculation of area in cm2) will be collected and the area in cm2 will be 
calculated by the eCRF. Instructions for primary ABSSSI measurements are provided in  
Appendix 5.  
• Local signs and symptoms of erythema (and any distant extension of erythema), swelling/edema, 
localized warmth, tenderness on palpation, drainage, fluctuance, and induration, as described in 
Appendix 6.  
In addition, record the following information at screening /baseline  only : 
• Primary a natomical site  
• Predisposing cause of infection , if any (e.g., trauma, arthropod bite, fungal dermatosis, surgery, 
spontaneous, etc.)  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 15 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Efficacy  assessments will include (see Section 9.1  for additional information) : 
• Early clinical response assessment based on the eCRF data at EA  where successful response ( i.e., 
"responder") is d efined as a reduction in primary ABSSSI lesion size ≥  20% compared to baseline, 
and the subject  did not receive a non- protocol specified systemic antibacterial agent with activity 
against Gram -positive organisms for the treatment of ABSSSI , and did not die of any cause up to 
EA. 
• Investigator ’s assessment of clinical response at  EOT  and PTE : Clinical success at EOT and PTE  is 
defined as resolution or near resolution of most baseline ABSSSI signs and symptoms , did not have 
any surgical procedure to treat the infection  after 72 hours post -baseline that was not planned at 
baseline, no new signs, symptoms, or complications attributable to the ABSSSI, did not receive a 
non-protocol specified systemic antibacterial therapy with activity again st Gram -positive organisms 
for the treatment of ABSSSI , and did not die of any cause up to EOT or PTE . 
• Investigator’s assessment of sustained clinical success and clinical relapse /failure  at LFU. Sustained 
clinical success is defined as no new signs or sym ptoms of primary ABSSSI after PTE. Clinical 
relapse /failure  is defined as new or worsened signs or symptoms of primary ABSSSI after PTE . 
Subject s who discontinue study drug  or withdraw from the study itself will undergo all EOT 
assessments on the day of study drug discontinuation or study withdrawal ( + 1 day). Subjects who 
discontinue study drug will remain in the study and complete all assessments specified for the PTE and 
LFU visits. For s ubject s who withdraw from the study , efforts will be made to perf orm follow -up safety 
assessments per study schedule.  The duration of treatment  within the s pecified window  will be 
determined by the Investigator based on the subject ’s clinical status (e.g., therapy can be discontinued if 
the subject  has improved, no more antibiotic treatment is medically necessary, and the risk of relapse is 
minimal ). 
Estimated Study Duration:  
Subjects  will receive study drug f or 10 to 14 days . Subjects will then be followed for up to 28 days after 
the last calendar day of study drug . Therefore, t he total duration of each subject ’s participation in the 
study will be up to 42 days, excluding the screening /baseline  visit that occurs within 24  hours prior to 
study drug administration on Day  1. 
Number of Subjects : 
Up to 200 (133 contezolid acefosamil :  67 linezolid ) adult subject s with ABSSSI will be enrolled in this 
study. Randomization will have a 2:1 (contezolid acefosamil  : linezolid ) allocation ratio with 
stratification for ABSSSI type.  
Study Drug, Dosage, and Route of Administration:  
The active study drugs are contezolid acefosamil  (IV and PO ) and linezolid (IV and PO ), which  will be 
administered for a total of 10 to 14 days. 
All subjects will start with IV therapy, with either contezolid acefosamil  1500 mg IV x 1 dose followed 
by 1000 mg  IV q12h (±  2 hours)  or linezolid 600 mg IV q12h (±  2 hours) , and all subjects  will receive 
at least 3 total doses of IV study drug . 
Subjects may receive the IV formulations for the entire treatment duration or be switched  to the PO 
formulations (after receiving at least 3 IV doses) to complete 10 to 14 days of treatment if the primary 
ABSSSI lesion has not increased in area from the screening/baseline assessment and the Investigator 
determines that the  subject ha s sufficient PO intake of food and drink to safely support the 
administration of PO doses of antibiotics.  
For subjects who switch from IV to PO treatment, 2 contezolid acefosamil  capsules  (each capsule 
containing 650 mg of contezolid acefosamil for a total of  1300 mg ) or 2 linezolid capsules (each capsule 
containing 300 mg of linezolid for a total of 600 mg) will be administered PO q12h [±  2 hours])  to 
complete  a total of 10 to 14 days  of treatment . The capsules containing contezolid acefosamil  tablets 
and capsules containing linezolid powder will have  approximate ly the same external appearance.  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 16 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Eligibility Criteria:  
Inclusion Criteria:  
1. Males or females ≥  18 years 
2. Willing and able to provide written informed consent  
3. ABSSSI that is confirmed or suspected to be caused by a Gram -positive pathogen , which meets the 
following criteria:  
a. Infection of the skin with a lesion size area of at least 75  cm2, or infection of the central face 
with a lesion size area of at least 50  cm2; lesion size measured by the area of redness, edema, or 
induration using manual measurement of the longest length multiplied by the greatest 
perpendicular width  
b. One of the following infection types:  
• Cellulitis/erysipelas: A diffuse skin infection charact erized by spreading areas of redness, 
edema, and/or induration  
• Wound infection: An infection characterized by purulent drainage from a wound with 
surrounding redness, edema, and/or induration, related to trauma or surgery  that occurs 
within 30  days of trau ma or surgery  
• Major cutaneous abscess: An infection characterized by a collection of pus within the 
dermis or deeper that is accompanied by redness, edema, and/or induration  
4. Clinical findings from both of the following categories  within 24 hours : 
a. At least 2 of the following local signs at the ABSSSI site:  
• Purulent or sero purulent  drainage/discharge  
• Erythema  
• Fluctuance  
• Heat/localized warmth  
• Pain/tenderness to palpation 
• Swelling/induration  
b. At least 1  of the following signs of systemic inflammation:  
• Fever or hypothermia (PO or rectal temperature ≥  38.0°C or ≤  36.0°C)  
• White blood cell (WBC) count ≥  10,000/mm3 or ≤  4,000/mm3 
• Immature neutrophils (bands) ≥  10%, irrespective of WBC count  
• Lymphadenopathy or lymphadenitis proximal to the ABSSSI  site 
• C-reactive protein (CRP) > upper limit of normal  
5. Females must be either postmenopausal for ≥2 years or surgically sterile (having undergone tubal 
ligation, hysterectomy, or bilateral oophorectomy) or, if of childbearing potential, must have a 
negative pregnancy test at screening /baseline  and be willing to use a highly effective method of 
contraception throughout the study such as 1 of the following:  
• Hormonal contraception (stable dose for 3 months)  
• Intrauterine device/ intrauterine hormone -releasing system  
• Barrier contraceptive method (diaphragm, cervical cap, contraceptive sponge, condom)  
6. Males if sexually active and nonsterile with female partners of childbearing potential must use 
2 methods of contraception (i.e., a barrier contraceptive such as condom with spermicidal 
foam) , and be willing to continue to use such highly effective birth control measures while 
participating in the study and for 70 days following participation in the study. Males must also 
refrain from sperm donations during this time. 
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 17 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Exclusi on Criteria : 
1. Prior receipt of any formulation of contezolid acefosamil  or contezolid 
2. ABSSSI with any of the following characteristics:  
a. Known or suspected to involve anaerobic organisms (e.g., perineal wound infection, gluteal 
decubitus ulcer, peri anal abscess, wound infection associated with surgery on gastrointestinal 
tract or female genital tract)  
b. Known or suspected invasive infection due primarily to fungal, mycobacterial, parasitic, or viral 
pathogens  
c. Involving an ischemic ulcer due to periphera l vascular disease  
d. Involving a decubitus ulcer  or perirectal abscess  
e. Involving a diabetic foot ulcer  
f. Involving a n infected burn  
g. Involving an underlying inflammatory skin disease that may obscure determination of response 
(e.g., chronic dermatitis) where in flammation may be prominent for an extended period of time, 
even after successful bacterial eradication has been achieved  
h. Involving pyoderma gangenosum  
i. Involving a bite from a human or animal other than an arthropod  
j. Involving a rapidly necrotizing process, such as necrotizing fasciitis  
k. Involving gangrene of any etiology 
l. Complicated by an immune deficiency in the subject  (e.g., development of ecthyma 
gangrenosum, cellulitis , or wound in a neutropenic subject ) 
m. Anatomically associated with prosthetic materials (e.g., venous catheters, permanent cardiac 
pacemaker battery packs, or joint replacement prostheses), even if the device is removed  
n. An infection complicating an area of the body that will require amputation  
o. Requiring significant surgical intervention (i.e . procedures that would not normally be 
performed at the bedside) that cannot be performed within 72 hours , unless previously planned , 
after initiating study drug therapy  
p. Estimated high cure rate after surgical incision alone or after aggressive local skin  care (e.g., 
minor cutaneous abscess or furuncle)  
q. Associated with infection at other anatomic sites or spaces, such as endocarditis or other 
endovascular infection, thrombophlebitis, osteomyelitis, or septic arthritis  
r. Anticipated need for antibacterial the rapy for >  14 days  
3. Pre-existing ABSSSI known or suspected to be caused by pathogens that are resistant to 
oxazolidinone  antibiotic s 
4. Inability to tolerate a PO study drug (e.g., nausea, vomiting, diarrhea, or any other condition that 
might impair ingestion or absorption of PO study drug)  
5. Poor venous access  
6. History of any intolerance, hypersensitivity or allergic reaction to any oxazolidinone antibiotic  
7. History of any intolerance, hypersensitivity or allergic reaction to aztreonam; note that while cross -
react ivity of aztreonam with other β -lactams is rare, this drug should be administered with caution 
to any subject with a history of hypersensitivity to β -lactams (e.g., penicillins, cephalosporins, 
and/or carbapenems)  
8. History of peripheral or optic neuropathy  
9. QTcF interval duration >  450 msec obtained as an average from the triplicate screening/baseline 
ECGs, history of QT prolongation, hypokalemia (serum potassium <  3.0 mEq/L) at 
screening/baseline, or other proarrhythmic conditions  
10. History of a known or suspected central nervous system (CNS) condition, such as hallucinations, 
depression, suicidal thoughts or suicidal acts, or of a CNS disorder that may predispose to seizures 
or lower the seizure threshold  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 18 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
11. History of known or suspected serotonin syndrome, neuroleptic malignant syndrome, or carcinoid 
syndrome  
12. Known or suspected pheochromocytoma or thyrotoxicosis or severe uncontrolled hypertension.  
13. History of known or suspected Clostridium difficile -associated diarrhea  
14. Evidence of significant hepatic, renal , hematologic, or immunologic disease as determined by the 
following:  
a. Total bilirubin >  2 times upper limit of normal  ( x ULN)  
b. Alanine amino transferase ( ALT ) or aspartate amino transferase ( AST ) > 3 x ULN  
c. Estimated or documented creatinine clearance of <  30 mL/min 
d. Manifestations of end -stage liver disease, such as ascites or hepatic encephalopathy  
e. Current or anticipated absolute neutrophils < 1500  neutrophils/mm3 
f. Platelet count < 75,000 cells/mm3 
g. Infection with human immunodeficiency virus (HIV) and a  known CD4 count <  200 cells/mm3, 
or another acquired immune deficiency syndrome (AIDS) -defining illness  
h. Receipt of cancer chemotherapy, radiotherapy, or potent, non- corticosteroid immunosuppressant 
drugs (e.g., cyclosporine, azathioprine, tacrolimus, immune -modulating monoclonal antibody 
therapy) within the past 3 months, or the receipt of corticosteroids ≥  10 mg of prednisone (or 
equivalent) per day for >  14 days in the prior 30 days 
15. Females who are pregnant or nursing  
16. Prior administration of systemic antibacte rial therapy  within 96 hours before randomization 
a. EXCEPTIONS: Subject s may be eligible if they meet the following conditions:  
EITHER:  
• Received a single dose of a non -oxazolidinone, short -acting, systemic antibiotic within 
96 hours prior to randomization. Note that such subject s will not comprise >  25% of 
randomized subjects . 
OR BOTH OF THE FOLLOWING:  
• Objective clinical evidence of treatment failure  (persistent pain, erythema, induration, or 
purulent drainage ) following at least 48  hours of prior, non- study, systemic antibacterial 
therapy  
AND  
• Microbiological evidence of failure (i.e. a Gram stain obtained from an appropriate ABSSSI 
specimen collected after the initiation of this prior therapy revealing WBC and  Gram -
positive cocci, or isolation of a Gram -positive pathogen from an appropriate ABSSSI 
specimen that is resistant to the prior systemic antibacterial therapy)  
17. Prior (within the past 2  weeks) administration of, or expected or required concomitant (from t he 
start of the study drug to EOT) administration of:  
a. Systemic adrenergic, dopaminergic, or serotonergic medications  
b. Monoamine oxidase inhibitors (MAOIs) (e.g., isocarboxazid, isoniazid, nialamide, phenelzine, 
procarbazine, and hydracarbazine)  
18. Life expectancy <  3 months or evidence of immediately life- threatening disease, including, but not 
limited to, current or impending respiratory failure, shock, acute coronary syndrome, unstable 
arrhythmias, hypertensive emergency, acute hepatic failure, active gastrointestinal bleeding, 
profound metabolic, or acute cerebrovascular events  
19. Unable to cooperate fully with the requirements of the study protocol, including the schedule of 
assessments, or likely to be non -compliant with any study requirements, or the I nvestigator 
determines that the subject should not participate in the study  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 19 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Pharmacokinetic Assessments:  
This study will be conduc ted at multiple clinical sites, and some will have the appropriate equipment 
and facilities (including refrigerated centrifug es and - 70ºC  freezers) and experienced personnel to 
adequately collect, handle, store, and ship PK samples for bioanalysis . PK assessments will only be 
performed at selected clinical sites with this capability, and PK samples will be obtained from as many 
subjects as possib le at these selected sites. Drug exposure will be predicted based on demographic data 
(e.g., body weight) for subjects from whom PK samples were not obtained.  
• One PK sample after the 1st IV dose  (to characterize the loading dose) : obtain 1 blood sample 
between  0.5 to 2 hours afte r the end of the 1st infusion  
• Three  PK samples with the 3rd IV dose (to characterize drug exposure and approaching of steady 
state):  
• Obtain a  1st blood sample (trough level ) within 2 hours before  the 3rd IV dose  
• Obtain a 2nd blood sample between 0.5 and 3 hours after the end of the 3rd IV dose  
• Obtain a 3rd blood sample between 4 and 11 hours after the end of the 3rd IV dose but 
before the 4th dose (IV or PO) of study drug  
• Three  PK samples at EOT  (to evaluate potential drug accumulation) : 
• Obtain 1 blood sample ( trough level ) within 2 hours before  the last dose  (IV or PO) 
• If the last dose is given PO : obtain 1 blood sample between  1.5 to 4 hours after the last 
dose, and obtain 1 additional sample b etween 5 to 12 hours after the last dose  
• If the last dose is given IV: obtain 1 blood sample between 0.5 and 3 hours after the end of 
the last infusion, and obtain 1 additional sample between 4 and 11 hours after the end of the 
last infusion  
The PK data ac quisition and analysis strategy entail the use of a sparse PK sampling schedule for 
subject s randomized to contezolid acefosamil . This PK sampling strategy is designed  to characterize the 
impact of the loading dose, and to  obtain adequate estimates of drug exposure after the 3rd  IV dose  and 
the final IV or PO dose. Additionally, given the range of demographic data in the expected subject 
population, these PK data will be used to perform  exploratory analyses on the impact of  demographic  
characteristics (e.g., weight, body mass index, age, gender, race) upon the PK (including clearance ) of 
the drug  and its metabolites . Only those PK samples collected from subject s randomized to contezolid 
acefosamil  will be analyzed. The bio analytical laboratory will measure plasma concentrations of 
contezolid acefosamil  metabolites  (MRX -1352, contezolid , and MRX -1320) using validated and 
sensitive methods . 
Efficacy Endpoints:  
The Primary efficacy  endpoint is early  clinical response at EA for the ITT population as described in 
Efficacy Assessments above and in Section 9.1.1.  
Secondary efficacy  endpoints will be determined at EA, Day 7, EOT, PTE , and LFU according to the 
table below. Early  clinical response is  defined in Table 2, Investigator’s assessment of clinical responses 
(including success and relapse) are defined in Table 3 , per-subject  microbiological responses are 
defined in Section  9.2.2, and microbiological responses per baseline pathogen are defi ned in 
Section  9.2.1 . The CACO is a composite assessment of the early  clinical response at EA and the 
Investigator’s assessment of clinical response at PTE (Section 12.6.2 .2). 
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 20 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Efficacy Endpoints  Efficacy Populations  
ITT MITT micro -
ITT CE-
EOT  CE-
PTE  ME 
Primary :       
Early clinical response at EA  √      
Secondary:        
Early clinical response at EA   √     
Early clinical response at EA (overall and 
by baseline pathogen)    √    
Percent reduction in lesion size at Day 7  √ √     
Investigator’s assessment of clinical 
response at EOT  √ √  √   
Investigator’s assessment of clinical 
response at PTE and LFU  √ √   √  
Per-subject microbiological response at 
PTE    √   √ 
Per-pathogen microbiological response at 
PTE   √   √ 
Investigators assessment of clinical 
response at PTE and LFU (overall and by 
baseline pathogen)    √   √ 
CACO  √  √  √  
CACO = composite assessment of clinical outcome (combined outcome of early clinical response at EA and 
Investigator’s assessment of clinical response at PTE); CE  = clinically evaluable; EA  = early assessment; 
EOT  = end of therapy; ITT  = intent -to-treat; LFU  = late follow -up; ME  = microbiologically evaluable; MITT = 
modified intent -to-treat; micro -ITT = microbiological intent -to-treat; PTE  = post therapy evaluation  
 
Safety and Tolerability Assessments:  
Safety will be assessed through the determination and recording of the occurrence of  adverse events 
(AEs) and AEs of special interest, as well as by adverse changes in vital signs, ECG parameters, and 
laboratory data. Hematology evaluations, serum chemistries, and urinalysis will be performed at 
screening /baseline , EA, Day  7 (±  1 day), EOT  (+ 1 day) , and PTE . Additional safety events that occur 
after PTE  will be assessed at LFU. Adverse events will be evaluated by relationship to study drug and 
severity . Serious adverse events (SAEs) will be identified.  
Stati stical Methods:  
Sample Size Considerations:  
This study is not powered for inferential statistical analysis. Up to 133  subjects (100 evaluable subjects) 
in the contezolid acefosamil group and up to 67 subjects (50 evaluable subjects) in the linezolid group 
will allow for planning of future studies. If the responder rate is 0.8 at EA using early  clinical response  
in the contezolid acefosamil group, then 133  evaluable subjects results in a 95% confidence  interval 
(CI) of (0.7 2, 0.86) for the responder rate.  
Clinical Protocol MRX4 -201  
 
MicuRx Pharmaceuticals, Inc.  Page 21 of 105 
CONFIDENTIAL  Final , 19 Oct  2018  
Analysis Populations : 
• ITT Population -  All randomized subject s will be included in the ITT population, regardless of 
whether study drug is administered.  
• MITT Population-  All randomized subjects in the ITT population, excluding subjects with only 
Gram-negative pathogen (s) at baseline . 
• Safety Population -  All subject s who receive any amount of study drug will constitute the safety 
population. Subject s in the s afety population wi ll be analyzed according to study drug received.  
• Micro-ITT Population -  All randomized subject s in the ITT population who have culture evidence of 
a baseline Gram -positive bacterial pathogen known to cause ABSSSI.  
• CE Populations  (CE-EOT, CE -PTE)  – All subject s in the ITT population who meet the minimal 
clinical disease criteria for ABSSSI ; receive at least 80% of expected doses based on length of 
therapy ; did not receive any potentially -effective systemic antibacterial therap ies other than protocol  
specified study drug(s) between Day  1 and timepoint for assessment  (except for adjunctive aztreonam 
or in cases of treatment failure) . 
o To be included in the CE -EOT population, the following conditions must be met:  
 Have an Investigator’s assessment of clinical response at EOT (i.e., response can’t  be 
indeterminate)  
 Had an EOT visit  
o To be included in the CE -PTE population, the following conditions must be met:  
 Have an Investigator’s assessment of clinical response at PTE  (i.e., response can ’t be 
indeterm inate unless the subject  is deemed a clinical failure at the EOT visit)  
 Had a PTE  visit  
In addition to meeting the above criteria, subject s must meet the following specific conditions  to be 
included in the CE populations : 
o Received at least 5 doses of  study drug therapy to be considered an evaluable failure  
o Received at least 7 doses  of study drug therapy to be considered an evaluable success  
o Did not have any major protocol violation  
• ME Population – All subject s in the micro -ITT population who also are in the CE -PTE population . 
• PK Population: All subject s who received at least 1 dose of contezolid acefosamil  and had at least 
1 blood sample collected for analysis of MRX -1352, contezolid, or MRX -1320. 
Statistical Analysis:  
All baseline data will be summarized by treatment group.  
Pharmacokinetic data will be summarized using descriptive statistics and graphically displayed , and 
population PK modeling analyses will be performed. 
The primary efficacy analysis will be based on the e arly clinical response at EA in the ITT population. 
The number and percentage of subject s in each treatment group classified as responders will be 
tabulated and 95%  CIs will be provided for each response rate. The 2 -sided 95%  CI for the difference in 
respo nse rates between the 2  treatment groups will also be computed. All secondary endpoints will be 
summarized by treatment group as specified. For outcomes expressed as proportions (other than per -
pathogen outcomes) , 95% CIs will be presented for descriptive purposes. Additional details will be 
provided in the Statistical Analysis Plan . 
Safety analyses include summaries of treatment -emergent AEs and SAEs , vital signs, laboratory 
evaluations (hematology, chemistry, and coagulation), and ECG parameters.  
Interim  Analysis:  
An interim analysis is not planned.  
 
Clinical Protocol MRX4 -201   
 
 
MicuRx Pharmaceuticals, Inc.   Page 22 of 105 
CONFIDENTIAL  Final, 19 Oct 2018  
Table 1:  Schedule of Events  
Procedure or Assessment  Screening/  
Baseline1 
(≤ 24 hrs 
of first 
dose)  Study Treatment Period  PTE5 LFU6 
Day 12 Day 2  EA3 
(48-72 
hours)  Day 7 
(± 1 day)  EOT4  
(+ 1 day)  7-14 Days 
After EOT  21-28 Days  
After EOT  
Informed consent7 X        
Medical/surgical history  X        
Prior and concomitant therapy8 X X X X X X X X 
Examination, measurement, and signs 
and symptoms of ABSSSI9 X10   X X X X  
Document primary ABSSSI lesion by 
digital photography11 X10   X X X   
Investigator’s assessment of clinical 
response       X X X 
Activity assessment12 X     X X X 
Complete physical examination13 X10     X   
Focused physical examination14    X X  X  
Vital signs15 X10   X X X X  
12-Lead ECG16 X10 X17  X  X X  
Height and weight  X        
Adverse events18 X X X X X X X X 
Laboratory tests19 X10   X X X X  
Serology tests 20 X        
Pregnancy test21 X10     X   
Estimate CrCl22 X        
PK samples23  X X   X   
Clinical Protocol MRX4 -201   
 
 
MicuRx Pharmaceuticals, Inc.   Page 23 of 105 
CONFIDENTIAL  Final, 19 Oct 2018  
Procedure or Assessment  Screening/  
Baseline1 
(≤ 24 hrs 
of first 
dose)  Study Treatment Period  PTE5 LFU6 
Day 12 Day 2  EA3 
(48-72 
hours)  Day 7 
(± 1 day)  EOT4  
(+ 1 day)  7-14 Days 
After EOT  21-28 Days  
After EOT  
ABSSSI specimen Gram stain and 
culture24 X10   X X X X  
Blood cultures25 X10   X X X X  
Randomization26  X       
Administration of study drug  
(10 to 14 days)27  X X X X X   
ABSSSI  = acute bacterial skin and skin structure infection; β –HCG  = beta-human chorionic gonadotropin; CrCl  = creatinine clearance; CRP = c -reactive protein; EA  = early 
assessment; ECG  = electrocardiogram; EOT  = end of therapy;  eRT = eResearch Technologies; LFU  = late follow -up; PK  = pharmacokinetic; PTE  = post therapy evaluation; 
UA = urinalysis.  
1. Screening/ baseline assessments must occur within 24  hours prior to first administration of study drug.  
2. Day 1 is the first day of study drug administration; subsequent study days are consecutive calendar days.  
3. Perform EA assessments at 48 to 72  hours after the start of the first dose of IV stud y drug.  
4. Perform EOT assessments on the last calendar day of study drug (+ 1 day). Subjects who prematurely discontinue study drug or withdraw from the study should have all 
EOT assessments performed on the day of discontinuation of study drug  or withdrawal  from  the study (+  1 day).  
5. Perform PTE assessments 7  to 14 days after EOT.  
6. Perform LFU assessments 21  to 28 days after EOT. If the subject has improved to the point that they have returned to their usual premorbid activity (work/school), and if 
the primary site has little or no pain, swelling, redness, or purulent/seropurulent drainage  at PTE, the LFU visit may be performed over the telephone.  
7. Written informed consent must be obtained prior to initiating any study assessment or procedure.  
8. Record all prior medications taken within 2  weeks prior to randomization; record all concomitant medications between Day  1 and EOT, and only concomitant 
antimicrobial agents and concomitant medications taken for an AE between EOT and LFU.  
9. Direct evaluation of sign s and symptoms of ABSSSI by the Investigator at EA, Day 7, EOT, and PTE; assessments include manual measurement of the primary ABSSSI 
lesion size (longest length and perpendicular width) with a ruler provided by the Sponsor ( Section 8.1). 
10. Procedures that must be repeated on Day 1 prior to dosing if they were collected >  24 hours prior to first administration of study drug.  
11. Document the primary ABSSSI lesion via digital photography at screening /baseline , EA, Day 7, and EOT using the digital camera provided by the Sponsor ( Section 8.3). 
12. At screenin g/baseline , record if the subject’s premorbid activities (work/school) are compromised. At subsequent visits, record the date the subje ct returned to premorbid 
level of activity (work/school), as applicable.  
13. Perform a complete physical examination (i.e., g eneral appearance, head, ears, eyes [including basic Snellen visual acuity  and visual field testing], nose, throat, dentition, 
thyroid, chest [heart, lungs], abdomen, skin/soft tissues, neurological, extremities, back, neck, musculoskeletal, lymph node s) at screening /baseline  and EOT.  
14. Perform a limited , symptom directed physical examination  as clinically indicated at EA , Day 7, and PTE. 
Clinical Protocol MRX4 -201   
 
 
MicuRx Pharmaceuticals, Inc.   Page 24 of 105 
CONFIDENTIAL  Final, 19 Oct 2018  
15. Record vital signs (heart rate, blood pressure, respiratory rate, and temperature) at screening/baseline, EA, Day  7, EOT, and PTE . If >  1 temperature is measured within a 
calendar day, record the highest daily temperature measured. Vital signs will be collected prior to collection of blood labor atory samples. Oral or rectal temperatures are 
acceptable; the site of measurement  will be collected in the eCRF.  
16. Obtain triplicate ECGs within a 15 -minute period, each separated by at least 1  minute, at screening/baseline, Day 1 (pre dose and postdose ), EA, EOT, and PTE. ECGs 
will be collected prior to collection of blood laboratory (including PK) samples . The time of prior dose of study drug and relationship of time of ECG to dose must be 
documented All ECGs will be performed on ECG machines provided by eRT and will be sent to eRT for central reading.  
17. Within 1 hour prior to start of IV infusion (unless s creening /baseline  ECG is performed in triplicate and is within 1  hour prior to start of IV infusion) and another within 
2 hours after completion of IV infusion.  
18. Adverse events are collected between written informed consent and LFU. During  the LFU phone call, symptoms related to possible relapse of ABSSSI will be evaluated 
as part of the safety assessment.  
19. Perform safety laboratory tests, including hematology, chemistry, and coagulation tests , UA, and CRP , at screening/ baseline, EA, Day  7, EOT, and PTE. Include urine 
microscopy if UA is positive for red blood cells, WBCs, or protein ( Appendix 4). Samples for screening/baseline tests will be drawn and sent to local laboratory (to 
confirm eligibility) and central laboratory. All subsequent laboratory tests will be drawn and sent to the central laboratory.  
20. Serology tests include Anti-HBcAg anti -HBsAg, HBsAg, HCV  Ab, HIV Ab (Appendix 4)  
21. Females of child bearing  potential up to 2 years postm enopause must have a serum or urine β –HCG pregnancy test at baseline and EOT (otherwise, females must be 
surgically sterile, i.e. , have had a tubal ligation, hysterectomy, or bilateral oophorectomy). Male and female subjects must agree to comply with usi ng a highly effective 
form of birth control  (see Section 10.3) from baseline through LFU. If the pregnancy test is positive at the EOT visit, or if a female partner of a male subject becom es 
pregnant, follow the reporting requirements in Section 10.3.  
22. Calculate estimated CrCl using screening/ baseline height (m), actual weight (kg), and serum creatinine ( Section  7.1). 
23. Obtain  PK samples  as follows  (Section  11):   
• One sample after 1st IV dose , between  0.5 to 2 hrs after the end of the 1st infusion;  
• Three samples w ith the 3rd IV dose : obtain a 1st blood sample within 2 hours before  the 3rd IV dose (trough level) , a 2nd blood  sample between 0.5  and 3 hours 
after the end of the 3rd IV dose, and a 3rd blood sample between 4 and 11 hours after the end of 3rd IV dose, but before the 4th dose  (IV or PO);  
• Three samples at EOT: obtain 1 blood sample within 2 hours before  the last dose  (IV or PO). If the last dose is given PO: obtain 1 blood sample between 1.5 to 4 
hours after the last dose and obtain 1 additional sample between 5 to 12 hours after the last dose . If the last dose is given IV: obtain 1 blood sample between 
0.5 and 3 hours after the end of the last infusion and obtain 1 additional  sample between 4 and 11 hours after the end of the last infusion.  
24. Obtain appropriate ABSSSI site specimen from all subjects  at screening/baseline, and perform G ram stain and culture at the local laboratory ( Section  8.2). The ABSSSI 
site specimen should be obtained before administration of antibacterial therapy whenever possible. Repeat post -screening/baseline ABSSSI specimen culture and Gram 
stain  at subseq uent visits only  if clinically indicated  (e.g., the subject is deemed a clinical failure or if purulence and discharge from the  ABSSSI site continues after 
screening/baseline).  
25. Two sets of blood cultures (each set consists 1 aerobic and 1  anaerobic blood c ulture bottle from 2  separate venipuncture sites) will be collected from all subjects, 
regardless of location of management (inpatient or outpatient)  (Section 8.2). The blood cultures should be obtained before administration of antibacterial therapy, 
whenever possible. Blood cultures must be repeated every 3 days (±  1 day) if the previous blood culture was positive, or at any time after screening /baseline  if clinically 
indicated.  
26. Verify that the subject meets all study inclusion and exclusion criteria before randomization on Day  1. 
27. Subjects receive study drug q12h (± 2 hours) for 10- 14 days. On Day  1, the first dose of study drug should be administered as quickly as possible after eligibility criteria 
are met. Subjects will receive the first 3 doses of study drug intravenously and then may switch to oral study drug if the primary ABSSSI lesion has not increased in area 
from the screening/baseline assessment and the Investigator determines that the  subject has sufficient PO intake of food and drink  to safely support the administration of 
PO doses of antibiotics . 
 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 25 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
2 INTRODUCTION 
2.1 Background  
Acute bacterial skin and skin structure infections (ABSSSI) are common infectious diseases; 
approximately 6.3 million physician’s office visits per year are attributable to this infection 
(Pallin, 2008). The frequency and severit y of ABSSSI, and the emergence of resistance to many 
of the antibacterial agents commonly used to treat this infection, have dramatically increased 
over the past 2 decades ( Stevens, 2014). For example, there was a 29%  increase in  the total 
hospital admissions for ABSSSI between 2000 and 2004 ( Edelsberg, 2009). In addition, annual 
emergency department visits for ABSSSI between 1993 and 2005 increased from 1.2 million to 
3.4 million patients ( Pallin, 2009). Skin and soft tissue infection and ABSSSI in hospitalized 
patients contribute to prolonged length of stay and increase costs of medical care, as well as play 
an important role in driving antimicrobial resistance emergence ( Rennie, 2003).  
The increases in incidence and severity of ABSSSI are in part attributed to the emergence of 
community -associated methicillin -resistant Staphylococcus aureus  (MRSA) (Edelsberg, 2009 ). 
Commu nity-associated MRSA has increased markedly to become the greatest problem facing 
therapy for ABSSSI in the outpatient setting ( Deresinski, 2005; Diep, 2004; Eron, 2003). In a 
large global surveillance study to determine the bacteriology of ABSSSI between 1998 and 2004, 
S. aureus  ranked first as the predominant ABSSSI pathogen in all regions studied (North 
America, Latin America, and Europe); among the North American S. aureus  isolates, the 
prevalence of MRSA increased from approximately 42% in 1998 to 52% in 2004 ( Moet, 2007).  
In the same global surveillance study, the second most frequently isolated Gram-positive 
pathogen of ABSSSI was Enterococcus  spp., w here the prevalence remained high in North 
America (approximately  10%) (Moet, 2007). Furthermore, the prevalence of 
vancomycin -resistant enterococci (VRE) was of greatest concern in North America compared 
with other regions, where rates of resistance increased from approximately  9% in 1998 to 15% in 
2004. In addition to S. aureus  and enterococci, streptococci (e.g., group A, B, C, or G 
streptococci) and other staphylococci (e.g., coagulase- negative species) remain important causes 
of ABSSSI.  
It is important to note that ABSSSI may involve aerobic G ram-negative pathogens or may be 
polymicrobial ( Gram-positive, G ram-negative bacteria, and possibly anaerobic bacteria), 
depending on host factors and risk factors ( Stevens, 2014). Therefore, the goal of clinical 
evaluation of ABSSSI aims to establish the specific microbial cause to help determine optimal 
pathogen- directed therapy, which takes into account pathogen -specific and local antibiotic 
resistance patterns.  As most cases of ABSSSI are caused by endogenous G ram-positive cocci 
(i.e., staphylococci and streptococci) ―many of which may be drug -resistant―empiric treatment 
algorithms are no longer simple; recent emerging resistance of S. aureus  to methicillin, 
erythromycin, clindamycin, tetracycline, and trimethoprim -sulfamethoxazole―and emerging 
resistance of streptococci to erythromycin and clindamycin―have dramatically altered options 
of empiric and definitive therapy.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 26 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
The oxazolidinone class of antimicrobials have provided an important therapeutic option in the 
treatment of ABSSSI. Linezolid, the first oxazolidinone, was approved in 2000 and is highly 
efficacious for the treatment of both community -acquired and hospital acquired infections 
(Wilcox, 2005). In the US, linezolid is indicated for the treatment of VRE infections (including 
cases with concurrent bacteremia), nosocomial p neumonia (caused by methicillin -sensitive S. 
aureus  [MSSA], MRSA, or S. pneumoniae , including multidrug- resistant [MDR] strains), 
uncomplicated and complicated skin and skin structure infections including diabetic foot 
infections without concomitant osteomyelitis (caused by MSSA, MRSA, Streptococcus 
pyogenes , or S. agalactiae ), and community -acquired pneumonia c aused by S. pneumoniae , 
including MDR strains and cases with concurrent bacteremia, or MSSA  (Zyvox® Prescribing 
Information, 2018). There is an extremely low propensity toward developing bacterial resistance 
to linezolid in all target pathogens, even after over 14  years of clinical use. Despite these 
benefits, linezolid is subject to serious safety limitations, primarily due to myelosuppression and 
monoamine oxidase inhibition with associated drug -drug interactions, central nervo us system 
(CNS) and blood pressure effects. While myelosuppression is reversible and uncommon with 
linezolid treatment regimens ≤  14 days, extended treatment is also associated with mitochondrial 
toxicity resulting in optical neuropathy with rare but irrev ersible vision impairments ( Zyvox® 
Prescribing Information, 2018).  
In June  2014, tedizolid (Sivextro®), a second oxazolidinone was approved by the Food and Drug 
Administration ( FDA ) for the treatment of ABSSSI caused by MSSA, MRSA,  various 
Streptococcus  species, and Enterococcus faecalis  (FDA, 2014). The availability of both oral 
(PO) and intravenous ( IV) formulations has added to their clinical utility, as have 
pharmacokinetic ( PK)/pharmacodynamic (PD) characteristics that offer, among other things, a 
bioavailability of 90 to  100%, possibility of once  daily (tedizolid) or twice  daily (linezolid) 
dosing, and excellent and prolonged tissue penetration ( Dryden, 2014; Flanagan, 2014).  
Introduction of new oxazolidinone compounds that are safe and effective, have a  PO and IV 
formulation, and have important differentiating features over existing agents are needed to 
ensure continued effective treatment of ABSSSI and other serious G ram-positive infections 
caused by emerging resistant G ram-positive pathogens.  
2.2 Description of Contezolid  and Contezolid Acefosamil  
MicuRx Pharmaceuticals , Inc.  pursued a research program to develop a novel oxazolidinone 
agent that maintains high antibacterial activity while potentially addressing the key toxicity 
issues associated with linezolid therapy. The initial drug candidate, contezolid (previously 
referred to as MRX -1), was well tolerated, safe, and shown to have efficacy com parable to 
linezolid ( Gordeev, 2014 ). Contezolid is a Biopharmaceutics Classification System (BCS) 
class  2 molecule (poorly soluble in water), and absorption of oral contezolid was markedly 
improved when administered with food. I n addition, the poor solubility made the production of 
an IV formulation impractical. To address these issues, contezolid acefosamil , a prodrug of 
contezolid, was developed to decrease the impact of food on oral absorption and to present the 
patient and ph ysician the opportunity to utilize the same molecular entity for both IV and oral 
therapy . The main objective of the contezolid acefosamil  and contezolid clinical program is to 
develop oxazolidinone antibiotic s with improved tolerability and reduced toxici ty compared to 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 27 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
the currently available oxazolidinones (linezolid and tedizolid) while maintaining efficacy in 
serious G ram-positive bacterial infections.  
Contezolid acefosamil , the sodium salt of a  contezolid prodrug with high aqueous solubility , 
degrades into bioactive contezolid in aqueous environments in  a 2-step process  (Figure 1) . In the 
first step , contezolid acefosamil  quickly degrades i nto an intermediate metabolite, MRX -1352, 
when given either by the oral (PO) or intravenous (IV) route , and the second step results in the 
active moiety, contezolid. Additionally, the primary metabolite of contezolid is MRX -1320. The 
structure of contezoli d has been previously published ( Gordeev, 2014). Neither contezolid 
acefosamil  nor MRX -1352 have direct antibacterial activity and must be converted to contezolid 
to become active. Neither contezolid acefosamil , nor MRX -1352, nor  the side chain fragments 
cleaved during biotransformation are associated with unique toxicities in animal models. 
Figure 1 : Contezolid Acefosamil  Metabolites  
 
The complete nonclinical toxicology program with contezolid acefosamil  demonstrated the 
following:   
• Whether given P O or IV, contezolid acefosamil has good tolerability and safety, and is 
comparable to contezolid in preclinical models of efficacy . 
• Contezolid acefosamil is well absorbed in animals as a PO  agent when dosed with and 
without food. 
A further description of the physical and chemical characteristics of contezolid and contezolid 
acefosamil is found in the Investigator’s Brochure. Contezolid acefosamil is expected to offer 
similar or  more consistent  (i.e., improved)  PK properties than contezolid and is expected to be 
available for both IV and PO administration in clinical practice. Therefore, contezolid acefosamil 
may provide an attractive option for ABSSSI and other significant Gram -positive infections in 
both hospi tal and community settings.  
2.3 Summary of Relevant Nonclinical Experience 
2.3.1 Pharmacology, Microbiology, Toxicology, and Safety  
The active pharmaceutical ingredient , contezolid has  demonstrate d excellent in vitro antibacterial 
activity against both nosocomial and community Gram-positive pathogens. Oral absorption of 
contezolid  in the mouse, rat, and dog was rapid with maximum time to absorption (T max) of 0.5 
to 1 hour and a half -life (t 1/2) of 1  to 2 hours. The mean effective protective dose (ED 50) was 
similar to  linezolid in in vivo mouse models of systemic and local infections caused by MRSA, 
penicillin -resistant S. pneumoniae , and VRE. Moreover, the minimum inhibitory concentration  
Contezolid  
Active moiety  

Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 28 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
for 90% of microbial strains (MIC 90) is <  2 µg/mL against recent US  surveillance isolates 
(Li, 2014 ). 
After IV administration in rats, contezolid acefosamil  was rapidly metabolized into contezolid 
after 30  minutes; the prodrug, contezolid acefosamil , was not detectable in rat blood specimens 
(whole blood supernat ant specimens). Peak concentrations of contezolid were demonstrated at  
0.7 hours. After multiple IV doses of 40 mg/kg contezolid acefosamil  in rats, no accumulation of 
the active molecule or its metabolites were noted over a 7- day period of consecutive 
administration s. Studies with radiolabeled 14C-MRX -1 indicated primarily fecal excretion within 
the first 24  hours after PO  administration.  
In toxicology studies, contezolid  was generally well tolerated after 4 -week PO dosing in rats and 
dogs. Results from contezolid acefosamil  toxicology studies indicated that contezolid acefosamil  
was not genotoxic or phototoxic and did not cause sensitization. C ontezolid acefosamil  did not 
cause hemolysis or red blood cell coagulation and was generally well tolerated in a  vascular 
irritation study. contezolid acefosamil  had negative results on the bacterial reverse mutation test, 
did not induce any structural or numerical chromosome aberrations in CHO -WBL cells, and 
showed no evidence of rat bone marrow micronucleus damage  or cytotoxicity. The no observed 
adverse effect level ( NOAEL ) of contezolid acefosamil  for potential reproductive and/or 
developmental toxicity was 120 mg/kg/dose twice daily ( BID) in male and female rats. The 
NOAEL of contezolid acefosamil  for embryo -fetal development retardation was 40 mg/kg/dose 
BID (80  mg/kg/day: C max = 14,300 ng/mL, area under the curve [ AUC ]0-24h = 139,000 h ⃰ ng/mL 
on gestation day 17). Further details regarding the microbiology, and animal PK/PD of 
contezolid and contezolid acefosamil are available in the contezolid acefosamil  IB. 
With its improved solubility, contezolid acefosamil  is expected to offer similar or more 
consistent  (i.e., improved)  PK properties than contezolid, and can be administered by both IV 
and PO routes of administration in clinical practice. The available in vitro microbiology and in 
vivo animal efficacy data support continued clinical development of contezolid acefosamil  as a 
potential human therapeutic agent for the treatment of moderate to severe bacterial infections 
caused by G ram-positive pathogens, most notably MRSA and other drug -resistant G ram-positive 
pathogens.  
2.4 Summary of Relevant Clinical Experience 
Contezolid is the active moiety of contezolid acefosamil . Several clinical studies were conducted 
with contezolid, including 2 Phase 1 clinical studies (MRX -I-01, MRX -I-02) and one proof -of-
concept Phase 2 clinical study  (MRX -I-03). From the Phase  1 and 2 studies, contezolid 
administered PO in single or multiple doses up to 800 mg every 12  hours for up to 28 days was 
well tolerated in healthy adult subjects.  
However, the physical and chemical characteristics of the active pharmaceutical ingredient 
ensured that no commercially practical IV formulation was likely to be developed for contezolid. 
Thus , research was directed toward finding a related compound with antimicrobial characteristics 
similar to contezolid but with greater solubility. C ontezolid acefosamil , the prodrug of 
contezolid, fits the required characteristics.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 29 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Two clinical studies have been completed  with contezolid acefosamil . MRX4 -001 was the first -
in-human study of PO contezolid acefosamil conducted in healthy volunteers  in the US  
(Section  6.2 of the Investigator’s Brochure ). MRX4 -002 was the first -in-human s tudy of IV 
contezolid acefosamil in healthy volunteers , and evaluated IV contezolid acefosamil 
administration and compared both the PO and IV administrations  (Section  6.3 of the 
Investigator’s Brochure ). An overview of the safety, tolerability, and PK from  these studies is 
presented below , with additional details provided in the Investigator’s Brochure.  
2.5 Safety and Tolerability of Contezolid Acefosamil  
In the Phase 1 contezolid acefosamil studies, safety and tolerability were assessed through 
adverse event reporting, collection of medical histories and concomitant medications, urine drug 
screens, urine and serum pregnancy tests, laboratory evaluations including hematology and 
coagulation tests, urinalyses, physical examinations, vital signs, and electrocardi ograms (ECG).  
In Study MRX4- 001, a total of 122 subjects were exposed to contezolid acefosamil or placebo 
administered orally in single doses of up to 3000 mg and multiple doses of up to 1500 mg every 
12 hours for 10 days. In Study MRX4 -002, a total of 98 subjects were enrolled, and 96 subjects 
were exposed to contezolid acefosamil or placebo administered via IV in single doses of up to 
2400 mg and multiple doses of up to 2100 mg QD for 10 days; 12 of 98 subjects also received 2 
doses of orally administered contezolid acefosamil 1500 mg q12h in the crossover portion of the 
study.  
In general, in both studies, contezolid acefosamil was well tolerated at these doses, and the safety 
profile of contezolid acefosamil was consistent with oxazolidinone  class effects . Findings 
included:  
• The majority of treatment- emergent adverse events ( TEAEs ) in both studies were mild in 
severity.  
• There were no severe or serious adverse events  (SAEs) or deaths . 
• There were no unusual or unexpected TEAEs judged related to study drug . 
• Overall, the nature and extent of TEAEs, and treatment -related TE AEs, were similar between 
all treatment groups for both PO  and IV administration, including placebo.  
• In Study MRX4- 001 (PO administration) , discontinuations due to TEAEs were observed in 
2 subjects (pyrexia in the 500 mg cohort, judged by the Investigator to be unrelated to study 
drug and vomiting in the 1500 mg cohort, judged possibly related to study drug). In Study 
MRX4 -002 (IV administration) , there were no discontinuations due to TEAEs; h owever, 
1 subject voluntarily withdrew consent from the study due to AEs of nausea, somnolence, 
asthenia, and headache which occurred within the first 12 hours after receiving a single 
1500 mg oral dose and were judged possibly related to study drug . 
• Durin g PO administration (Study MRX4 -001), the most frequently reported treatment -related 
TEAEs in study Part 1 (single ascending doses of contezolid acefosamil or placebo) were 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 30 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
headache and nausea. The most frequently reported treatment -related TEAE in Part 2 
(multiple ascending doses of contezolid acefosamil or placebo) was nausea. The most 
frequently reported treatment -related TE AEs during Part 3 (contezolid acefosamil or placebo 
and omeprazole) were headache, nausea, and vomiting. 
• During IV administration (S tudy MRX -002), the most frequently reported TEAEs for IV 
contezolid acefosamil and IV placebo involved the infusion site. In Part 1, only 1 AE, 
dysgeusia, was considered related to IV contezolid acefosamil. In Part 2, the most frequently 
reported AEs relat ed to IV contezolid acefosamil were infusion site irritation and infusion 
site pain. In Part 3 (crossover portion investigating IV and oral formulations), the most 
frequently reported AE related to contezolid acefosamil was headache.  
• Two AEs of neutropenia  were reported in Study MRX4- 001 (all in subjects treated with PO 
contezolid acefosamil), and 3 in Study MRX4- 002 (2 in subjects treated with IV contezolid 
acefos amil and 1 in subject treated with placebo); all 5 events were National Cancer Institute 
(NCI)  Common Terminology for Adverse Event (CTCAE) Grade 2 (moderate) and none 
were judged related to study drug.  
• No impact of contezolid acefosamil administration (PO or IV) on laboratory values or ECGs 
interpretations was observed; no clinically significant l aboratory values were attributed to the 
study treatment, and there were no significant results on any ECG interpretation. 
• In general, contezolid acefosamil was well tolerated when given orally as a single 1500 mg 
dose in combination with omeprazole. 
For mo re details on the PK of contezolid acefosamil in the MRX -001 and MRX -002 studies, see 
Sections 6.2 and 6.3 of the Investigator’s Brochure. 
2.6 Pharmacokinetics of Contezolid Acefosamil  
In Study MRX04- 001, t he PK of orally administered contezolid acefosamil was  evaluated after 
single ascending doses of 250, 500, 750, 1000, 1500, 2000, 2500, and 3000 mg (including an 
evaluation of food effect at the 1500 mg dose), multiple ascending doses of 500 mg q12h, 7500 
mg q12h, 1000 mg q12h, and 1500 mg q12h for 10 days, a nd in a crossover study alone at 
1500 mg and when co -administered with omeprazole.  
In Study MRX4- 002, t he PK of IV contezolid acefosamil was evaluated after single ascending 
doses of 150, 300, 600, 1200, 1800, 2100, and 2400 mg, multiple ascending doses of 600 mg 
q12h, 900 mg q12h, and 2100 mg QD for 10 days, and a crossover study comparing IV 
(2100 mg) and  oral (2 doses of 1500 mg tablets q12h) formulations of contezolid acefosamil. 
The general findings are described below.  
• Contezolid acefosamil was rapidly metabolized after both single and multiple oral doses of 
contezolid acefosamil. When contezolid acefo samil was administered orally, no quantifiable 
contezolid acefosamil concentrations were observed at any of the sampled timepoints, and 
therefore PK parameters for contezolid acefosamil could not be estimated. When 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 31 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
administered via IV, blood concentrations  of contezolid acefosamil increased with dose and 
declined rapidly after the infusion, with an estimated T 1/2 of 8 to 11 minutes. 
• Contezolid acefosamil concentrations were transient and very low after IV administration 
and undetectable after oral administr ation compared with those observed for the contezolid 
acefosamil metabolites.  
• Exposure to the active moiety, contezolid, in blood increased approximately dose -
proportionally with increasing oral and IV doses of contezolid acefosamil, particularly after 
multiple doses. During multiple dosing, there was no apparent accumulation for the  2100 mg 
QD IV regimen or for oral regimens of up to 1000 mg q12h; however, contezolid 
concentrations do gradually increase in systemic circulation over time as time to steady s tate 
may require up to 7 days when oral or IV contezolid acefosamil is dosed above 1000 mg 
q12h. Exposure after 10 days may increase up to 2 fold when dosed q12h given IV and up to 
1.7 fold when 1500 mg is given orally q12h.  
• Exposure to contezolid in blood after oral ly administered  contezolid acefosamil 1500 mg 
q12h (2 doses separated by 12 hours) was similar to that observed after contezolid acefosamil 
IV 2100 mg (single dose); the bioavailability of contezolid after orally administered 
contezolid acefosam il was approximately 66% of that after IV contezolid acefosamil. Based 
on relative amounts of MRX -1352, contezolid in blood and plasma, and MRX -1320 in 
plasma, there was no appreciable binding to blood components. 
• Although oral administration of contezolid acefosamil 1500 mg under fed conditions resulted 
in a delay in contezolid T max by approximately 0.8 hours , from 2.42 hours to 3.25 hours, the 
maximum contezolid exposure (C max) was similar after administration of 1500 mg contezolid 
acefosamil under fed an d fasted conditions; the geometric mean ratio was 91.83%. An 
increase in total contezolid exposure (AUC 0-t, AUC 0-∞) of approximately 24% was observed 
in the presence of food; geometric mean ratios were 123.77% and 123.74%, respectively. 
Intrasubject variab ility ranged from 14.78% (AUC 0-∞) to 19.20% (C max). Therefore, the drug 
product can be taken with or without food. 
• After co -administration of contezolid acefosamil plus omeprazole, maximum contezolid 
exposure (C max) was approximately 20% higher compared to that after administration of 
contezolid acefosamil alone. Total contezolid exposure (AUC 0-t and AUC 0-∞) was similar 
across treatments. Intrasubject variability ranged from 16.49% (AUC 0-t) to 16.57% (AUC 0-∞). 
Therefore, no significant drug interaction is noted with concomitant omeprazole  treatment.  
• No clear gender -related trends were observed.  
For more details on the PK of contezolid acefosamil in the MRX -001 and MRX -002 studies, see 
Sections 6.2 and 6.3 of the Investigator’s Brochure. 
2.7 Summary and Rationale  for Study  
There is an unmet need for additional antibiotic  choices to treat Gram -positive bacterial 
infections caused by organisms such as MRSA  and VRE. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 32 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Contezolid acefosamil , a sodium salt of a contezolid prodrug, is a synthetic antibiotic in the 
oxazolidinone class of antimicrobials. Due to the low solubility of contezolid and inability to 
produce a practical IV formulation using contezolid, an orally bioavailable and water soluble 
new molecular entity ( contezolid acefosamil ) was developed , a full battery of preclinical studies 
was performed , and a successful P hase 1 program  evaluating both the oral and IV formulations 
of contezolid acefosamil  was completed under a US IND . 
Contezolid is a novel oxazolidinone with potent in vitro activity against aerobic and anaerobic 
Gram -positive pathogens, with demonstration of clinical efficacy in ABSSSI  in 2 previous 
Phase 2 studies . Contezolid acefosamil , which rapidly converts to contezolid, is expected to offer 
patie nts and physicians an effective and better tolerated option for the treatment of serious 
Gram -positive bacterial infections. Contezolid acefosamil  will be available in both IV and PO 
formulations . 
Both contezolid and contezolid acefosamil  have proven to be  highly efficacious in various 
models of animal infections caused by Gram -positive bacteria, including drug- resistant strains of 
S. aureus , Streptococcus pneumoniae , and enterococci. The animal models used for evaluation 
included murine sepsis and thigh infection.  
The therapeutic benefit of linezolid (comparator) for the treatment of ABSSSI has been 
established ( Zyvox® Prescribing Information, 201 8). Based on linezolid prescribing information, 
contezolid acefosamil, an oxazolidinone, is contraindicated in patients with known 
hypersensitivity to oxazolidinones and in patients taking any monoamine oxidase inhibitors 
(MAOIs) or within 2  weeks of taking an MAOI. Warnings and precautions in the label include 
the risks for myelosuppression, peripheral and optic neuropathy, serotonin syndrome, 
Clostridium difficile -associated diarrhea, potential drug interactions producing hypertension, and 
hypoglycemia. Further information is provided in the contezolid acefosamil IB and can also be 
obtained from the prescribing i nformation for linezolid ( Zyvox® Prescribing Information, 2018). 
Refer to the IB for additional information. 
The current study is a Phase 2, multicenter, randomized, double -blind study designed to evaluate 
the safety and efficacy of IV and PO administered contezolid acefosamil compared to linezolid 
(Zyvox®) in adult subject s with ABSSSI. The study design incorporate s recommendations from 
the US Food and Drug Administration 2013 Guidance for Industry (ABSSSI: Developing Drugs 
for Treatment) ( FDA, 2013). The primary efficacy endpoint of early  clinical response at early 
assessment aligns with the current FDA guidance. The secondary efficacy endpoint of the 
Investigator’s assessment of clinical response at PTE is based on current EU guidance ( EMA, 
2013). The safety parameters monitored during the study are well -accepted measures of safety in 
clinical study subjects . Contezolid acefosamil  PK concentrations will not be assessed in this 
study based  on Phase 1 study results indicating rapid conversion (within 0.25 hours) of 
contezolid acefosamil  to MRX -1352, an  intermediate metabolite of the prodrug, and subsequent 
conversion to active contezolid. Blood specimens will be collected to understa nd the PK 
performance of contezolid acefosamil  tablets used in this study population. The levels of the 
following contezolid acefosamil  metabolites will be assessed: MRX -1352, contezolid, and 
MRX-1320. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 33 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
2.8 Rationale for Dose Regimens  
The contezolid acefosamil dose regimen chosen for evaluation in this study is derived from 
3 lines of evidence:  
• From clinical PK/PD studies in the mouse thigh infection model.  
• From the Phase  1 studies in which administration of contezolid acefosamil was generally safe 
and well tole rated when administered to healthy volunteers at doses up to 2100 mg IV QD 
over 60 minutes for 10 days (MRX4 -002), and when contezolid acefosamil was administered 
at doses up to 1500 mg PO BID for 10  days (MRX4 -001).  
• Exposure of contezolid in blood after t hese respective doses was similar, the bioavailability 
of contezolid after contezolid acefosamil administered PO was approximately 66% of that 
after contezolid acefosamil administered via IV. And the exposure of 1000 mg of contezolid 
acefosamil IV q12h and 1300 mg contezolid acefosamil q12h by the PO route only slightly 
exceed the (contezolid) drug exposure when contezolid is given under optimal conditions. 
• From 2 Phase  2 studies which showed that contezolid dosed at 800 mg twice daily was 
non-inferior to l inezolid  600 mg given twice daily. 
The linezolid dose regimen is based on the  current prescribing information ( Zyvox® Prescribing 
Information, 2018).  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 34 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
3 STUDY DESIGN  
3.1 Study Objectives  
The objectives of this study are to compare contezolid acefosamil to linezol id in treating ABSSSI 
that is confirmed or suspected to be caused by Gram -positive pathogens.  
Primary : 
• Evaluate early clinical response of contezolid acefosamil compared to linezolid at early 
assessment (EA; 48 to 72 hours after the start of the first dose  of IV study drug)  in the intent -
to-treat (ITT) population  
• Evaluate safety and tolerability of both contezolid acefosamil IV and PO formulations 
compared with linezolid  
Secondary : 
• Evaluate early clinical response at:  
- EA in the MITT population 
- EA (overall and by baseline pathogen) in the microbiological intent -to-treat (micro -ITT) 
population 
• Evaluate percent reduction in lesion size from baseline in ABSSSI lesions at Day 7 in the 
ITT and modified intent -to-treat (MITT) populations  
• Evaluate the Investigator’ s assessment of clinical response in the ITT, MITT, and clinically 
evaluable (CE) populations at each timepoint:  
- End of therapy (EOT; last day of study drug) in the ITT, MITT, and CE -EOT populations  
- Post therapy evaluation (PTE; 7 to 14 days after the EOT)  in the ITT, MITT, and CE -
PTE populations  
- Late follow -up (LFU; 21 -28 days after EOT) in the ITT, MITT, and CE -PTE populations  
• Evaluate per -subject microbiological response at:  
- PTE in the micro -ITT population 
- PTE in ME population  
• Evaluate per -pathogen micro biological response at:  
- PTE in the micro -ITT population 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 35 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
- PTE in the ME population 
• Evaluate Investigator’s assessment of clinical response in the micro -ITT and ME populations 
at: 
- PTE (overall and by baseline pathogen)  
- LFU (overall and by baseline pathogen)  
• Characterize the PK of 3 contezolid acefosamil metabolites (MRX -1352, contezolid, and 
MRX -1320) using sparse PK sampling in adult subjects with ABSSSI  
• Evaluate composite assessment of clinical outcome (CACO) in the ITT, micro -ITT, and CE -
PTE populations  
3.2 Study Design  Details  
This is a Phase 2, multicenter, randomized, double -blind safety and efficacy study of contezolid 
acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV every 12 hours (q12h) (±  2 hours)  for 
at least 3  total IV doses , followed by 1 300 mg P O q12h (±  2 hours ) compared with linezolid 
600 mg IV q12h (±  2 hours)  for at least 3 total IV doses followed by 600 mg PO q12h 
(± 2 hours)  in adult  subject s with ABSSSI. Subjects will receive study drug for a total of 10 to 
14 days.  
Up to 200 subjects (133 contezolid acefosamil :  67 linezolid ) will be enrolled to achieve 
approximately 150 (100 contezolid acefosamil : 50 linezolid ) clinically evaluable subjects at 
approximately 5 to 10 sites with in the US  and randomized 2:1 ( contezolid acefosamil  : linezolid) 
for treatment of ABSSSI that is confirmed or suspected to be due to a Gram -positive bacterial 
pathogen. Randomization will be stratified by ABSSSI types to better ensure proper balance 
between the treatment groups.  Subject s will receive at leas t 3 doses  of the IV formulation of 
study drug  before switching to the PO formulation . Subject s will receive study drug 10  to 
14 days as described in Section  3.5. 
Screening/baseline assessments for study eligibility will be performed within 24 hours  prior to 
the start of the first dose of study drug. Subject s who provide informed consent , are willing and 
able to collaborate and cooperate with study protocol requirements, and meet all study eligibility 
criteria will be randomized in the study.  
Gram stain and culture specimens of the ABSSSI site must be collected from all subject s for 
micro biologic evaluation  at screening/baseline. ABSSSI site specimens (purulent discharge, skin 
biopsy, or aspiration at the leading edge of the cellulitic area) in addition to blood cultures from 
2 separate venipuncture sites, will be obtained from all subject s prior to administration of 
antibacterial therapy whenever possible. All ABSSSI site specimens will be processed for Gram 
stain and culture at the local laboratory, and all blood cultures will be processed at the local 
laboratory. All bacterial isolates that are identified from an ABSSSI site specimen or blood 
culture at the local laboratory will be sent to the central laboratory for confirmation of species 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 36 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
identification and antimicrobial susceptibility testing  (Section  8.2). Microbiological methods will 
be detailed in the Laboratory Manual.  
If Gram -positive and Gram -negative pathogens are suspected (Gram stain sug gests both a 
Gram -positive and Gram -negative pathogen) or proven from screening/baseline microbiologic 
laboratory results or history , the subject  will be eligible for treatment under this protocol. 
Subject s with both Gram -positive and Gram -negative pathoge ns will receive adjunctive 
antimicrobial therapy with parenteral aztreonam ( Section  5.1.3) . Subject s with only 
Gram -negative pathogens are not eligible for continued treatment under this protocol and will be 
discontinued from the study as soon as Gram stain or culture confirms that the subject ’s infection 
has no Gram -positive pathogen contributing to the subject ’s disea se. If no Gram -negative  
pathogens  are isolated from the screening/baseline cultures by Day  3, aztreonam will be 
discontinued. Subjects with suspected infections primarily due to anaerobic organisms as the 
cause for ABSSSI or subjects requiring empiric adju nctive anaerobic antimicrobial coverage are 
excluded from treatment under this protocol . 
Prompt enrollment procedures are encouraged to allow for prompt administration of study drug. 
Subject s who received prior systemic antibacterial therapy with Gram -positive activity within 
96 hours prior to randomization are excluded from the study unless clear clinical evidence of 
prior treatment failure within the prior 96  hours is available ( Section  4.2). However, one 
exception to this criterion is the receipt of a single dose of a short -acting, non- oxazolidinone 
antibiotic ( Section 5.2) . Subject s who received a single dose of a short -acting non- oxazolidinone 
Gram -positive antibiotic within 96  hours prior to randomization will not comprise >  25% of 
randomized subjects . 
It is expected that most subject s will remain in the hospital or clinic while receiving IV treatment 
with study drug for a minimum of 3  total IV doses ; however , subject s who are clinically stable 
and have adequate home support with reliable transportation to/fr om the hospital or clinic may 
leave and return to the hospital or clinic for  IV infusions. Study drug IV infusions are not to be 
administered at home. Subjects may receive the IV formulation for the entire treatment duration. 
If the  primary ABSSSI lesion has not increased in area from the screening/baseline assessment 
and the  Investigator determine s that the subject has  sufficient PO intake of food and drink to 
safely support the administration of PO doses of antibiotics, subjects ma y be switched to the PO 
formulation. Subjects who are switched from the IV to the PO formulation of study drug must 
remain in the hospital or clinic for observation for at least 90 minutes after the first PO dose . The 
subject may be discharged on PO medica tion only after good tolerability has been demonstrated 
with the initial dose of PO treatment ( Section  3.5).  
Subject s will undergo follow -up visits as described in Table 1 and Section  7. Subject s must be 
evaluated directly by an  Investigator  (i.e., return to clinic for required assessments if being 
managed in the outpatient setting) from screening/baseline  through PTE. If the subject  has 
improved to the point that they have returned to their usual premorbid activity (work/school) , 
and if the primary ABSSSI  site has  little or no pain, swelling, redness or purulent /seropurulent  
drainage  at the PTE visit, the LFU visit may be performed over the telephone  (Section  8.1). 
Additionally, documentation of the primary ABSSSI lesion by digital photography will occur at 
screening/baseline and at various timepoints during and after study treatment ( Section  8.3). 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 37 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
ABSSSI specimen G ram stain and cultures will be collected from the primary site of infection at 
each visit from EA  through LFU only if clinically indicated (e.g., the subject is deemed a cl inical 
failure  or relapse or purulence and discharge from the ABSSSI site continues after 
screening/baseline) . 
Subject s will be monitored for the occurrence of AEs throughout the study, including AEs that 
are associated with the oxazolidinone class of anti biotics. Physical examinations, vital signs, 
ECGs, and clinical laboratory tests ( hematology, chemistry , coagulation, and UA ) will be 
performed at screening/baseline and at various timepoints during and after study treatment 
(Table 1) . 
3.3 Number of Subject s 
Up to 200 (133 contezolid acefosamil :  67 linezolid ) adult subjects with ABSSSI will be enrolled 
in this study. Randomization will have a 2:1 (contezolid acefosamil: linezolid) allocation ratio 
with stratification for ABSSSI type.  
3.4 Randomization  & Blinding  
Efforts will be made to enroll a mixture of ABSSSI types (cellulitis/erysipelas, wound infection, 
and major cutaneous abscess); however, subjects with major cutaneous abscess should not 
comprise > 30% of randomized subjects . Additionally, subjects who rece ived a single dose of a 
short -acting non- oxazolidinone Gram -positive antibiotic within 96 hours prior to randomization 
will not comprise > 25% of randomized subjects . 
Subjects will be randomized to treatment provided they meet all inclusion and no exclusion 
criteria (see Section 4.1 and Section 4.2, respectively). Subject s will be randomized using an 
interactive web response system ( IWRS ) to contezolid acefosamil  or linezolid  with a 2:1 ratio . 
Randomization will be stratified by ABSSSI type  (cellulitis/erysipelas, wound infection, or 
major cutaneous abscess)  to better ensure proper balance between the treatment groups . After 
informed consent has been obtained and study eligibility established, the study site’s Pharmacist 
or Pharmacist’s desi gnee will obtain the study drug assignment from the IWRS . A subject  is 
considered randomized when the Pharmacist or Pharmacist’s designee receives the 
randomization number or study drug assignment . 
This is a double -blind study. Those blinded to study drug assignment include the Sponsor, 
Investigator, study statistician, clinical study personnel participating in direct subject  care, or 
those involved in clinical evaluations. Those unblinded to study drug assignment include the 
pharmacy personnel, the unblinded study monitor, and the bioanalytical laboratory. Blinded 
personnel must not make any effort to determine which study drug therapy is being administered. 
Blinded personnel will remain blinded to study drug assignment until all subject s have 
completed the  study and the database is locked. Procedures to ensure that the blind is maintained 
are detailed in the Study Procedures Manual.  
If study drug  is determined not to be safe and /or not  tolerated, the study drug assignment for 
those subject s with a significa nt safety concern may be unblinded. The Investigator and M edical 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 38 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Monitor will review the data, discuss the findings, and jointly decide to unblind the treatment 
assignment, continue enrollment, or terminate enrollment in the study.  
The blind may  also be broken i n the case of a medical emergency requiring the Investigator to 
know the identity of the study drug to appropriately guide the subject ’s medical management.  
Emergency unblinding should take place through the IWRS system for both IV and oral dos es, 
and both the Clinical Research Organization ( CRO ) and the Sponsor should be notified. Prior to 
any unblinding, the Investigator is strongly advised to discuss options with the Medical Monitor 
or appropriate Sponsor study personnel. If the blind is broken for any reason and the Investigator  
is unable to contact the Sponsor before unblinding, the Investigator must notify the Sponsor as 
soon as possible, without revealing the subject ’s study drug treatment assignment (unless 
important to the safety of subj ects remaining in the study) . All instances of unblinding  will be 
thoroughly investigated and documented by the unblinded study monitor . 
3.5 Study  Treatment  
Study treatments include contezolid acefosamil  and linezolid  administered  as IV infusions 
followed by P O dosing  as follows : 
• Contezolid acefosamil  1500 mg IV will be infused over 60 minutes (±  5 minutes) for  1 dose 
followed by at least 2 IV doses of  1000 mg IV infused over 60 minutes (±  5 minutes) q12h 
(± 2 hours) for at least 3 total IV doses , followed by contezolid acefosamil  1300 mg 
(2 capsules each with 650 mg of contezolid acefosamil) PO q12h (±  2 hours ), for a total of 
10 to 14 days of treatment . 
• Linezolid 600 mg IV will be infused over 60 minutes (±  5 minutes) q12h (±  2 hours) for at 
least 3 total IV doses , followed by linezolid 600 mg ( 2 capsules each of 300 mg linezolid) PO 
q12h (±  2 hours) , for a total of 10 to 14 days of treatment . 
Treatment with study drug will commence with the IV formulation as soon as possible aft er 
eligibility criteria are met . Treatment with the IV formulation will continue for at least 3 total IV 
doses , after which subject s may be switched to the PO formulation if the primary ABSSSI lesion 
has not increased in area from the baseline/screening assessment and the Investigator d etermines 
that the  subject has  sufficient PO intake of food and drink to safely support the administration of 
PO dos es of antibiotics ; however, subject s may receive the IV formulation for the entire 
treatment duration . It is expected that most subject s will remain in the hospital or clinic while 
receiving IV treatment with study drug for a minimum of 3  total IV doses ; however , subjects  
who are clinically stable and have adequate home support with reliable transportation to/from the 
hospital or clinic may  leave and  return to the hospital or clinic for IV infusions. Stu dy drug IV 
infusions are not to be administered at home. Subject s who are switched from the IV to the PO 
formulation of study drug must remain in the hospital or clinic for observation for at  least 90 
minutes after the first PO dose, and until the initial dose of the PO formulation is clearly 
tolerated  in the judg ment  of the Investigator . During outpatient management, subject s will record 
study drug dosing details on subject -specific drug acco untability logs.  
To maintain the study blind, both contezolid acefosamil  and linezolid PO  study drug will be 
encapsulated to approximate the same external appearance. Either  study drug product may be 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 39 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
taken with or without food. Subject s randomized to contezolid acefosamil  will receive 2 capsules 
(650 mg each) q12h (±  2 hours) , and subject s randomized to linezolid will receive  2 capsules 
(300 mg  each)  q12h (±  2 hours) . Additional treatment information is provided in Section  5. 
Subjects  are to  receive 10  to 14 calendar days of study drug. The duration of treatment within the 
specified window will be determined by the Investigator based on the subjec t’s clinical status 
(e.g., therapy can be discontinued if the subject  has improved, no more antibiotic treatment is 
medically necessary, and the risk of relapse is minimal).  
Prior to any premature discontinuation of study drug, the study site personnel should notify the 
Medical Monitor if the subject ’s medical condition allows (see Section  4.6 for follow -up of 
subject s who prematurely discontinue study drug or study).  
3.6 Duration  
Subject s will receive study drug for 10 to 14 days . Subject s will then be followed for up to 
28 days after the last calendar day of study drug. Ther efore, the total duration of each subject ’s 
participation in the study will be up to 42 days, excluding the screening/baseline  visit that occurs 
within 24 hours prior to the start of study drug administration on Day  1. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 40 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
4 SELECTION AND WITHDR AWAL OF SUBJECT S 
4.1 Inclusion Criteria  
Subjects  must meet the following inclusion criteria: 
1. Males or  females ≥  18 years  
2. Willing and able to p rovide written informed consent  
3. ABSSSI that is confirmed or suspected to be caused by a Gram-positive pathogen, which 
meets the following criteria: 
a. Infection of the skin with a lesion size area of at least 75  cm2, or infection of the central 
face with a lesion size area of at least 50  cm2; lesion size measured by the area of redness, 
edema, or induration using manual measurement of the longest length multiplied by the 
greatest perpendicular width 
b. One of the following infection types:  
▪ Cellulitis/erysipelas: A diffuse skin infection characterized by spreading areas of 
redness, edema, and/or induration 
▪ Wound infection: An infection characterized by purulent drainage from a wound with 
surrounding redness, edema, and/or induration, related to trauma or surgery that 
occurs within 30 days of trauma or surgery  
▪ Major cutaneous abscess: An infection characterized by a collection of pus within the 
dermis or deeper that is accompanied by redness, edema, and/or induration  
4. Clinical findings from both of the following categories  within 24 hours : 
a. At least 2 of the following local signs at the ABSSSI site:  
▪ Purulent or seropurulent  drainage/discharge  
▪ Erythema  
▪ Fluctuance  
▪ Heat/localized warmth  
▪ Pain/tenderness to palpation 
▪ Swelling/induration  
b. At least 1 of the following signs of systemic inflammation:  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 41 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
▪ Fever or hypothermia ( PO or rectal temperature ≥  38.0°C or ≤  36.0°C)  
▪ White blood cell  (WBC) count ≥  10,000/mm3 or ≤ 4,000/mm3 
▪ Immature neutrophils (bands) ≥  10%, irrespective of WBC count  
▪ Lymphadenopathy or lymphadenitis proximal to the ABSSSI site  
▪ C-reactive protein (CRP) > upper limit of normal  
5. Females must be either postmenopausal for ≥ 2 years or surgically sterile (having undergone 
tubal ligation, hysterectomy, or bilateral oophorectomy) or, if of childbearing potential, must 
have a negative pregnancy test result at screening /baseline and be willing to use a highly 
effective method of c ontraception throughout the study such as 1 of the following:  
▪ Hormonal contraception (stable dose for 3 months)  
▪ Intrauterine device/ intrauterine hormone -releasing system  
▪ Barrier contraceptive method (diaphragm, cervical cap, contraceptive sponge, 
condom)  
6. Males if sexually active and nonsterile with female partners of childbearing potential must 
use 2 methods of contraception (i.e., a barrier contraceptive such as condom with spermicidal 
foam) , and be willing to continue to use such highly effective  birth control measures while 
participating in the study and for 70 days following participation in the study. Males must 
also refrain from sperm donations during this time. 
4.2 Exclusion Criteria  
Subject s must NOT meet any of the following exclusion criteria: 
1. Prior receipt of any formulation of contezolid acefosamil  or contezolid. 
2. ABSSSI with any of the following characteristics:  
a. Known or suspected to involve  anaerobic organisms (e.g., perineal wound infection, 
gluteal decubitus ulcer, perianal abscess, wound i nfection associated with surgery on 
gastrointestinal tract or female genital tract)  
b. Known or suspected invasive infection due primarily to fungal, mycobacterial, parasitic, 
or viral pathogens  
c. Involving an ischemic ulcer due to peripheral vascular disease  
d. Involving a decubitus ulcer or perirectal abscess  
e. Involving a diabetic foot ulcer  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 42 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
f. Involving an infected burn  
g. Involving an underlying inflammatory skin disease that may obscure determination of 
response (e.g., chronic dermatitis) where inflammation may be pr ominent for an extended 
period of time, even after successful bacterial eradication has been achieved  
h. Involving pyoderma gangenosum  
i. Involving a bite from a human or animal other than an arthropod  
j. Involving a rapidly necrotizing process, such as necrotizing  fasciitis  
k. Involving gangrene of any etiology  
l. Complicated by an immune deficiency in the subject  (e.g., development of ecthyma 
gangrenosum, cellulitis , or wound in a neutropenic subject ) 
m. Anatomically associated with prosthetic materials (e.g., venous cathe ters, permanent 
cardiac pacemaker battery packs, or joint replacement prostheses), even if the device is 
removed  
n. An infection complicating an area of the body that will require amputation  
o. Requiring significant surgical intervention (i.e., procedures that w ould not normally be 
performed at the bedside) that cannot be performed within 72 hours , unless previously 
planned, after initiating study drug therapy.  
p. Estimated high cure rate after surgical incision alone or after aggressive local skin care 
(e.g., minor  cutaneous abscess or furuncle)  
q. Associated with infection at other anatomic sites or spaces, such as endocarditis or other 
endovascular infection, thrombophlebitis, osteomyelitis, or septic arthritis  
r. Anticipated need for antibacterial therapy for >  14 days  
3. Pre-existing ABSSSI known or suspected to be caused by pathogens that are resistant to 
oxazolidinone  antibiotics  
4. Inability to tolerate  a PO  study drug (e.g., nausea, vomiting, diarrhea, or any other condition 
that might impair ingestion or absorption of PO  study drug)  
5. Poor venous access  
6. History of any intolerance, hypersensitivity or allergic reaction to any oxazolidinone 
antibiotic  
7. History of any intolerance, hypersensitivity or allergic reaction to aztreonam; note that while 
cross -reactivity of aztreonam with other β -lactams is rare, this drug should be administered 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 43 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
with caution to any subject  with a history of hypersensitivity to β -lactams (e.g., penicillins, 
cephalosporins, and/or carbapenems)  
8. History of peripheral or optic neuropathy  
9. QTcF interval duration >  450 msec obtained as an average from the triplicate 
screening/baseline ECGs, history of QT prolongation, hypokalemia (serum potassium 
< 3.0 mEq/L) at screening/baseline, or other proarrhythmic conditions  
10. History of a known or suspected CNS  condition, such as hallucinations, depression, suicidal 
thoughts or suicidal acts, or of a CNS disorder that may predispose to seizures or l ower the 
seizure threshold 
11. History of known or suspected serotonin syndrome, neuroleptic malignant syndrome, or 
carcinoid syndrome  
12. Known or suspected pheochromocytoma or thyrotoxicosis or severe uncontrolled 
hypertension  
13. History of known or suspected Clost ridium difficile -associated diarrhea  
14. Evidence of significant hepatic, renal, hematologic, or immunologic disease as determined by 
the following:  
a. Total bilirubin >  2 times upper limit of normal ( x ULN)  
b. Alanine amino transferase ( ALT ) or aspartate amino tran sferase (AST)  > 3 x ULN  
c. Estimated or documented creatinine clearance (CrCl) of <  30 m L/min 
d. Manifestations of end- stage liver disease, such as ascites  or hepatic encephalopathy  
e. Current or anticipated as absolute neutrophils  < 1500 neutrophils/mm3 
f. Platelet count < 75,000 cells/mm3 
g. Infection with human immunodeficiency virus (HIV) and a known CD4 count 
< 200 cells/mm3, or another acquired immune deficiency syndrome (AIDS) -defining 
illness  
h. Receipt of cancer chemotherapy, radiotherapy, or potent, non- corticoste roid 
immunosuppressant drugs (e.g., cyclosporine, azathioprine, tacrolimus, 
immune -modulating monoclonal antibody therapy) within the past 3 months, or the 
receipt of corticosteroids ≥  10 mg of prednisone (or equivalent) per day for >  14 days in 
the prior 30 days  
15. Females who are pregnant or nursing 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 44 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
16. Prior administration of systemic antibacterial therapy  within 96 hours before randomization 
a. EXCEPTIONS: Subject s may be eligible  if they meet the following conditions:  
EITHER:  
▪ Received a single dose of a non -oxaz olidinone, short -acting, systemic antibiotic 
within 96 hours prior to randomization ( Appendix  1). Note that such subject s will not 
comprise >  25% of  randomized subjects  
OR BOTH OF THE FOLLOWING:  
▪ Objective clinical evidence of treatment failure ( persistent pain, erythema, induration, 
purulent drainage ) following at least 48  hours  of prior, non- study, systemic 
antibacterial therapy  
AND  
▪ Microbiological evidence of failure (i.e., a Gram stain obtained from an appropriate 
ABSSSI specimen collected after the initiation of this prior therapy revealing WBC 
and Gram -positive cocci, or isolation of a Gram -positive pathogen from an 
appropriate ABSSSI specimen that is resistant to the prior systemic antibacter ial 
therapy)  
17. Prior (within the past 2  weeks) administration of, or expected or required concomitant (from 
the start of the study drug to EOT) administration of: 
a. Systemic adrenergic, dopaminergic, or  serotonergic medications  (Appendix 3)  
b. Monoamine oxidase inhibitors (MAOIs) (e.g., isocarboxazid, isoniazid, nialamide, 
phenelzine, procarbazine, and hydracarbazine)  
18. Life expectancy < 3 months or evidence of immediately life -threatening disease, including, 
but not limited to, current or impending respiratory failure, shock, acute coronary syndrome, 
unstable arrhythmias, hypertensive emergency, acute hepatic failure, active gastrointestinal 
bleeding, profound metabolic, or acute cerebrovascular events  
19. Unable to cooperate fully with the requirements of the study protocol, including the schedule 
of assessments, or likely to be non- compliant with any study requirements, or the 
Investigator determines that the subject  should not participate in the study  
4.3 Subject  Withdrawal  from the Study  
Subject s should be encouraged to complete all study assessments. All subject s have the right to 
withdraw at any time during the study without prejudice . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 45 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
4.4 Replacement of Subject s 
None of the  subject s will be replaced  once they have been randomized. 
4.5 Study Termination by Sponsor and Termination Criteria  
The Sponsor re serves the right to terminate any investigational site or the  clinical study at any 
time. Reasons for termination may include, but are not limited to, the following:  
• Unacceptable safety and tolerability  
• The incidence or severity of AEs or SAEs in this study indicates a potential health hazard to 
subject s 
• Serious or persistent noncompliance by the Investigator  with the protocol, clinical research 
agreement , Good Clinical Practice ( GCP ), or applica ble regulatory gui delines in conducting 
the study  
• Institutional Review Board ( IRB) decision to terminate or suspend approval for the 
Investigator  
• Investigator  request  to withdraw from participation  
• Subject  enrollment is unsatisfactory  
4.6 Follow -up of Subject s Prematurely Discontinued from Study Drug or Withdrawn 
from Study  
Subjects who prematurely discontinue study drug will remain in the study. Efforts will be made 
to complete all protocol -specified assessments listed for the EOT visit at the time of study drug 
discontinuation (+ 1 day) ( Section  7.7), and to perform follow -up safety and outcome 
assessments specified for the PTE visit ( Section  7.8) and the LFU visit ( Section 7.9)  as 
scheduled. C omplete safety assessments at the EOT visit before beginning rescue therapy , as 
appropriate . Any ongoing AEs should be followed to resolution or to a satisfactory outcome, as 
determined by the Investigator.  
For subject s who withdraw or are withdrawn  from the study  itself , efforts will be made to 
complete all protocol -specified assessments listed for the EOT visit at the time of withdrawal 
(+ 1 day) (Section  7.7), as appropriate, and to perform follow -up safety assessments as specified 
for the PTE visit ( Section  7.8) and the LFU visit ( Section 7.9) as scheduled. C omplete the safety 
assessments at t he EOT visit before beginning rescue therapy , as appropriate . Any ongoing AEs 
should be followed to resolution or to a satisfactory outcome, as determined by the Investigator. 
Subject s who withdraw will not be replaced.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 46 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
5 TREATMENT OF SUBJECT S 
5.1 Study Drug  
5.1.1 Contezolid Acefosamil Study Drug  
Contezolid acefosamil  study drug will be supplied as  lyophilized powder for reconstitution as an 
IV formulation and  an immediate release oral formulation. The clinical label will identif y the 
product by name, lot number, S ponsor, storage conditions, and expiry date. Administration of the 
study drug is limited for investigational use only. Refer to the Pharmacy Manual for additional 
information. 
5.1.1.1 Contezolid Acefosamil for Intravenous Administration 
Contezolid acefosamil drug product will be supplied in 20 ml vials containing 1000 mg, of 
contezolid acefosamil, 24.53 mg of sodium citrate dihydrate, and 9.60 mg of citrate is produced 
by filter sterilization and lyophilization. The drug product was produ ced for the S ponsor by 
Lyophilization Services of New England.  
The drug product powder is to be reconstituted in 300 mL of 5% dextrose in water (D5W) or 
normal saline (NS) for intravenous administration. The first IV dose of contezolid acefosamil 
will be 1500 mg, and all subsequent IV doses will be 1000 mg each. The contezolid acefosamil 
solution in either a diethylhexyl phthalate ( DEHP ) containing or non -DEHP containing IV bag is 
stable for up to 16 hours at 25ºC  (77ºF) , and stable for up to 48 hours at 4º C (39.2ºF) . To ensure 
long term stability of the drug product, the lyophilized vials will be maintained at - 20ºC at the 
investigative site until it is to be reconstituted for use in the clinic.  
An unblinded pharmacist will prepare and blind the contezolid acefosamil IV infusion and will 
be unblinded to the  subject’s assigned treatment; however, all other staff will be blinded to the 
subject’s treatment.  Please refer to the Pharmacy Manual for details on dose preparation and 
administration.  
5.1.1.2 Contezolid Acefosamil for Oral Administration  
Contezolid acefosamil  for PO administration is an immediate -release tablet containing  650 mg 
contezolid acefosamil . To maintain the study blind, contezolid acefosamil  tablets will be 
over-encapsulated to approxim ate the same external appearance as linezolid study drug.  All PO 
doses of contezolid acefosamil will be 1300 mg (2 capsules). Contezolid acefosamil capsules 
will be included as part of a blinded kit to ensure  all study staff will be blinded to the subject’ s 
treatment.  
5.1.2 Linezolid  Study Drug  
Linezolid (Zyvox®) is an FDA -approved commercially available product and will be supplied as 
IV and PO formulations. The clinical label will identify the product by name, lot number, 
Sponsor, storage conditions, and expiry  date. Refer to the Pharmacy Manual for additional 
information. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 47 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
5.1.2.1 Linezolid for Intravenous Administration  
Linezolid for IV administration will be provided as 300 mL (600 mg linezolid) single -use, ready  
to use flexible plastic infusion bags  in a foil laminate overwrap . All IV doses of linezolid will be 
600 mg. Please refer to the Pharmacy Manual for details on dose preparation and administration. 
The unblinded pharmacist will prepare and blind the linezolid IV infusion and will be unblinded 
to the  subject’s assigned treatment; however, all other staff will be blinded to the subject’s 
treatment.  
5.1.2.2 Linezolid for Oral Administration  
Linezolid for PO administration will be provided as 300 mg capsules. To maintain the study 
blind, linezolid capsules will approximate the same external appearance as contezolid acefosamil  
study drug. All PO doses of linezolid will be 600 mg (2 capsules). Cap sules containing linezolid 
will be included as part of a blinded kit to ensure  all study staff will be blinded to the subject’ s 
treatment.  
5.1.3 Adjunctive Therapy 
Linezolid ha s no useful antimicrobial activity against G ram-negative pathogens and is not 
indicated for the treatment of G ram-negative infections; it is critical that specific G ram-negative 
therapy with aztreonam be initiated immediately if a concomitant G ram-negative pathogen is 
documented or  suspected . The PK of linezolid and  aztreonam are not altered when co -
administered  (Zyvox® Prescribing Information , 2018).  
According to standard of care treatment guidelines, s ubject s will receive adjunctive antimicrobial 
therapy with parenteral  aztreonam (1  to 2 g IV / intramuscular ( IM) q8h, not to exceed 6 g/day) 
for confirmed or suspected aerobic G ram-negative pathogens as causes of the ABSSSI in 
addition to G ram-positive pathogens. Outpatients may receive either IM or IV aztreonam at the 
Investigator's discretion  (e.g., IV aztreonam may be administered as outpatient parenteral 
antibiotic therapy  in an infusion center ). If no Gram -negative pathogen  is isolated from the 
screening/basel ine cultures by Day 3, aztreonam is to be discontinued. 
Parenteral aztreonam will be provided by the study sites and should be prepared and 
administered in accordance with current FDA label information ( Azactam® Package Insert, 
2013).  
5.1.4 Dose Adjustment  
No adjustments to study drug doses or frequencies are allowed.  
5.1.5 Study Drug Compliance  
Each dose of IV study drug will be administered by study staff , who are oriented to the details of 
the clinical protocol  and under direct supervision by the Investigator.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 48 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
The following study drug compliance information will be documented as study i nformation and 
reported in the  electronic case report form ( eCRF ): 
• The dates and times of administration of each IV study drug  infusion.  
• For IV infusion, the infusion start and stop times  will be recorded , and specify if the total 
volume of study drug solution was administered (if infusion is halted or interrupted for any 
reason, record the time of premature discontinuation and re -initiation of infusion) . An 
unblinded member of the st udy staff will inspect t he infusion line and bag at the end of 
infusion to confirm that the full dose has been infused, followed by a rapid IV push to clear 
any residual study drug in the line. Infusion bags will be retained by the pharmacy for drug 
accountability purposes until after the s tudy close -out monitoring visit by the unblinded 
monitor. 
• The total volume infused for IV infusion, and number of capsules  administered for PO 
administration . 
For a ny infusion that is incomplete or otherwise not adm inistered over 60 minute s (± 5 minutes) , 
the actual volume infused, infusion duration, and conditions or complications that prevented 
complete and/or timely administration must be documented.  In any case, study site personnel 
should strive to administer the entire dose regardless of the inter -current problems of  drug  
administration . 
Recording of the date and whether each dose of study drug was administered will be used to 
document compliance with the assigned dosing regimen for oral drug . Subject s managed as 
outpatients will be given diaries to log times and dates of study drug administration; this 
information will be entered in the eCRF.  The determination of blood concentrations of 
contezolid acefosamil  (and metabolites) during the analytical phase will serve as a further check 
of compliance.  
5.1.6 Study Drug Storage  
Unused study drug supplies should be stored according to the directions on the study drug labels. 
• Contezolid acefosamil : Lyophilized contezolid acefosamil  (for IV formulation) must be 
stored in a secure area (e.g., a locked freezer), protected from moisture, and kept at or below 
-20°C until the time of preparation for study drug administration. Once reconstituted with 
D5W  or NS , the solution is st able in either a DEHP  containing or non- DEHP containing IV 
bag for up to 16 hours at 25ºC (77ºF), and stable for up to 48 hours at 4ºC (39.2ºF) . 
Contezolid acefosamil  capsules ( over-encapsulated tablets ) must be stored at 2 to 8ºC  
(35.6 to 46.4ºF)  at the s tudy site but can be stored at 20 to 25ºC (68 to 77ºF) after dispensing 
to the study subject  for up to 7 days . 
• Linezol id: Store infusion bags at 20 to 25ºC (68 to 77ºF)  and p rotect from light. It is 
recommended that the infusion bags be kept in the overwrap until ready to use. Each 
overwrap contains a peel -off label. Apply the peel -off label to the infusion bag for barcode 
scanning before use. Protect infusion bags from freezing ( Zyvox® Prescribing Information, 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 49 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
2018).  For lin ezolid capsules, please refer to storage instructions for contezolid acefosamil 
capsules . Keep bottles tightly closed to protect from moisture.  
Refer to the Pharmacy Manual for any additional storage, handling, or updated stability data of 
the study drug s upplies . 
5.1.7 Study Drug Accountability  
All supplies of contezolid acefosamil  and linezolid  required for completion of this study will be 
provided by the Sponsor.  Adjunctive therapy with aztreo nam will be supplied by the study sites.  
The unblinded pharmacy pers onnel are responsible for ensuring that a current record of 
inventory and drug accountability is maintained during study conduct . A specifically designated 
unblinded study monitor or designee will be responsible for drug accountability at the site. The 
Investigator is ultimately responsible for ensuring that a current record of inventory/drug 
accountability is maintained. Inventory and accountability records must be readily available for 
inspection by the Sponsor or designee, or applicable  regulatory author ities at any time.  
Each shipment of study drug will contain a packing slip or equivalent to assist in maintaining 
current and accurate inventory records. Upon receipt of the study drug, the unblinded pharmacy 
personnel will visually inspect the shipment an d verify the number and condition of  study drug 
(vials , infusion bags, capsules ) received. Refer to the Pharmacy Manual for additional 
information. 
Sites  will be provided with subject -specific drug accountability logs and  subjects  will be 
instructed to maintain a diary of their drug dosing during outpatient management  throughout the 
treatment period . 
5.1.8 Study Drug Handling and Disposal  
Only upon written authorization from MicuRx  or its representative, all partially used study drug 
must be destroyed at the investigative site or at another s ite designated by the Sponsor. 
Unopened drug kits will be destroyed at a site designated by the Sponsor. The Investigator is 
responsible for ensuring that MicuRx , or its representative, has provided w ritten authorization 
that procedures for proper disposal of the study drug have been established, and that appropriate 
records of the disposal are documented and maintained.  
5.2 Prior & Concomitant Therapy  
All prescription medications and  over -the-counter medi cations, including  herbal, nutritional, and 
dietary supplements ( e.g., any antacid, iron supplement, or multivitamin) administered within 
2 weeks ( 14 days ) prior to randomization and during the study  between Day  1 and EOT will be  
documented in the eCRF.  Only concomitant antimicrobial agents and concomitant medications 
taken for an AE between EOT and LFU will be documented. Any changes in prior or 
concomitant medications will also be recorded.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 50 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Subject s who have received prior systemic antibacterial therapy within 96  hours  prior to 
randomization are general ly excluded from the study; however, exceptions  to this criterion 
include : 
• Receipt of a short -acting, systemic, non- oxazolidinone antibiotic and  
• Clear failure of an alt ernative course of prior antibiotic therapy ( Section  4.2, Appendix  1). 
In addition, the following medications are not allowed from 2 weeks prior to administration of 
study drug through EOT (Section  4.2): 
• Systemic  adrenergic, dopaminergic, or serotonergic medications ( Appendix 3)  
• Any MAOI ( e.g., isocarboxazid, isoniazid, nialamide, phenelzine, procarbazine, and 
hydracarbazine)  
Concomitant topical or systemic antibacterial therapy, other than study drug and adjunctive 
parenteral aztreonam, is not allowed between screening/baseline and PTE (unless the subject  is a 
clinical failure) . 
The following additional adjunctive therapy is a llowed, as clinically indicated:  
• Daily dressing changes  
• Topical solutions including nonspecific antimicrobial  solutions  (e.g., povidone -iodine); 
however, topical therapy with specific antibacterial activity is not allowed (e.g., mupirocin, 
retapamulin, fus idic acid)  
• Surgical debridement  
• Hyperbaric oxygen treatments  
• Surgical interventions ( i.e., incision and drainage, aspiration puncture, or excision with or 
without grafting) planned at the initiation of treatment through 72 hours after the start of 
dosing 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 51 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
6 SUBJECT  RESTRICTIONS  
Subject s are required to:  
• Avoid taking any of the following concomitant medications between  Day 1 (first  
administration of study drug)  and EOT  (last calendar day of study drug ). 
○ Any adrenergic, dopaminergic, or serotonergic medication, including selective serotonin 
reuptake inhibitors ( SSRIs ) or tricyclic antidepressants  (Appendix 3) . 
○ Any MAOI ( e.g., isocarboxazid, isoniazid, nialamide, phenelzine, procarbazine, and 
hydracarbazine) . 
○ Any non -study systemic antibiotic  or topical antimicrobial therapy with specific 
antibacterial activity (e.g., topical mupirocin, retapamulin, or fusidic acid); note that the  
use of topical solutions including nonspecific antimicrobial solutions  (e.g., povidone -
iodine) are allowed . 
○ Note : While hypoglycemic medications are not contraindicated, such agents (e.g., insulin 
or PO  hypoglycemic) should be used with caution. Postmarketing cases of  symptomatic 
hypoglycemia have been reported in subject s with diab etes mellitus receiving 
hypoglycemic age nts when treated with linezolid. While a causal relationship  between 
linezolid (or other oxazolidinones) and hypoglycemia has not been established, diabetic 
subject s should be cautioned of potential hypoglycemic  reactions when treated with study 
drug. If hypoglycemia occurs, a decrease in the dose the  hypoglycemic agent, or 
discontinuation of the hypoglycemic agent  and/or study drug  may be required.  
• Avoid consumption of large amounts of foods or beverages with high -tyramine content, 
including those foods that have been processed by aging, fermentation, pickling , or smoking 
to improve flavor (e.g., aged cheeses, fermented or air -dried meats, s auerkraut, soy sauce, tap 
beers ) from Day  1 to EOT; see Appendix 2 for a detailed list. 
• Females must be either postmenopausal for ≥2 years or surgically sterile (having undergone 
tubal ligation, hysterectomy, or bilateral oophorectomy) or, if of childbearing potential, must 
have a negative serum or urine pregnancy test (β -HCG) at screening/baseline and be willing 
to use a highly effective method of contraception throughout the study such as 1 of the 
following:  
○ Hormonal contraception (stable dose for 3 months)  
○ Intrauterine device/ intrauterine hormone -releasing s ystem  
○ Barrier contraceptive method (diaphragm, cervical cap, contraceptive sponge, condom)  
• Males (if sexually active and nonsterile) with female partners of childbearing potential must 
use 2 methods of contraception ( i.e., a barrier contraceptive such as condom with spermicidal 
foam) and be willing to continue to use these same birth control measures while participating 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 52 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
in the study (and for 70 days following participation in the study). Males must also refrain 
from sp erm donations during this time . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 53 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
7 STUDY PROCEDURES  
The schedule of events is provided in Table 1.  
• Written informed consent must be obtained prior to initiating any study assessment or 
procedure.  
• It is expected that most subject s will remain in the hospital or clinic while receiving IV study 
drug for a minimum 3  infusions ; however , subject s who are clinically stable and have 
adequate home support with reliable transportation to/from the hospital or clinic may leave 
and return to the hospital or clinic for IV infusions. Study drug IV infusi ons are not to be 
administered at home. Subject s who are switched to the PO formulation of study drug must 
remain in the hospital or clinic for observation for  at least 90 minutes after the first PO dose, 
and until the initial dose(s) of the PO formulation  are clearly tolerated  in the judgment of the 
Investigator  (Section  3.5).  
• All assessments and  procedures on dosing days are obtained pre dose, unless otherwise 
specified . 
• After screening/baseline, microbiological assessments (ABSSSI site and/or blood cultures) 
should be repeated only if clinically indicated ( e.g., if a subject is deemed a clinical failure or 
if purulence and discharge from the ABSSSI site continues after screening/baseline).  
• Refer to Section 4.6 for follow -up of subject s who prematurely discontinue study drug or the 
study.  
7.1 Screening /Baseline  
Study eligibility  must be confirmed within 24 hours  prior to the first administration of stud y 
drug. The following screening /baseline  assessments and procedures will be performed ≤24 hours 
of first dose  (see Table 1 for those assessments that need to be repeated predose on Day 1 if the 
first dose of study drug is administered > 24 hours after the screening/baseline assessments) : 
• Obtain written informed c onsent prior to initiating any study -related assessment or procedure  
• Obtain complete medical  and surgical  history  
• Obtain prior and concomitant medication history . Record all prior medications taken within 2 
weeks prior to randomization ( Section  5.2). 
• Perform ABSSSI clinical assessments:  
○ Perform primary ABSSSI site measurement and a  direct evaluation of signs and 
symptoms of ABSSSI  (Section  8.1, Appendix  5, Appendix  6). 
○ Perform digital photography of the primary ABSSSI lesion wi th a digital camera 
provided by the Sponsor ( Section  8.3, Appendix 7).  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 54 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Perform a complete physical examination (i.e., general appearance, head, ears, eyes  
[including basic Snellen visual acuity and visual field testing] , nose, throat, dentition, 
thyroid, chest [heart, lungs], abdomen, skin/soft tissues , neurological, extremities, back, 
neck, musculoskeletal, lymph nodes). 
• Record vital signs (heart rate, blood pressure, respiratory rate, and temperature). If 
> 1 temperature is measured within a calendar day, record the highest daily temperature 
measured. Vital signs will be collected prior to collection of blood laboratory samples. Oral 
or rectal temperatures are acceptable; the site of measurement will be collected in the eCRF . 
• Record height and weight . 
• Obtain triplicate 12 -lead ECG recordings within a 15- minute period, each separated by at 
least one minute. The ECG recordi ngs will be obtained prior to collection of blood laboratory 
samples.  All ECGs will be performed using the ECG machines provided by eResearch 
Technologies (eRT)  and will be sent to eRT for central reading . 
• Assess, identify, and record any AEs or SAEs from the time the informed consent is signed.  
• Perform microbiological assessments  (see Section  8.2); additional microbiological specimen 
collection and processing details are available in the Laboratory Manual:  
○ Obtain appropriate ABSSSI site specimen for bacterial culture and Gram stain from all 
subjects  and refer the specimens for Gram stain and culture to the local laboratory for 
processing. The ABSSSI site specimen should be obtained before administration of 
antibacterial therapy whenever possible. Repeat ABSSSI specimen cultures and Gram 
stain at subsequent visits only if clinically indicated ( e.g., if subject is deemed a clinical 
failure or purulence and discharge at the ABSSSI site continues after screening/baseline ). 
○ Obtain 2 sets of blood cultures (each consisting of 1 aerobic and 1  anaerobic blood 
culture bottle from 2  separate venipuncture sites) from all subject s. The blood cultures 
should be obt ained before administration of antibacterial therapy, whenever possible. 
Blood cultures must be repeated every 3 days (±  1 day) if the previous blood culture was 
positive, or at any time after screening/baseline if clinically indicated. If the repeat blood 
culture remains positive with the bacterial pathogen initially isolated , the Investigator 
must consider modifying the subject ’s antibiotic therapy  and discuss the case with the 
Medical Monitor . 
• Record if the subject ’s premorbid activities (work/school) are compromised  
• Obtain samples for laboratory assessments (see Appendix 4 for specific tests ). Laboratory 
samples for screening/baseline will be drawn and sent to both the local laboratory (for 
eligibility) and to the  central laboratory.  
○ Obtain blood samples for hematology, chemistry , CRP , serology, and coagulation tests . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 55 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
○ Obtain urine sample for UA ( includes urine microscopy if UA is positive for RBCs, 
WBCs, or protein) . 
○ Perform serum or urine β -HCG pregnancy test for females of childbearing  potential up to 
2 years postmenopause . (Alternatively, females must be surgically sterile, i.e. , have had a  
tubal ligation, hysterectomy, or bilateral oophorectomy.)  
○ Obtain the subject’s estimated CrCl. T he subje ct’s estimated CrCl will be calculated by 
the local laboratory (for eligibility purposes) using screening/baseline height (m), actual 
weight (kg), and serum creatinine:  
Males:  
CrCl =  (140 – age in years) × weight (kg)  
 72 × serum creatinine (mg/dL)  
 
Females:  
CrCl =  (140 – age in years) × weight (kg) × 0.85  
 72 × serum creatinine (mg/dL)  
• Verify that the subject  meets all inclusion criteria (Section   4.1) and none of the exclusion 
criteria ( Section  4.2).  
7.2 Day 1 
Day 1 is the first day of  study drug administration; subsequent study days are consecutive 
calendar days. Select screening/baseline assessments need to be repeated on Day 1 (predose) if 
the screening /baseline  assessments occurred  > 24 hours before the first dose of study drug  is 
administered (see Table 1). Eligible subjects are randomized on Day 1. It is expected  that most 
subjects will remain in the hospital or clinic while receiving the IV formulation of study drug  for 
a minimum of 3 IV dos es; however, subjects who are clinically stable and have adequate home 
support may leave and return to the hospital or clinic for IV infusions. Study drug IV infusions 
are not to be administered at home ( Section  3.5).  
The following will be performed  on Day 1 : 
• Verify the subject  meets all inclusion criteria and exclusion criteria before randomization 
(Section 4.1 and Section 4.2, respectively ). 
• Randomize the subject to treatment.  
• IV study drug  will be administered  q12h ( ± 2 hour ) as described in Section 3.5. 
• A PK sample will be collected from those who elect to participate in the PK portion of the 
study  between 0.5 and 2 hours  after the 1st IV dose, as outlined in S ection 11.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 56 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Obtai n triplicate 12 -lead ECG recordings within a 15- minute period, each separated by at 
least one minute, within 1 hour prior to the start of IV infusion and 2 hours after the 
completion of the IV infusion. The ECG recordings will be obtained prior to collecti on of 
any blood laboratory samples. 
• Assess, identify, and record any AEs or SAEs.  
Refer to Section 4.6 for follow -up of subject s who prematurely discontinue  study drug or the 
study.  
7.3 Day 2 
On Day  2, subject s continue to receive the IV formulation of study drug to complete  at least  a 
total of  3 infusions . Subject s who are switched from the IV to the PO formulation of study drug 
must remain in the hospital or clinic for observation for at least 90 minutes after the first PO 
dose, and until the initial dos e of the PO formulation is clearly tolerated  in the judgment of the 
Investigator  (Section  3.5). 
No specific assessments or procedures are scheduled on Day  2 except PK samples  at select sites:  
• Obtain specimen for PK assessments at specified sites for selected subjects:  
○ Obtain a  1st blood sample (trough level) within 2 hours before  the 3 rd IV dose, a 2nd 
blood sample between 0.5 and 3 hours after  the end  of the 3rd  IV dose , and a 3rd blood 
sample between 4 and 11 hours after the end of the 3rd IV dose  but before the 4th dose of 
study drug (IV or PO).  
In-person evaluation by the Investigator is not required unless clinically indicated (e.g., perform 
microbiological assessments, including ABSSSI  site specimen and blood cultures, only if 
clinically indicated  [e.g., if study drug is prematurely withdrawn for insufficient therapeutic 
effect] ). Subject s continue to receive blinded study drug  q12h (±  2 hours)  and any new 
concomitant medication s and AEs or SAEs are recorded.  
Refer to Section 4.6 for follow -up of subject s who prematurely discontinue study drug or the 
study.  
7.4 Early Assessment  
Perform EA assessments 48 to 72 hours after the start of the first dose of IV study drug . Clinical 
assessments of ABSSSI from this visit will be used to programmatically determine the clinical 
response based on data recorded on the eCRF  (Section  9.1.1).  If the subject  is receiving 
adjunctive antimicrobial therapy with aztreonam and no Gram -negative pathogen is isolated 
from the screening/baseline cultures by Day  3, aztreonam should be discontinued ( Section  5.1.3) . 
The following will be performed:  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 57 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Record any new concomitant medications ; veri fy the subject  is not taking any restricted 
medications ( Section 6).  
• Perform ABSSSI clinical assessments:  
○ Perform primary ABSSSI site measurement and a direct evaluation of signs and 
symptoms of ABSSSI ( Section  8.1, Appendix  5, Appendix  6). 
○ Perform digital photography of the primary ABSSSI lesion with a digital camera 
provided by the Sponsor ( Section  8.3, Appendix 7).  
• Perform a limited , symptom directed physical examination  as clinically indicated . 
• Record vital signs (heart rate, blood pressure, respiratory rate, and temperature) as described 
in Section  7.1. 
• Obtain triplicate 12 -lead ECG recordings within a 15- minute period, each separated by at 
least one minute, prior to collection of laboratory ( including PK) blood samples. Time of 
prior dose of study drug  and relationship of time of ECG to dose  must be documented.  
• Assess, identify, and record any AEs or SAEs . 
• Perform microbiological assessments as described in Section 7.1 and Section  8.2, including 
ABSSSI site specimen ( if clinically indicated ) and blood cultures  (if previous blood culture 
was positive or  if clinically indicated ). 
• Obtain samples for laboratory assessments after a minimum 8 -hour fast ( Appendix 4):  
○ Obtain blood samples for hematology, chemistry, CRP,  and coagulation tests . 
○ Obtain urine sample for UA ( includes urine microscopy if UA is positive for RBCs, 
WBCs, or protein).  
• Continue study drug administration q12h (±  2 hours) . If the subje ct received optional 
adjunctive parenteral aztreonam and no G ram-negative pathogen was isolated from ABSSSI 
site specimen culture or blood culture by Day  3, aztreonam must be discontinued 
(Section  5.1.3) . 
Refer to Section 4.6 for follow -up of subject s who prematurely discontinue study  drug or the 
study.  
7.5 Early Assessment to Day 6 
No specific assessments or procedures are scheduled between EA and  Day  6. In-person 
evaluation by the Investigator need not occur unless clinically indicated . Examples include : 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 58 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Clinically indicated microbiological assessments as described in Section 7.1 and Section  8.2, 
including ABSSSI site specimen ( if clinically indicated ) and blood cultures (if previous 
blood culture was positive or if clinically indicated). 
• Investigator has determined that the subject  may be switc hed from the IV formulation of 
study drug to the PO formulation . 
Record any new concomitant medications and record any AEs or SAEs if the subject  is seen 
during an unscheduled visit.  
Refer to Section 4.6 for follow -up of subject s who prematurely discontinue study drug or the 
study.  
7.6 Day 7 
The subject  will be seen on Day  7 (±  1 day) primarily for safety assessments and to evaluate for 
signs and symptoms of ABSSSI. The following will be performed:  
• Record any new concomitant medications; verify the subject  is not taking any restricted 
medications ( Section 6) . 
• Perform ABSSSI clinical assessments:  
○ Perform primary ABSSSI site measurement and a direct evaluation of signs and 
symptoms of ABSSSI  (Section  8.1, Appendix  5, Appendix  6). 
○ Perform digital photography of the primary ABSSSI lesion with a digital camera 
provided by the Sponsor ( Section  8.3, Appendix 7).  
• Perform a limited , symptom directed physical examination as clinically indicated.  
• Record vital s igns (heart rate, blood pressure, respiratory rate, and temperature) as described 
in Section 7.1. 
• Assess, identify, and record any AEs or SAEs.  
• Perform microbiological assessments as described in Section 7.1 and  Section  8.2, including 
ABSSSI site specimen ( if clinically indicated ) and blood cultures (if previous blood culture  
was positive or if clinically indicated ). 
• Obtain samples for laboratory assessments after a minimum 8 -hour fast ( Appendix 4):  
○ Obtain blood samples for hematology, chemistry, CRP, and coagulation tests . 
○ Obtain urine s ample for UA ( includes urine microscopy if UA is positive for RBCs, 
WBCs, or protein).  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 59 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Continue study drug administration q12h (±  2 hours ) 
Refer to Section 4.6 for follow -up of subject s who prematurely discontinue study drug or the 
study.  
7.7 End of Therapy  
Perform EOT assessments on the last  calendar day of study drug administration  (or the next day). 
The EOT visit will alternatively be performed for subject s who withdraw from study drug 
treatment ( Section  4.6). 
Subject s will receive study drug for 10 to 14 days as described in Section  3.5. If a subject  
requires a longer course of therapy for any reason (e.g., unresolved ABSSSI, S. aureus  
bacteremia, deep -seated abscesses [e.g., p soas abscess, epidural abscess], osteomyelitis, 
endocarditis), the subject  will be deemed a clinical failure and open -label antimicrobial(s) should 
be started , at the discretion of the Investigator. Such cases must  be discussed with the Medical 
Monitor. 
The following will be performed:  
• Record any new concomitant medications; verify the subject  is not taking any restricted 
medications  (Section 6) . 
• Perform ABSSSI clinical assessments:  
○ Perform ABSSSI site measurement and a direct evaluation of signs and symptoms of 
ABSSSI  (Section  8.1, Appendix  5, Appendix  6). 
○ Perform digital photography of the primary ABSSSI lesion with a digital camera 
provided by the Sponsor ( Section  8.3, Appendix 7).  
○ Perform Investigator’s assessment of clinical response  (Section  9.1.2) . 
• Perform a complete physical examination , including eye examination [i.e., Snellen visual 
acuity and visual field testing] as described in  Section  7.1. 
• Record vital signs (heart rate, blood pressure, respiratory rate, and temperature)  as described 
in Section  7.1. 
• Obtain triplicate 12 -lead ECG recordings within a 15- minute period, each separated by at 
least one minute. The ECG recordings will be obtained prior to collection of blood laboratory 
(including PK) samples. Time of prior dose of study drug  and relationship of time of ECG to 
dose must be documented. 
• Assess, identify, and record any AEs or SAEs.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 60 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Record the date the subject returned to premorbid level of activity (work/school), as 
applicable.  
• Perform microbiological assessments as described in Section 7.1 and Section  8.2, including 
ABSSSI site specimen (if clinically indicated ) and blood cultures ( if previous blood culture 
was positive  or clinically indicated ). 
• Obtain samples for laboratory assessments after a minimum 8 -hour fast ( Appendix 4):  
○ Obtain blood samples for hematology, chemistry, CRP, and coagulation tests . 
○ Obtain urine sample for UA ( includes urine microscopy if UA is positive for RBCs, 
WBCs, or protein).  
○ Obtain blood or urine sample for β -HCG pregnancy test (females of childbearing  
potential up to 2 years post menopaus e). (Alternatively, f emales  must be surgically sterile; 
i.e., have had a tubal ligation, hysterectomy, or bilateral oophorectomy.)  
• Obtain specimen for PK assessments  at specified sites for  selected subjects : 
○ Obtain one blood sample ( trough level ) within 2 hours before  the last  dose  (IV or PO ).  If 
the last dose is given PO: obtain 1 blood sample between 1.5 to 4 hours after the last 
dose, and obtain 1 additional sample between 5 to 12 hours after the last dose.  If the last 
dose is given IV: obtain 1 blood sample between 0.5 and 3 hours after the end of the last 
infusion, and obtain 1 additional sample between 4 and 11 hours after the end of the last 
infusion ( Section  11). 
Refer to Section 4.6 for follow -up of subject s who prematurely discontinue study  drug or the 
study.  
7.8 Post Therapy E valuation  
Perform PTE assessments 7  to 14 days after EOT . The following will be performed:  
• Record any new concomitant medications (antimicrobial agents only) . 
• Perform clinical assessments:  
○ Perform a direct evaluation of signs and symptoms of ABSSSI  (Section  8.1, Appendix  5, 
Appendix  6). 
○ Perform Investigator’ s assessment of clinical response ( Section  9.1.2) . 
• Perform a limited , symptom directed physical examination as clinically indicated.  
• Record vital signs (heart rate, blood pressure, respiratory rate, and temperature) as described 
in Section  7.1. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 61 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Obtain triplicate 12 -lead ECG recordings within a 15 -minute period, each separated by at 
least one minute. The ECG recordings will be obtained prior to collection of blood laboratory 
samples.  
• Assess, identify, and record any AEs or SAEs.  
• Record the date the subject  returned to premorbid level of activit y (work /school ), as 
applicable.  
• Perform microbiological assessments as described in Section 7.1 and Section 8.2 including 
ABSSSI site specimen (if clinically indicated ) and blood cultures  (if previous blood culture 
was positive , or if clinically indicated).  
• Obtain samples for laboratory assessments after a minimum 8 -hour fast ( Appendix 4):  
○ Obtain blood samples for hematology, chemistry, CRP, and coagulation tests . 
○ Obtain urine sample for UA (urine microscopy if UA is positive for RBCs, WBCs, or 
protein).  
Refer to Section 4.6 for follow -up of subject s who prematurely discontinue from the study.  
7.9 Late Follow -up 
The LFU assessment, designed to provide an assessment of durability of response , is performed 
21 to  28 day s after EOT . If the subject  has improved to the point that they have returned to their 
usual premorbid activity (work/school) , and if the primary ABSSSI site had little or no pain, 
swelling, redness , or purulent/seropurulent drainage  at the PTE visit, then the LFU visit  may be 
performed over the telephone. Symptoms related to possible relapse of ABSSSI (primary site) 
will be evaluated as part of the safety assessment. If conducted by telephone and clinical 
relapse/failure  is suspected, the subject  shoul d be examined and evaluated in -person.  
The following will be performed : 
• Record any new concomitant medications (antimicrobial agents only) . 
• Perform Investigator’s assessment of clinical response ( Section  9.1.2) . 
• Record the date the subject  returned to premorbid level of activity (work/ school), as  
applicable.  
• Assess, identify, and record any AEs or SAEs.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 62 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
8 ASSESSMENT OF THE ACUTE BACTERIAL SKIN AND SK IN 
STRUCTURE INFECTION  
8.1 Clinical Assessments  
All subject s must have their primary ABSSSI site evaluated by the Investigator, including 
ABSSSI site measurements described below.  Digital photographs of the ABSSSI site will also be 
taken as described in Sectio n 8.3. When conducting a clinical examination of the primary 
ABSSSI site, the Investigator will perform and record the following:  
• Extent of the infection (area in cm2), as measured by the area of redness, edema, or 
induration using manual measurement of the longest length multiplied by the greatest 
perpendicular width, with a ruler provided by the Sponsor. Note that only measurement of 
the longest length and the greatest perpendicular width (and not calculation of area in cm2) 
will be collected and the area in cm2 will be calculated by the eCRF. Instructions for primary 
ABSSSI measurements are provided in Appendix 5. 
• Local signs and symptoms of erythema (and any distant extension of erythema), 
swelling/edema, localized warmth, tenderness on palpation, drainage, fluctuance, and 
induration as described in Appendix 6.  
In addition, record the following information  at screening/baseline only : 
• Primary a natomical site  
• Predisposing cause of infection, if any (e.g., trauma, arthropod bite, fungal dermatosis, 
surgery, spontaneous, etc.)  
8.2 Microbiological Assessments  
As detailed in Section 7.1, all subject s enrolled  with ABSSSI  in this study must undergo 
microbiological assessments (i.e., ABSSSI site specimens and blood cultures) at 
screening/baseline and these samples  should be obtained from all subjects prior to administration 
of antibacterial therapy whenever possible.  
The screening/baseline microbiological assessments are critical, in that microbiological response 
is an important s econdary outcome of the study ( Section 3.1). Also, the antibacterial spectrum of 
study drug ( contezolid acefosamil  or linezolid) is limited to G ram-positive pathogens ( e.g., 
staphylococci and streptococci); therefore, it is important to determine whether non -Gram-
positive pathogens are involved in the ABSSSI , in addition to G ram-positive pathogens . 
Adjunctive parenteral aztreonam should be adminis tered for confirmed or suspected aztreonam -
susceptible aerobic G ram-negative pathogens as causes of the ABSSSI in addition to G ram-
positive pathogens  (Section  5.1.3) ; however, subject s with suspected G ram-negative pathogens 
only (e.g., infection caused by Pseudomonas aeruginosa in a subject  with severe burns) must be 
excluded. Similarly, polymicrobial ABSSSI involving anaerobic organisms must be excluded 
from the study , as empiric antibiotics with anti- anaerobic activity are not al lowed , and subject s 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 63 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
with suspected or known mycobacterial or fungal ABSSSI are not eligible for study entry 
(Section  4.2).  
The met hod used for obtaining a microbiological ABSSSI site specimen for Gram stain and 
culture depends on the ABSSSI type:  
• For cellulitis, obtain a specimen by needle aspiration or skin biopsy at the proximal leading 
edge of erythema, edema, or induration for Gr am stain and aerobic bacterial culture. 
• For wound infection, obtain a deep -site tissue specimen (e.g., tissue biopsy) or needle 
aspiration from an area that is physically contiguous with the wound for Gram stain and 
aerobic bacterial culture.  
• For major cut aneous abscess, obtain purulent material during the drai nage procedure for 
Gram  stain and aerobic bacterial culture.  
Superficial swabs of infected areas are not acceptable, due to the high probability that such 
specimens could be contaminated with clinical ly insignificant, and therefore misleading, isolates. 
However, deep swabs taken during significant surgical interventions are acceptable.  
In addition, 2 sets of blood cultures (each consisting of 1 aerobic and 1  anaerobic blood culture 
bottle from 2 separate venipuncture sites) will be collected from all subject s, regardless of 
location of management (inpatient  or outpatient). The blood cultures should be obtained before 
administration of antibacterial therapy, whenever possible. Blood cultures must be repeated 
every 3 (±  1) days if the previous blood culture was positive , or at any time after 
screening/baseline if clinically indicated . If the repeat blood culture remains positive with the 
bacterial pathogen  initially isolated , the Investigator must consider modifying the subject ’s 
antibiotic therapy and discuss the case with the Medical Monitor.  
After screening/baseline, microbiological assessments (ABSSSI site and/or blood cultures) 
should be repeated only when clinically indicated (e.g., at  EOT if study drug is prematurely  
withdrawn for insufficient clinical effect [ clinical failure ] at the time of relapse or recurrence 
after EOT , or if purulence and discharge from the ABSSSI site continues after 
screening/baseline).  
For all  microbiological specimens (ABSSSI site and blood), Gram stain, and culture  should be 
performed at the local laboratory according to local standards of care. If bacterial growth occurs 
from culture, the isolate(s) must be sent to the central laboratory for confirmation of  organism 
identity (to genus and species level) and susceptibility. Refer to the Laboratory Manual for 
specific procedures pertaining to the collection, processing, storage , and shipment of bacterial 
isolates . 
Antimicrobial susceptibility testing should be  performed at the local laboratory according to 
local standards of care; all clinically significant G ram-positive pathogens should be tested locally 
for linezolid susceptibility, as appropriate. Note that susceptibility testing for contezolid 
acefosamil  will not be available at the local laboratory. After the cultured isolates are sent to the 
central laboratory, the central laboratory will test all G ram-positive isolates for both linezolid and 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 64 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
contezolid acefosamil  susceptibilities. Staphylococcus aureus  will also be tested for oxacillin 
susceptibility as a marker for methicillin resistance by both the central and local laboratories. All 
clinically significant non -anaerobic G ram-negative isolates will be tested for aztreonam 
susceptibility by both the centra l and local laboratories.  
The local laboratory should retain all isolates until confirmation of a viable organism is received 
from the central laboratory. Back up cultures will be requested when the central laboratory does 
not receive a viable culture, or  recovers an organism different from the one recorded by the local 
laboratory. Refer to the Laboratory  Manual for additional details.  
8.3 Digital Photography  
Documentation of the primary ABSSSI lesion by digital photography will occur at 
screening/baseline, EA , Day 7, and EOT  using the digital camera provided by the Sponsor . 
Investigators must follow the specific digital photograph procedures that are detailed in the 
Infection Site Assessment and Measurement Manual  and Appendix  7. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 65 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
9 ASSESSMENT OF EFFICACY  
9.1 Clinical Response  Definitions  
9.1.1 Early  Clinical Response  
Objective determinations of early clinical response will be made at EA (responder , 
nonresponder , or indeterminate ) as defined in  Table 2 . Clinical responses will be classified 
programmatically based on data recorded on the eCRF. 
Table 2:  Clinical Response Definitions – Early Clinical Response  
Time point 
Classification  Definition  
Early Assessment:   
Responder  Percent reduction in primary ABSSSI lesion size is ≥ 20% compared to baseline  
Did not receive a non -protocol specified systemic antibacterial agent with activity 
against Gram -positive organisms  for the treatment of ABSSSI  
Did not die of any cause up to EA  
Nonresponder  Percent reduction in primary ABSSSI lesion size is < 20% compared to baseline , or 
Received a non -protocol specified systemic antibacterial agent with activity against 
Gram -positiv e organisms  for the treatment of ABSSSI , or 
Died of any cause up to EA  
Indeterminate  Study data are unavailable for evaluation of efficacy for any reason (e.g., missing 
data, lost to follow -up, did not attend the EA clinic appointment)  
ABSSSI  = acute bacterial skin and skin structure infection ; EOT  = end of therapy ; I & D = incision and drainage ; 
PTE = post therapy evaluation  
9.1.2 Investigator’s Assessment  of Clinical Response  
The Investigator’s assessment of clinical response at EOT, PTE, and LFU  will be classified as 
defined in Table 3 . Investigator  assessed clinical failures at EOT will be carried forward as the 
clinical response at PTE. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 66 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Tabl e 3: Clinical Response Definitions – Investigator’s Assessment  
Time point 
Classification  Definition  
EOT and PTE:   
Success  Resolution or near resolution of most baseline ABSSSI signs and symptoms  
No surgical procedure to treat the infection after  72 hours post -baseline that was not 
planned at baseline  
No new signs, symptoms or complications attributable to the ABSSSI  
No inter -current non -protocol specified systemic antibacterial therapy with activity 
against Gram -positive organisms for the treatment of ABSSSI  
Did not die of any cause up to EOT or PTE 
Failure  Lack of resolution or near resolution of most baseline ABSSSI signs and symptoms  
Any surgical procedure to treat the infection >  72 hours post -baseline that was 
unplanned at baseline  
New signs, symptoms, or complications attributable to the ABSSSI  
Inter -current non-protocol  specified antibacterial therapy administered for the treatment 
of the primary ABSSSI lesion or might have potential antibiotic  activity directed toward 
the Gram -positive  pathogens implicated in the ABSSSI  
Died of any  cause up to EOT and PTE  
Indeterminate  Study data are unavailable for evaluation of efficacy for any reason (e.g., missing data, 
lost to follow -up). No baseline Gram -positive organisms for the treatment of ABSSSI . 
LFU:   
Sustained clinical  
success  No new signs or symptoms of primary ABSSSI after PTE  
Clinical 
relapse/failure  New or worsened signs or symptoms of primary ABSSSI after PTE  
Indeterminate  Study data are unavailable for evaluation of efficacy for any reason (e.g., missing data, 
lost to follow -up). No baseline Gram -positive organisms for the treatment of ABSSSI . 
 
ABSSSI  = acute bacterial skin and skin structure infection; EA  = early assessment; EOT  = end of therapy; I  & D = incision and 
drainage; LFU  = late follow -up; PTE = post therapy evaluation  
Prior to any premature discontinuation of study drug, the study site personnel should notify the 
Medical Monitor if the subject ’s medical condition allows.  
Data for all subject s will be  reviewed to ensu re the Investigators are followi ng the protocol 
defined criteria for clinical response  and queries will be  issued  as needed  to clarify any response  
that does  not meet the protocol de finition. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 67 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
9.2 Microbiological Response Definitions  
9.2.1 Per-Pathogen Microbiological Response  
A microbiological outcome at the PTE vi sit will be determined in the micro -ITT and ME 
populations  for each pathogen isolated from the ABSSSI site or blood at screening/baseline. 
Microbiological outcome categories include  eradication, presumed eradication, persistence, 
presumed persistence, and indeterminate, as defined in  Table 4 . Favorable microbiological 
outcomes include  eradication or presumed eradication. Unfavorable microbiological outcomes 
include  persistence or presumed persistence.  
Table 4:  Microbiological Outcome Categories  
Outcome  Category  Definition  
Eradication  An adequate source specimen demonstrates absence of the original 
screening/baseline  pathogen  
Presumed eradication  An adequate source specimen was not available to culture and the subject  was 
assessed as a clinical success by the Investigator  at PTE 
Persistence  An adequate source specimen demonstrates continued presence of the original 
screening/baseline  pathogen  
Presumed persistence  An adequate source specimen was not available to culture and the subject  was 
assessed as a clinical failure by the Investigator  at PTE 
Indeterminate  An adequate source specimen was not available to culture and the subject ’s 
clinical response was assessed as indeterminate  
9.2.2 Per-Subject  Microbiological Response  
An overall microbiological response at the PTE visit will be determined in the micro -ITT and 
ME populations for each subject  based on individual outcomes for each screening/baseline 
pathogen. For  a subject  to have a favorable per -subject  microbiological response, the outcome 
for each screening/baseline pathogen must be favorable (eradicated or presumed eradicated , as 
defined in Table 4 ). For  a subject  to have an unfavorable per -subject  microbiological response, 
the outcome for a screening/baseline pathogen must be unfavorable (persistence, presumed 
persistence, as defined i n Table 4 ). If the same pathogen is isolated from multiple sites (e.g., 
blood and ABSSSI site culture), the worst response will be used to determine the per -subject  
microbiological response. 
9.2.3 Emergent Infections  
ABSSSI caused by pathogens first appearing after screening/baseline will be categorized as 
either superinfections or new infections as defined in Table 5 . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 68 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Table 5:  Emergent Infections  
Category  Definition  
Superinfection  Isolation of a new pathogen(s) (other than the original screening/baseline 
pathogen[s]) from the prim ary ABSSSI site and from an appropriate ABSSSI 
specimen which is accompanied by signs and symptoms of infection requiring 
alternative systemic antimicrobial therapy during the period up to and including 
EOT , based on the Investigator’s assessment of clinic al response.   
New infection  Isolation of a new pathogen(s) (other than the original  screening/baseline 
pathogen[s])  from the primary ABSSSI site and  from an appropriate ABSSSI 
specimen which is accompanied by signs and symptoms of infection requiring 
alternative systemic antimicrobial therapy after EOT , based on the Investigator’s 
assessment of clinical response.  
ABSSSI  = acute bacterial skin and skin structure infection; EOT  = end-of-therapy  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 69 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
10 ASSESSMENT OF SAFETY 
All subject s will be monitored for the occurrence of AEs throughout the study, including AEs of 
special interest that are associated with the oxazolidino ne class of antibiotics . 
Electrocardiograms, hematology evaluations, chemistry, coagulation, and UA will be performed 
at screening/baseline and at various timepoints during and after the dosing period ( Table 1 ). Each 
recorded AE will be described by its duration (i.e., start and end dates), severity, seriousness, and 
suspected relationship to the study drug. Adverse events will be graded as mild, m oderate, or 
severe, as detailed in Section 10.1.2_Assessment_of_Severity . Relationship of the AE to stud y 
drug will be characterized as related  (including possibly related or definitely related) and 
unrelated , as detailed in  Section  10.1.3. 
As detailed in Section 3.4, if study drug is determined not to be safe and tolerated, the study drug 
assignment for those subject s with a signifi cant safety concern may be unblinded after discussion 
between the Investigator and Sponsor. The blind may also be broken in the case of a medical 
emergency requiring the Investigator to know the identity of the study drug to appropriately 
guide the subject ’s medical management. Prior to any unblinding, the Investigator is strongly 
advised to discuss options with the Medical Monitor or appropriate Sponsor study personnel. If 
the blind is broken for any reason and the Investigator is  unable to contact the Sponsor before 
unblinding, the Investigator must notify the Sponsor as soon as possible, without revealing the 
subject ’s study drug treatment assignment (unless important to the safety of subject s remaining 
in the study). All instances of unblinding will be t horoughly investigated and documented by the 
unblinded study monitor . 
Reports of AEs will be collected for all subject s from the  time informed consent is signed.  The 
Investigator  will assess all AEs and SAEs and record the following information on the 
appropriate eCRF page:  
• Date and time  of onset  
• Date of resolution or stabilization  
• Severity  
• Relationship to study drug 
• Action taken with study medication  
The Investigator  should disti nguish between local and systemic AEs . An example  of a possible 
systemic AE include s generalized rash or pruritus related to an allergic reaction . An example of a 
possible local AE include s a focal  rash or irritation that is localized to a cutaneous area 
surrounding a venous blood draw . 
Clinically indicated laboratory tests (emergency or unscheduled tests) should be conducted at the 
local laboratory.  For example, laboratory workup of an AE of anemia could include iron tests, 
reticulocyte count, and blood s mear, among other local laboratory tests. The Investigator  should 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 70 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
employ best medical judgment in determining how to manage AEs and SAEs. Any questions 
regarding AE or SAE management should be directed to the Medical Monitor. 
Prior to any  premature discont inuation of study drug  or unblinding of study drug assignment , the 
study site personnel should notify the Medical Monitor  if the subject ’s medical condition allows . 
10.1 Adverse Events  
10.1.1 Definition  
An AE  is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related. An AE  can be any unfavorable or unintended sign, symptom, or 
disease temporally associated with the use of a drug, without any judgment about causality . 
Adverse events are collected from the time the informed consent is signed.  
An AE does not  include the following:  
• Medical or surgical procedures (e.g. , surgery, endoscopy, tooth extraction, transfusion); the 
condition that necessitates the procedure is an AE . 
• Any pre -existing  disease or condition, or laboratory  or ECG  abnormality , present or detected 
prior to administration of study drug  that does not worsen.  
• Laboratory  or ECG  abnormalities without clinical manifestations, which do not require 
medical inter vention, or that do not result in termination or delay of study medication (see 
Section 10.2_Reporting_ Laboratory_and  for further detail).  
• Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery, social, or convenience admissions) . 
• Overdose of any study drug or concomitant medication without any signs or symptoms, 
unless the subject  is hospitalized for observation.  
• Worsening of the primary ABSSSI for which the subject was enrolled . 
10.1.2 Assessment of Severity 
Severity of AE s will be assessed by the Investigator  was mi ld, moderate, or severe ( Table 6 ). 
This assessment is subjective and the Investigator  should use medical judgment to com pare the 
reported AE to similar types of events  observed in clinical practice.  It is important to recognize 
that severity is not equivalent to event seriousness  (see Section 10.1.4.2) . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 71 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Table 6:  Guidelines for Severity Assessments  
Severity  Definition  
Mild  Symptom(s) barely noticeable to the subject, transient, or does (do) not make the 
subject uncomfortable. The AE does not influence regular, daily performance or 
functioning (e.g., functioning at work or school). Special treatment (e.g., with a 
prescription drug) is not ordinarily required for relief of symptom(s).  
Moderate  Symptom(s) of a suff icient severity introduce a low level of inconvenience or concern 
to the subject. The AE may alter regular, daily performance or functioning (e.g., 
functioning at work or school), but is ameliorated with simple therapeutic measures.  
Severe  Symptom(s) of a sufficient severity to cause the subject severe discomfort, interrupt 
daily activities, or lead to cessation of administration of study drug. Treatment for 
symptom(s) is needed. A severe AE does not necessarily qualify as an SAE 
(Section  10.1.4.2).  
 
10.1.3 Relationship to Study Drug 
For each reported AE, the Investigator  must make an assessment of the relationship of the event 
to the study  drug using the following scale:  
• Unrelated : The event is definitely not associated with administration of study drug , and is 
judged clearly due to causes other than the study drug . 
• Possibly related  (Suspected Adverse Reaction [SAR]) : A causal relationship between the 
study drug and the AE  is at least a reasonable possibility, i.e. the relationship cannot be ruled 
out. This implies a lesser degree of certainty about causality than a definitely related AE. 
Additional evidence to suggest a SAR includes:  
○ Indivi dual occurrences of uncommon AEs that are known to be strongly associated with 
drug exposure (e.g., angioedema, blood dyscrasias, rhabdomyolysis, hepatic injury, 
anaphylaxis, Stevens -Johnson Syndrome) . 
○ One or more occurrences of an AE that is uncommon in t he study population, but not 
commonly associated with drug exposure (e.g., heart valve lesions in young adults, 
intussusception in healthy infants) . 
• Definitely Related  (Adverse Reaction) : A causal relationship between the study drug and the 
AE is definite . 
These criteria, in addition to good clinical judgment, should be used as a guide for determining 
the causal assessment. If the event is believed to be unrelated to administration of study drug , 
then an alternative explanation should be provided. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 72 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
10.1.4 Serious A dverse Event s 
An SAE is defined as any adverse experience occurring at any dose of study medication that 
occurs between the time informed consent is signed and within 30 days after the final 
administration of study drug that results in any of the following  outcomes:  
• Death  
• Life-threatening situation ( subject  is at immediate risk of death)  
• Inpatient hospitalization (excluding hospitalization prior to randomization due to initial 
management of ABSSSI at baseline and new hospitalizations due to progression of t he 
underlying primary ABSSSI lesion ) or prolongation of existing hospitalization 
• Persistent or si gnificant disability/incapacity  
• Congenital anomaly/birth defect in the offspring of a subject  who received study drug 
• Events that jeopardize the subject  suffic iently that medical or surgical intervention may be 
required to prevent one of the above outcomes  (e.g., bronchospasm requiring urgent 
management in an emergency room, blood dyscrasias that do not result in hospitalization, 
seizures that do not result in hospitalization)  
10.1.4.1 Serious Adverse Event Reporting 
The Sponsor has requirements for expedited reporting of SAEs meeting specific criteria to 
worldwide regulatory authorities. Therefore, the Sponsor must be notified immediately regarding 
any SAE that occurs af ter administration of study drug. All SAEs must be reported to the  
Medical Monitor wit hin 24 hours  of the investigational site’s knowledge of the event.  
The study site will transmit a SAE Report (SAER) by email (preferred) or facsimile (back up) to 
InClin Drug Safety . An initial report can be made via telephone in the case of an urgent event or 
question, but a completed SAER must still be emailed or faxed within 24 hours of the site’s 
knowledge of the event. The investigational site will be provided with SA ER forms wherein the 
following information is requested. In addition, relevant eCRF pages should be appended to 
communicate relevant study drug and subject outcome information. The information needed for 
completing an SAER is as follows : 
• Subject  identifica tion, Investigator name, and site number . 
• SAE information: event term, onset date, severity, and causal relationship. 
• The outcomes attributable to the event (e.g., death, a life -threatening AE, in patient  
hospitalization, prolongation of existing hospitaliz ation, a persistent or significant disability 
or incapacity, or other important medical event[s]) . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 73 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• A summary of relevant test results, pertinent laboratory data, and any other relevant medical 
history . 
• The first and last dates of administration of study dr ug. NOTE: As this is a double -blind 
study, SAERs should not indicate specific study drug assignments . 
• Indicate if the study drug was discontinued or if the administration of study drug schedule 
modified . 
• Supplemental information may include the following h ospital records: laboratory results, 
radiology reports, progress notes, admission and emergency room notes, holding and 
observation notes, discharge summaries, autopsy reports, and death certificates . 
The SAER should be faxed within 24 hours  with as much of the above information as available 
at the time. The following minimum information is required for reporting an SAE: subject  
identification, reporting source, and an event or outcome. Supplemental information may be 
transmitted using a follow -up report and should not delay the initial report. The Sponsor may 
contact the investigational site to solicit additional information or to follow -up on the event.  
The Investigator must take all therapeutic measures necessary for resolution of the SAE. Any 
medications  or procedures necessary for treatment of the SAE must be recorded on the 
appropriate pages of the eCRF.  
10.1.4.2  “Serious” V ersus “Severe” Adverse Events  
To avoid confusion or misunderstanding over the difference between the terms "serious" and 
"severe," which ar e not synonymous, the following note of clarification is provided (excerpted 
from International Council for Harmonisation [I CH] E2A ): 
The term "severe" is used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocar dial infarction); the event itself, however, may be of relatively minor 
medical signific ance (such as severe headache).  This is not the same as "serious," which is based 
on subject /event outcome or action criteria usually associated with events that pose a  threat to a 
subject 's life or functioning. Seriousness (not severity) serves as a guide for defining regulatory 
reporting obligations. 
10.1.4.3 SAE Definition Clarifications  
• Death is an outcome of an AE, and not an AE in itself . 
• All deaths during administration of study drug or occurring within 30 days of the last 
administration of study drug, regardless of cause or relationship, must be reported using the 
SAER . 
• “Occurring at any dose” does not imply that the subject  is actively receiving study dru g at the 
time of the event . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 74 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• “Life -threatening” means that the subject  was at immediate risk of death from the event as it 
occurred. This does not include an event that might have led to death, had it occurred with 
greater severity.  
• Complications that occur  during hospitalizations are AEs. If an AE prolongs hospitalization, 
it is an SAE.  
• “Inpatient hospitalization” means the subject  has been formally admitted to a hospital for 
medical reasons, for any length of time. This may or may not be overnight. It does not 
include presentation and care within an emergency department (although an emergency 
department visit may define a medically  important event, which is also considered an SAE).  
• The Investigator  should attempt to establish a diagnosis of the event based on signs, 
symptoms, and other clinical information. In such cases, the diagnosis should be documented 
as the AE or SAE, rather t han as the individual signs or symptoms. 
10.1.5 Treatment -emergent Adverse Event  
A treatment -emergent adverse event ( TEAE ) is defined as an AE that occurs during or after the 
first administration of study drug and up through the last study visit or evaluation, or  an SAE that 
occurs during or after the first  administration of study drug up through 30 days after the final 
administration  of study drug.  
10.1.6 Life-threatening Adverse Event  
A life -threatening AE is an AE that, in the view of either the Investigator  or S ponsor, places the 
subject  at immediate risk of death.  It does not include an AE that, had it occurred in a more 
severe form, might have caused death.  
10.1.7 Unexpected Adverse Event  
An AE is considered “unexpected” if it is not listed in the IB or is not listed at th e specificity or 
severity that has been observed; or, if an IB is not required or available, is not consistent with the 
risk information described in the general investigational plan. For example, under this definition, 
hepatic necrosis would be unexpected (by virtue of greater severity) if the IB referred only to 
elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral 
vasculitis would be unexpected (by virtue of greater specificity) if the IB listed only cerebral 
vascular accidents. "Unexpected," as used in this definition, also refers to AEs that are mentioned 
in the IB as occurring with a class of drugs or as anticipated from the pharmacological properties 
of the drug, but are not specifically mentioned as occurring with the particular drug under 
investigation.  
Some AEs are listed in the IB as occurring with the same class of drugs, or as anticipated from 
the pharmacological properties of the drug, even though they have not been observed with the 
drug under investigation.  Such events would be considered unexpected until they have been 
observed with the drug under investigation. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 75 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
10.2 Reporting Laboratory and Electrocardiogram Abnormalities  
Laboratory and ECG abnormalities should not be recorded as AEs unless they are associated 
with clinical signs or symptoms, or require medical intervention. However, laboratory and ECG 
abnormalities (e.g., clinically significant changes detected on clinical chemistry, hematology, 
UA, etc.) independent from the underlying medical condition that re quire medical or surgical 
intervention, or lead to study drug interruption or discontinuation, must be r ecorded as an AE if 
applicable.  If the laboratory abnormality is part of a clinical condition or syndrome, it should be 
recorded as the syndrome or diag nosis rather than an isolated laboratory or ECG abnormality. In 
addition, laboratory and ECG abnormalities or other abnormal test assessments that are 
associated with signs or symptoms must be recorded as AEs if they meet the definition of an AE 
(or SAE).  
10.3 Risks for Women of Child bearing  Potential  
The risks of treatment with contezolid acefosamil  during pregnancy have not been fully 
evaluated. Therefore, females must be either postmenopausal for ≥ 2 years or surgically sterile 
(having undergone tubal ligation, hysterectomy, or bilateral oophorectomy) or, if of childbearing 
potential, must have a negative serum or urine pregnancy test (β –HCG) at screening/baseline and 
be willing to use a highly effective method of contraception throughout the study such as 1 of  the 
following:  
• Hormonal contraception (stable dose for 3 months)  
• Intrauterine device/ intrauterine hormone -releasing s ystem  
• Barrier contraceptive method (diaphragm, cervical cap, contraceptive sponge, condom)  
Additionally, m ales (if sexually active and non sterile) with female partners of  childbearing 
potential must use 2 methods of contraception (i.e., a barrier contraceptive such as condom with 
spermicidal foam) , and be willing to continue to use these same birth control measures while 
participating in the  study (and for 70 days following participation in the study). Males must also 
refrain from sperm donations during this time. 
Female subject s must be instructed to inform t he Investigator immediately if they be come 
pregnant during the study.  Male subject s must also be instructed to inform the Investigator 
immediately if a female partner becomes pregnant through at least 70  days (10 weeks) after 
dosing. In the event of a confirmed pregnancy, the following actions should be taken:  
• Study drug should be stopped immediately . 
• The pregnancy should be reported to the  Medical Monitor within 24 hours  of notification 
using the Pregnancy Report Form.  
• The I nvestigator should counsel the subject  regarding the possible effects of prior study drug 
exposure on the fetus and the need to inform the study site of the outcome of the pregnancy . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 76 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• The subject  must be monitored until the immediate post- natal period or until  termination of 
the pregnancy. The outcome should be reported to the Medical Monitor using the Pregnancy 
Outcome  Form. 
Pregnancy is not an AE, in and of i tself.  However, any pregnancy complication or elective 
termination of a pregnancy for medical reasons wil l be recorded as an AE or SAE. A  
spontaneous abortion is always considered an SAE and will be reported as described in the AE 
and SAE sections. Furthermore, any SAE occurring as an adverse pregnancy outcome post -study 
must be reported to the Medical Monitor. 
10.4 Adverse Event Follow -up 
All A Es and SAEs will be followed to resolution or stabilization.  Adverse events  that have not 
resolved by a  study visit, but have  stabilized, will be categorized as such in the database.  
Non-serious AEs that are ongoing at the end of the study will be identifi ed as ‘Ongoing’ . 
10.5 Study Termination or Temporary Suspension  
The study may be terminated if significant violations of GCP that compromise the ability to 
achieve the study objectives or compromise subject safety are observed at any time during the 
study ( Section 4.5). The study may be temporarily suspended or terminated should the 
Investigator, Sponsor, or IRB determine that the safety of study subjects is significantly 
jeopardized. The decision for a temporary or per manent study hold will depend on the nature, 
frequency, and severity of AEs that were observed in all enrolled subjects to date. In a temporary 
study hold, no additional subjects will be enrolled into the study or dosed with study drug until 
the study team  (including the Investigator and the Medical Monitor) decides it is safe to proceed 
with the study. The study will be terminated or temporarily suspended if any of the following 
events occur in a single subject who is receiving active contezolid acefosamil  (as determined 
after unblinding) during the study period:  
• Hy’s law criteria met ; these are defined as elevations of ALT or AST  to > 3 times  ULN  and 
elevation of serum total bilirubin to ≥  2 times ULN with  serum alkaline phosphatase  < 2 
times ULN , and no other disease or condition can be found to explain the liver test 
abnormalities  (FDA, 2009)  
• Clinically significant cardiac arrhythmia (e.g., Torsade de Pointes)  
• Symptomatic anemia with a hemoglobin level <  8.0 g/dL, as confirmed  on repeat testing, or 
requirement for blood transfusion 
• Platelet count <  50 x  103/mm3, as confirmed on repeat testing 
• WBC count <  2.0 x  103/mm3 or absolute neutrophil count <1,000/mm3, as confirmed on 
repeat testing  
• Rash defined as an SAE ( Section 10.1.4)  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 77 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
• Peripheral or optic neuropathy  
• Serotonin syndrome  
• Seizure 
• Anaphylaxis or allergy -related angioedema  
As noted above, safety assessments will be monitored and evaluated on a regular basis by the 
study team, and any abnormal clinical or laboratory findings or trends will be closely monitored 
and followed regardless of severity or causality (e.g., before an event reaches a severe grading 
level or reaches a termination criterion cutoff).  
10.6 Data Monitoring Committee  
A DMC will not be utilized in this study.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 78 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
11 ASSESSMENT OF PHARMACOKINETICS  
This study will be conducted at multiple clinical sites, and some will have the appropriate 
equipment and facilities (including refrigerated centrifuges and - 70ºC freezers) and experienced 
personnel to adequately collect, handle, store, and ship PK samples for bioanalysis. PK 
assessments will only be performed at selected clinical sites with this capability, and PK samples 
will be obtained from as many subjects as possible at these selected sites. Drug exposure will be 
predicted based on demographic data (e.g., body weight) for subjects from whom PK samples 
were not obtained.  
• One PK sample after the 1st IV dose (to characteriz e the loading dose): obtain 1 blood 
sample between 0.5 to 2 hours after the end of the 1st infusion 
• Three PK samples with the 3rd  IV dose  (to characterize drug exposure and approaching of 
steady state) :  
○ Obtain a 1st blood sample (trough level) within 2 hours before  the 3rd IV dose  
○ Obtain a 2nd blood sample between 0.5 and 3 hours after the end of the 3rd IV dose  
○ Obtain a 3rd blood sample between 4 and 11 hours after the end of the 3rd IV dose but 
before the 4th dose (IV or PO)  of study drug . 
• Three PK  samples  at EOT  (to evaluate potential drug accumulation) :  
○ Obtain 1 blood sample (trough level)  within 2 hours  before  the last dose (IV or PO)  
○ If the last dose is given PO: obtain 1 blood sample between 1.5 to 4 hours after the last 
dose, and obtain 1 additional sample between 5 to 12 hours after the last dose  
○ If the last dose is given IV: obtain 1 blood sample between 0.5 and 3 hours after the end 
of the last infusion, and obtain 1 additional sample between 4 and 11 hours after the end 
of the last infusion 
The PK data acquisition and analysis strategy entail the use of a sparse PK sampling schedule for 
subject s randomized to contezolid acefosamil . This PK sampling strategy is designed  to 
characterize the impact of the loading dose, and to obtain adequate estimates of drug exposure 
after the 3rd IV dose and the final dose  (IV or PO) . Additionally, given the range of demographic 
data in the expected subject population, these PK data will be used to perform exploratory 
analyses on the impact of demographic characteristics (e.g., weight, body mass index , age, 
gender, race) upon the PK (including clearance) of the drug and its metabolites. Only those PK 
samples collected from subject s randomized to contezolid acefosamil  will be analyzed.  
The bioanalytical  laboratory will measure plasma concentrations of contezolid acefosamil  
metabolites  (MRX -1352, contezolid, and MRX -1320)  using  validated  and sensitive  bioanalytical 
methods . Specific instructions for the collection of plasma drug concentration specimens  will be 
provided in the Laboratory M anual and  should be reviewed prior to collection. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 79 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
When more than one assessment is scheduled at any given timepoint, clinical assessments s hould 
precede all blood draws , including ECGs . For subject s managed as outpatients, schedule the 
clinic visits appropriately to collect PK samples at the end of IV therapy and the EOT visit as 
described above . 
The PK population is defined in Section 12.2. Selected PK samples may be used in the 
identification of contezolid acefosamil  metabolites. Additional details will be provided in the 
PK Analysis Plan . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 80 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
12 STATISTICAL METHODS  
All data will be summarized  separately by study drug ( contezolid acefosamil  or linezolid). 
Descriptive statistics ( number, mean, standard deviation, median, minimum, and maximum) will 
be presented for continuous variables for each study drug. Frequency distributions (count s and 
percentages) will be presented for categorical variables.  Listings will be provided for individual 
subject  study data.  
A comprehensive Statistical Analysis Plan (SAP) will be prepared and finalized prior to database 
lock. 
12.1 Determination of Study Sampl e Size  
This study is not powered for inferential statistical analysis. Approximately 133  subjects 
(100 evaluable subjects) in the contezolid acefosamil group and 67 subjects (50 evaluable 
subjects) in the linezolid group will allow for planning of future studies. If the responder rate is 
0.8 at EA using early clinical response in the contezolid acefosamil g roup, then 133 evaluable 
subjects results in a 95% confidence interval (CI) of (0.72, 0.86) for the responder rate.  
12.2 Analysis Populations  
The analysis populations are defined in Table 7 , and the relationship between the analysis 
populations are displayed in Figure 2 . 
Table 7:  Analysis Populations  
Analysis 
Populations  Definitions  
ITT Population  All randomized subjects will be included in the ITT population, regardless of whether 
study drug is administered . 
MITT Population  All randomized subjects in the ITT population, excluding subjects with only a Gram-
negative pathogen( s) at baseline.  
Safety Population  All subject s who receive any amount of study drug will constitute the safety population. 
Subjects  in the safety populati on will be analyzed according to study drug received.  
Micro-ITT 
Population  All randomized subject s in the ITT population who have culture evidence of a baseline 
Gram -positive bacterial pathogen known to cause ABSSSI.  
CE Populations  
(CE-EOT, CE -PTE) All s ubjects in the ITT population who meet the minimal clinical disease criteria for 
ABSSSI; receive at least 80% of expected doses based on length of therapy; did not 
receive any potentially -effective systemic antibacterial therapies other than protocol 
speci fied study drug(s) between Day  1 and timepoint for assessment (except for 
adjunctive aztreonam or in cases of treatment failure).  
To be included in the CE -EOT population, the following conditions must be met:  
• Have an Investigator’s assessment of clinical r esponse at EOT (i.e., response 
can’t be indeterminate)  
• Had an EOT visit  
To be included in the CE -PTE population, the following conditions must be met:  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 81 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Analysis 
Populations  Definitions  
• Have an Investigator’s assessment of clinical response at PTE (i.e., response 
can’t be indeterminate unle ss the subject  is deemed a clinical failure at the EOT 
visit)  
• Had a PTE visit 
In addition to meeting the above criteria, subject s must meet the following specific 
conditions  to be included in the CE population : 
• Received at least 5 doses of study drug therapy to be considered an evaluable 
failure  
• Received at least 7 doses of study drug therapy to be considered an evaluable 
success  
• Did not have any major protocol violation 
ME Population  All subject s in the micro -ITT population who also are in the CE -PTE population . 
PK Population  All subject s who receive at least 1  dose of contezolid acefosamil  and had at least 1  blood 
sample collected for analysis of MRX -1352, contezolid , or MRX -1320.  
ABSSSI  = acute bacterial skin and skin structure infection; CE  = clinically evaluable; EOT  = end of therapy; 
ITT = intent -to-treat; ME  = microbiologically evaluable; ME = microbiologically evaluable; micro -
ITT = microbiological intent- to-treat; PK = pharmacokinetic; PTE = post therapy evaluation  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 82 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Figure 2 : Overview of Analysis Populations  
 
ABSSSI  = acute bacterial skin and skin structure infection; CE  = clinically evaluable; EOT  = end of therapy; 
ITT = intent -to-treat; ME  = microbiologically evaluable; ME = microbiologically evaluable; micro -
ITT = microbiological intent- to-treat; MITT= modified intent -to-treat; PK = pharmacokinetic; PTE = post therapy 
evaluation  
12.3 Determination of Inclusion in Populations  
Inclusion in the ITT, safety, and PK populations will be determined programmatically from 
eCRF data. Inclusion in the MITT and micro -ITT population will be determined by the M edical 

Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 83 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Monitor. The M edical M onitor will decide whether each isolate is considered a pathogen. 
Inclusion in the CE populations will be determined based on a combinati on of programmatic and 
manual review  by the Medical Monitor . Inclusion in the ME population will be determined 
programmatically. All manual review s and determinations  of population inclusion/exclusion will 
be done prior to study unblinding . 
12.4 Analysis of Stu dy Population s and Subject  Characteristics  
Enrollment, study drug administered, premature discontinuations from study medication, 
withdrawals from the study , and  protocol deviations will be summarized by treatment group . A 
protocol deviation is defined as a ny variation from the protocol (e.g., enrollment of a subject  who 
did not meet all inclusion and exclusion criteria , failure to perform the assessments and 
procedures within the required time frame ). 
Demographics (age, race, sex), description of the baseline ABSSSI type, medical history, and 
baseline clinical signs and symptoms of ABSSSI will be summarized by treatment group. 
Baseline pathogens identified at the primary ABSSSI site will also be summarized by treatment 
group.  
The number and percentage of subject s in each population and reasons for exclusion from 
populations will be listed and summarized by treatment group.  
12.5 Study Drug Exposure  
By treatment group summaries will be provided for the total number of doses, the number of IV 
doses, and the num ber of PO doses. Compliance to study drug will be calculated based on the 
total number of doses taken, divided by the total number of expected doses.  
12.6 Efficacy Analyses  
Primary and secondary efficacy evaluations will be summarized by analysis population, as  
indicated in  Table 8 . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 84 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Table 8:  Summary of Primary and Secondary Efficacy Evaluations  
by Analysis Population  
Efficacy Endpoints  Efficacy Populations  
ITT MITT micro -
ITT CE-EOT  CE-PTE  ME 
Primary :       
Early clinical response at EA  √      
Secondary:        
Early clinical response at EA   √     
Early clinical response at EA (overall 
and by baseline pathogen)    √    
Percent reduction in lesion size at 
Day 7  √ √     
Investigator’s assessment of clinical 
response at EOT  √ √  √   
Investigator’s assessment of clinical 
response at PTE and LFU  √ √   √  
Per-subject microbiological response 
at PTE    √   √ 
Per-pathogen microbiological 
response at PTE    √   √ 
Investigators assessment of clinical 
response at PTE and LFU (overall 
and by baseline pathogen)    √   √ 
CACO  √  √  √  
CACO = composite assessment of clinical outcome (combined outcome of early clinical response at EA and 
Investigator’s assessment of clinical response at PTE); CE  = clinically evaluable; EA  = early assessment; EOT  = end 
of therapy; ITT  = intent -to-treat; LFU  = late follow -up; ME  = microbiologically evaluable; MITT = modified intent -
to-treat; micro -ITT = microbiological intent -to-treat; PTE  = post therapy evaluation  
12.6.1 Primary Efficacy Evaluation  
The primary efficacy analysis is a n examination  of the number of responders in the contezolid 
acefosamil  treated group vs the number of responders in the linezolid group at EA in the ITT 
population. This aligns with the FDA’s primary efficacy endpoint of interest in ABSSSI studies 
(FDA, 2013 ). Subject s will be programmatically categor ized into responders, non- responders or 
indeterminate based on the eCRF data as previously discussed in Section 9.1.1. Subject s who are 
lost to fol low-up or who have missing data will be classified as indeterminate. The number of 
responders, non -responders, and indeterminate responses will be summarized by treatment group 
and a n exact  95% CI will be provided for the responder rates in each treatment group. The 
difference between the responder rates will be calculated and 95% CI  for the difference between 
response rates will be calculated  using a Wald continuity correction.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 85 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
12.6.2 Secondary and Additi onal Efficacy Evaluations  
12.6.2.1 Percent Reduction in Lesion Size  
Changes from baseline in the percent reduction in lesion area at Day 7 will be summarized by 
treatment group in the ITT and MITT populations  and also by treatment group excluding patients 
who took non- study  antibiotics with the potential to have activity against ABSSSI through the 
study visit. 
12.6.2.2 Clinical Outcomes  
Early c linical response at EA  will be classified programmatically based on eCRF data as 
previously discussed in Section 9.1.1. The number and percentage of subject s classified 
programmatically as a responder, nonresponder , and indeterminate  at EA will be tabulated for 
the populations specified in Table 8  for both treatment groups , and the difference in response 
rates will be summarized along with the 95%  CI for the rate of response.  
The Investigator’s assessment  of clinical response will be classified as previously discussed in 
Section  9.1.2. The number of subject s with an Investigator’s assessment of clinical success, 
clinical failure , and indeterminate at EOT  and PTE  will be tabulated for both treatment groups 
for the populations specified in Table 8  (by definition, subject s with an indeterminate response 
will be excluded  from summaries in the CE -EOT and CE- PTE populations). The 95%  CI will be 
provided for the rate of clinical success for each treatment group. The difference in clinical 
success rates will also be summarized. The 95%  CI will be provided for the difference  in rates of 
success at PTE in the ITT  and CE -PTE populat ions only , which are the primary analyses of 
interest in the EU ( EMA, 2013) . The durability of clinical response (rate of sustained clinical 
response and clinical relapse/failure ) at LFU will be summarized by treatment group in the 
micro -ITT and ME populations. 
The rates of success as assessed by the CACO ( Table 9 ) will be summarized in the ITT, micro -
ITT, and CE -PTE populations. The CACO will be programmatically determined from the 
programmatic assessment of early clinical response at the EA visit and the Investigator’s 
assessment of clinical response at PTE. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 86 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Table 9:  Composite Assessment of Clinical Outco me 
Early Clinical Response at  
EA Visit  Investigator’s Assessment of 
Clinical Response at PTE Visit  Composite Assessment of  
Clinical Outcome  (CACO)  
Responder  Success  Success  
Responder  Failure  Failure  
Responder  Indeterminate Indeterminate 
Nonresponder  Success  Failure  
Nonresponder  Failure  Failure  
Nonresponder  Indeterminate Failure  
Indeterminate Success  Indeterminate 
Indeterminate Failure  Failure  
Indeterminate Indeterminate Indeterminate 
EA = early assessment; PTE  = post therapy evaluation  
12.6.2.3 Microbiological Outcomes  
The number and percentage of subject s with favorable microbiological responses will be 
summarized  at PTE in the ME and micro -ITT populations. R esponses include eradication, 
presumed eradication, persiste nce, presumed persistence, and indeterminate  (Table 4 ). To have 
an overall favorable microbiological response, the outcome for each baseline pathogen must be 
favorable. Of these responses, eradication and presumed eradication will be re garded as a 
favorable outcome. Persistence and presumed persistence will be regarded as an unfavorable 
outcome. If a subject  has > 1 baseline pathogen, all pathogens must have a favorable response to 
have overall favorable response. A 2 -sided exact 95% CI will be constructed for the percentage 
of subjects with favorable and non- favorable response and a 95% CI will be calculated for the 
difference in the per -subject  favorable microbiological response  using a Wald continuity 
correction. 
Microbiologic response by baseline pathogen will be determined as the proportion of patients 
with a favorable microbiological response (eradication or presumed eradication) at the PTE visit 
for each pathogen isolated at  baseline from the ABSSSI site. The number and percentage of 
patients in each treatment group with a microbiologically favorable outcome will be tabulated for 
the micro -ITT and ME analysis sets.  
The number and percentage of subject s in each treatment group with an Investigator’s 
assessment of clinical response of success at the PTE and LFU visit will be tabulated by baseline 
pathogen in the micro -ITT and ME populations. The number and percentage of subject s in each 
treatment group who are responders at the EA visit using early  clinical response will also be 
tabulated by baseline pathogen in the micro -ITT population. 
Emergent infections  (e.g., superinfection, new infection)  will not be considered in the 
microbiological response  and will be listed separately ( Section 9.2.3) . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 87 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
12.7 Safety Analyses  
Evaluation of the safety and tolerability of contezolid acefosamil  (IV and PO) q12h (±  2 hours)  
for 10  to 14 days in the treatment of ABSSSI is an important objective for this Phase  2 study. 
Safety will be evaluated by presenting summaries of AEs, vital signs, laboratory evaluations 
(hematology , chemistry, and coagulation) , and ECG parameters.  For each safety paramete r, the 
last assessment made prior to the first administration of study drug will be used as the baseline 
for all analyses.  
The incidence of TEAEs (defined in Section 10.1.5) will be presented by SOC and PT according 
to Medical Dictionary of Regulatory Activities ( MedDRA®); by SOC, PT, and relationship to 
study drug ; and by SOC, PT, and severity.  In addition, the incidence of SAEs and TEAEs 
leading to discontinuation of study drug will be presented by SOC , PT, and relationship to study 
drug. If the incidence of SAEs and TEAEs leading to discontinuation of study drug is low, only a 
listing will be provided.  
Descriptive statistics of vital signs at each timepoint measured, as well as the change from 
baseline and potentially clinically significant changes , will be presented  by treatment group . 
Potentially clinically significant changes will be defined in the SAP. Descriptive statistics for 
ECGs will also be presented for each timepoint measured. Descriptive statistics for clinical 
laboratory tests and for the change from baseline will be presented by study visit  and treatment 
group.  
12.8 Pharmacokinetic Analyses  
Characterization of the population P K of contezolid acefosamil  metabolites (IV and PO) q12h 
(± 2 hours)  in the treatment of ABSSSI is an important secondary objective for this study. 
Plasma samples from subject s in the PK population ( Section  12.2) will be analyzed for 
contezolid acefosamil  metabolite  concentration  (MRX -1352, contezolid, and MRX -1320)  using 
validated and sensitive bioanalytical methods . Key basic PK parameters will be assessed at the 
end of the first dose of IV therapy, prior to and at 2 timepoints after  the end of the third dose of 
IV therapy , and prior to and a fter 2 timepoints after the end of the last dose  or infusion (IV or 
PO) at the EOT visit (refer to Section  11 for the timing of the analysis) . Only those PK samples 
collected from subject s randomized to contezolid will be analyzed.   
Pharmacokinetic data w ill be summarized using descriptive statistics and graphically displayed, 
and population PK modeling analyses will be performed. Further details of the PK sample 
collection and analyses are provided the PK Analysis Plan  and Laboratory Manual . 
12.9 Handling of D ropouts, Missing, Unused and Spurious Data  
Every effort will be made to collect all data at specified times. For the primary efficacy outcome 
measure, per -subject  clinical response rate at EA in the ITT p opulation, subject s with a missing 
EA visit will be classified as indeterminate . Missing data for secondary efficacy outcomes will 
be handled similarly. A detailed description of the handling of drop outs and missing, unused, 
and spurious data will be provided in the SAP . 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 88 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
13 ADMINISTRATIVE CONSIDE RATIONS  
13.1 Ethical Conduct of Study  
This study will be conducted in accordance with applicable United States (US) FDA clinical trial 
regulations and guidelines, the ICH (E6) GCP guidelines, the European Union Directive 
2001/20/EC for clini cal trials conducted in the European Union, and the IRB/EC/REB and local 
legal requirements.  
13.2 Informed Consent  
This study will be conducted in compliance with ICH E6 GCP: Consolidated Guidelines 
pertaining to informed consent. Subjects will give written con sent to participate in the study at 
the first visit, prior to initiation of any study -related procedure, after having been informed about 
the nature and purpose of the study, participation and termination conditions, risks, and benefits. 
A copy of the info rmed consent document must be provided to the subject. If applicable, it will 
be provided in certified translation for non- English -speaking subjects. Signed consent forms 
must remain in the subject’s study file and be available for verification by the Sponsor or 
representatives of a competent regulatory agency at any time.  
13.3 Institutional Review Board Approval  
This study will be conducted in compliance with the protocol approved by the IRB and 
according to ICH and GCP consolidated guidelines and the ethical principles of the Declaration 
of Helsinki. 
No major deviation from the protocol will be implemented without the prior review and approval 
of the IRB except when it may be necessary to eliminate an immediate hazard to a research 
subject. In such case, the de viation will be reported to the IRB as soon as possible. 
This protocol, the informed consent document, and all relevant supporting data must be 
submitted to the IRB for approval. Approval by the IRB of the protocol, informed consent 
document, and any adver tisement used to recruit study subjects must be obtained before the 
study may be initiated.  
The Investigator is responsible for informing the IRB of any changes made to the protocol, and 
to advise them, at least once a year, about the progress of the study. The Investigator is also 
responsible for notifying the IRB of any SAEs and significant AEs that occur during the study.  
13.4 Investigator Requirements  
Each Investigator must adhere to the protocol as detailed in this document and agree that the 
Sponsor or Sponsor representative must approve any change to the protocol before seeking 
approval from the IRB. Each Investigator will be responsible for enrolling only those subject s 
who have met the protocol inclusion and exclusion criteria.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 89 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
13.5 Electronic Case Report Forms and Data Capture System  
This study will be performed using an eCRF. All eCRF data are to be completed by designated 
site personnel. All data entry, modification, or deletion will be recorded automatically in the 
electronic audit trail. All electron ic data entered by the site (including the electronic audit trail) 
will be maintained or made available at the site in compliance with 21 CFR Part 11 and other 
applicable retention regulations. 
Before the first subject  is dosed at an investigational site, the Sponsor or Sponsor representative 
will meet with the Investigator and the study center’s personnel to train them on recording the 
data on the eCRFs using an electronic data capture system. The Investigator or designee will be 
responsible for reviewing eCRFs, resolving data queries generated by the Sponsor or Sponsor 
representative via the system, providing missing or corrected data, and approving all change s 
performed on the subject  data. This approval method will include applying an electronic 
signatur e, a uniquely assigned user name, and a password that together will represent a 
traditional handwritten signature.  This electronic signature will be certified as outlined in 21 
CFR Part 11. The Sponsor will retain the original eCRF data and audit trail. An electronic or 
certified paper copy of all completed eCRF data, including query resolution correspondence, will 
be provided to the I nvestigator at the end of the study.  
Queries may be issued electronically to the clinical study center and answered electron ically by 
that study center’s personnel. The identifying information (assigned user name, date, and time) 
for both the originator of the query and the originator of the data change (if applicable) will be 
collected.  
All data collected in the context of this study will be stored and evaluated per regulatory 
requirements and applicable guidance for electronic records.  
13.6 Source Data & Document Maintenance 
All data collected on the eCRFs must have a source record.  
The Investigator agrees by his/her participation that the results of this study may be used for 
submission to national or international registration. The Sponsor or Sponsor’s representative has 
ethical, legal, and scientific obligations to monitor this study in a detailed and orderly manner in 
accordance with established research principles and applicable local regulations. As part of a 
concerted effort to fulfill these obligations, the Sponsor’s monitors or representatives will visit 
the center during the study on a regular basis, in addition to maintaining telephone and written 
communication. 
The Investigator is required to provide the Sponsor with all study data, complete reports, and 
access to all study records. The Investigator must retain a comprehensive and centralized filing 
system of all clinical study -related documentation that is suitable for inspection by the Sponsor 
and representatives of regulatory authorities. The Investigator will allow the Sponsor or its 
representative, or an appropriate representative of the competent authorities, to inspe ct all 
clinical study -related documentation for confirmation of data throughout the study period.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 90 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Data generated by this study must be available for inspection by any regulatory authorities, by 
the Sponsor and by the IRB as appropriate. At a subject ’s requ est, medical information may be 
given to his or her personal physician or other appropriate medical personnel responsible for his 
or her welfare. Medical information obtained from subject s during the course of  this study is 
confidential and disclosure to third parties other than those noted above is prohibited. 
13.7 Study Monitoring Requirements  
The Sponsor or Sponsor representative will conduct center visits to inspect study data, subject s’ 
medical records, and eCR Fs in accordance with current ICH E6 GCP guideline, and the 
respective US or foreign regulations and guidelines, as applicable. The Sponsor or Sponsor 
representative will also be able to review query status remotely, which may warrant additional 
communicat ion with the Investigator and the study center’s personnel. The Investigator will 
make available to the Sponsor, or Sponsor representative, source documents, signed informed 
consent forms ( ICFs ), and all other study -related documents.  
The Investigator will  allow the Sponsor or Sponsor representative and applicable regulatory 
authorities to inspect facilities and records relevant to this study.  
13.8 Study Completion 
The Sponsor requires the availability of the following data and materials before a study can be 
considered complete or terminated:  
• Laboratory findings, clinical data, and all special test results from baseline through LFU for 
subject s enrolled . 
• eCRFs (including queries) properly completed by appropriate study personnel and 
electronically signed and dat ed by the Investigator . 
• Complete drug accountability records (drug inventory log and an inventory of returned or 
destroyed clinical material) . 
• Copies of protocol amendments and IRB approval and notification, if appropriate . 
• A summary of the study prepared by the Investigator (an IRB summary letter is acceptable) 
Trial  Conduct & Ethical Considerations . 
This study will be co nducted in compliance with the ICH  of Technical Requirements for 
Registration of Pharmaceuticals for Human Use E6 GCP : Consolidated Guide lines, the ethical 
principles of the Declaration of Helsinki, FDA GCP guidelines, and any additional IRB-required 
procedures.  
13.9 Quality Control and Quality Assurance  
Written standard operating procedures (SOPs) will be followed to ensure that the study is 
conducted and data are generated, documented (recorded), and reported in compliance with the 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 91 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
protocol, GCP, and the applicable regulatory requirements. Quality control (QC) will be applied 
to each stage of data handling. Regular moni toring, as defined in ICH  GCP, S ection 1.8, “The act 
of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and 
reported in accordance with the protocol, SOPs, GCP, and the applicable regulatory 
requirement(s)”, will be conducted throughout  the conduct of the study.  
The purpose of monitoring is to verify that:  
• Rights and well -being of the human subject s are protected;  
• The reported study data are accurate, complete, and verifiable from source documents;  
• The conduct of the study is in compliance with the currently approved protocol and 
amendment(s), with GCP, and with the applicable regulatory requirements;  
• Monitoring is an integral role in the QC of a clinical trial and is designed to verify the quality 
of the study.  
To fulfill the qua lity assurance requirements of GCP, audits will be conducted to assess and 
assure the reliability and integrity of a study’s QC systems and recognized standards.  
The purpose of an audit is to:  
• Ensure subject safety;  
• Assure compliance to study protocol procedures, regulatory requirements, and SOPs;  
• Assure data quality.  
13.10 Retention of Records  
Essential documents pertaining to the conduct of this study and the distribution of investigational 
drugs including eCRFs , ICFs , laboratory test results, and medicatio n inventory records should be 
retained until at least 2 years after the last approval of a marketing application in an ICH region 
and until there are no pending or contemplated marketing applications in an ICH region or at 
least 2  years have elapsed since the formal discontinuation of clinical development of an 
investigational product. These documents should be retained for a longer period however if 
required by the applicable regulatory requirements or by an agreement with the Sponsor. It is the 
responsibi lity of the Sponsor to notify the I nvestigator/institution as to when these documents no 
longer need to be retained.  
13.11 Finance and Insurance  
The financing and insurance for this study are outlined in the Clinical Trial Agreement.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 92 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
13.12 Publication Policy  
The data generated in this clinical study are the exclusive property of the Sponsor and are 
confidential. The Sponsor will make all reasonable efforts to publish the results of the study in an 
appropriate peer -reviewed journal. Authorship on the primary publication of the results from this 
study will be based on contributions to study design, enrollment, data analysis, and interpretation 
of results . 
  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 93 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
14 REFERENCES  
Azactam® (aztreonam) [Package Insert]. Princeton, NJ. Bristol -Myers Squibb, 2013. 
Bressler AM, Zimmer SM,  Gilmore JL, Somani J. Peripheral neuropathy associated with 
prolonged use of linezolid. Lancet Infect Dis . 2004;4:528- 31. 
Committee for Medicinal Products for Human Use (CHMP). Addendum to the Guideline on the 
Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. European 
Medicines Agency. 2013;EMA/CPMP/351889/2013. Available at: 
http://www.ema.e uropa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_00112
0.jsp&mid=WC0b01ac0580034cf2  
Deresinski S. Methicillin -resistant Staphylococcus aureus : an evolutionary, epidemiologic, and 
therapeutic odyssey. Clin Infect Dis . 2005;40:562- 573. 
Diep BA, Sensabaugh GF, Somboona NS, Carleton HA, Perdreau- Remington F. Widespread 
skin and soft -tissue infections due to two methicillin -resistant Staphylococcus aureus  strains 
harboring the genes for Panton–Valentine leucocidin. J Clin Microbiol . 2004;42: 2080- 2084. 
Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J 
Antimicrob Chemother . 2011; 66 Suppl 4: iv7–iv15. 
Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue 
infections. Emerg Infect Dis . 2009; 15:1516–8. 
Flanagan S, Fang E, Munoz KA, Minassian SL, Prokocimer PG. Single - and multiple -dose 
pharmacokinetics and absolute bioavailability of tedizolid. Pharmacother . 2014;34(9):891- 900. 
French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51, Suppl. S2: 
ii45-ii53. 
Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft 
tissue infections: expert panel recommendations on key decision points . J Antimicrob  
Chemother . 2003;52 Suppl 1:i3- i17. 
Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for 
Industry —Acute B acterial Skin and Skin Structure I nfections: Developing D rugs for T reatment . 
Oct 2013. Available at : http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071185.pdf  
Food and D rug A dministration, Center for Drug Evaluation and Research. Guidance for 
Industry —Drug -Induced Liver Injury:  Premarketing Clinical Evaluation. Jul 2009.  Available at:  
https://www.fda.gov/downloads/guidances/UCM174090.pdf .  
Food and Drug Administration. FDA approves Sivextro to treat skin infections. FDA News 
Release 2014. Available at: 
https://www.fda.g ov/downloads/aboutfda/centersoffices/oc/officeofscientificandmedicalprogram
s/ucm569664.pdf  
Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ. Hematologic effects 
of linezolid: Summary of clinical experience. Antimicrob Agents Chemother. 
2002;46:2723- 2726. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 94 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX -I) with an improved class 
safety profile. J Med Chem . 2014;57:4487- 4497. 
Holden K. Meal Ideas and Menus: Avoiding High -tyramine Foods Made Easy. Teva 
Neuroscience, Inc., 2 006. Kansas City. PDF accessed at 
http://www.mc.vanderbilt.edu/documents/neurology/files/Tyramine%20Menu%20Book%20062
27101.pdf  
Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. 
Scand J Infect Dis . 2005;37(2):153- 4. 
Li CR, Zhai QQ,Wang XK,et al. In vivo antibacterial activity of MRX -I, a new oxazolidinone, 
Antimicrob Agents Chemother . 2014;58(4):2418- 2421. 
Miettinen O and Nurminen M. Comparative analysis of two rates. Statistics in Medicine. 
1985;4(2):213- 26. 
Moet GJ, Jonesa RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin 
and soft tissue infections in North America, Latin America, a nd Europe: Report from the 
SENTRY Antimicrobial Surveillance Program (1998 –2004). Diagn Microbiol Infect Dis . 
2007;57:7- 13. 
Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US 
emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, 
during the emergence of community -associated methicillin -resistant Staphylococcus aureus. Ann  
Emerg Med . 2008;51:291–8. 
Pallin DJ, Espinola JA, Leung DY, Hooper DC, Camargo CA Jr. Epidemiology of dermat itis and 
skin infections in United States physicians’ offices, 1993–2005. Clin Infect Dis . 2009;49:901–7. 
Ramsey TD, Lau TTY, Ensom MHH. Serotonergic and adrenergic drug interactions associated 
with linezolid: a critical review and practical management app roach. Annals Pharmacother . 
2013;47:543- 560. 
Rayner CR, Baddour LM, Brimingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in 
the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004;32:8- 14. 
Rennie RP, Jones RN, Mutnic k AH. Occurrence and antimicrobial susceptibility patterns of 
pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial 
Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis . 
2003;45:287- 293. 
Rubenstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, 
Remington J. Worldwide assessment of linezolid’s clinical safety and tolerability: 
comparator -controlled phase III studies. Antimicrob Agents Chemother. 2003;47(6): 1824- 1831.  
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL. Practice 
guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by 
the Infectious Diseases Society of America. Clin Infect Dis . 2014;59(2):e10–52. 
Versalovic J, Carroll KC, Funke G, et al. Manual of Clinical Microbiology, 10th Edition. ASM 
Press, Inc. 2011. Washington, D.C.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 95 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother. 
2005;6(13):2315- 2326.  
Zyvox® (Linezolid) [Prescribing Information]. New York, NY. Pfizer, 2018. 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 96 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Appendix 1.  Allowed Prior A ntibiotics  
Prior (within 96 hours  prior to randomization) administration of systemic antibacterial therapy is 
an exclusion criterion ( Section 4.2) ; however, subject s may be eligible for the study despite  prior 
antimicrobial therapy if they received a single dose of a non -oxazolidinone, short -acting 
systemic antibiotic within 96  hours  prior to randomization. Alternatively, subject s may be 
eligible despite prior antimicrobial therapy if there is 1) objective clinical evidence of treatment 
failure such as persistent pain, erythema, induration, and/or purulent drainage (if present) 
following at least 48  hours  of prior, non- study, systemic antibacterial therapy ; and 2) 
microbiological evidence of failure (i.e., a Gram stain obtained from an appropriate ABSSSI 
specimen collected after the initiat ion of this prior therapy revealing WBC and Gram -positive 
cocci, or isolation of a Gram -positive pathogen from an appropriate ABSSSI specimen that is 
resistant to the prior systemic antibacterial therapy) . 
For the purposes of this protocol, short -acting is  defined as having a dosage frequency of more 
than QD. The allowed and disallowed antibacterials  listed in Table 10  are based in part from the 
antimicrobial agents listed in the 2014  Infectious Diseases Society of America ( IDSA ) 
Guidelines for the management of skin and soft tissue infections ( Stevens, 2014). If a subject  
received a prior short -acting systemic antibiotic that is not listed here, the Investigator mus t 
contact the Medical Mo nitor to ensure subject  eligibility.  
Table 10:  Allowed and  Disallowed Prior Antibiotics in Study  MRX4 -201 
Allowed  Antibiotics  
(One dose within 96 hours prior to randomization)  Disallowed  Antibiotics  
Penicillins : 
Amoxicillin  Nafcillin  NONE  
Amoxicillin -Clavulanate  Oxacillin   
Amoxicillin -Sulbactam  Penicillin -G  
Ampicillin  Penicillin -V  
Ampicillin -Sulbactam  Piperacillin   
Dicloxacillin  Piperacillin -Tazobactam   
Cephalosporins : 
Cefaclor  Cefpodoxime  Ceftriaxone  
Cefadroxil  Cefprozil   
Cefazolin  Ceftaroline   
Cefdinir  Ceftazidime   
Cefepime  Ceftibuten   
Cefixime  Cefuroxime   
Cefditoren  Cephalexin   
Cefotaxime  Loracarbef   
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 97 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Allowed  Antibiotics  
(One dose within 96 hours prior to randomization)  Disallowed  Antibiotics  
Carbapenems:  
Doripenem  Ertapenem  
Imipenem   
Meropenem   
Glycopeptides : 
Televancin  Dalbavancin  
Vancomycin  Oritavancin  
Fluoroquinolones : 
Ciprofloxacin Levofloxacin  
 Moxifloxacin  
Macrolides : 
Clarithromycin  
Erythromycin  Azithromycin  
Clarithromycin XL  
Tetracyclines : 
Doxycycline  
Minocycline  Minocycline Extended Release 
Miscellaneous : 
Clindamycin  
Metronidazole 
Trimethoprim -sulfamethoxazole/Co -trimoxazole  Daptomycin  
Oxazolidinones : 
NONE  Linezolid  
Tedizolid  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 98 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Appendix 2.  Avoidance of High -Tyramine Foods and Drinks  
As linezolid and other oxazolidinones are MAOIs , a significant pressor response has been 
observed in normal adult subjects receiving linezolid and concomitant tyramine doses of 
> 100 mg ( Zyvox® Prescribing Information, 2018 ); therefore, subject s receiving linezolid or 
contezolid acefosamil  need to avoid consuming  large amounts of foods or beverages with 
high-tyramine content. Foods high in tyramine content include those that may have undergone 
protein changes by aging, fermentation, pickling, or smoking to improve flavor, such as aged 
cheeses, fermented or air -dried meats, sauerkraut, soy sauce, and tap beers ( Table 11 ). The 
tyramine content of any protein- rich food may be increased if stored for long periods or 
improperly refrigerated.  
The following table of high- tyramine foods and drinks to avoid in large amounts  during study 
drug administration in this study has been modified from "Meal Ideas and Menus: Avoiding 
High -tyramine Foods Made Easy" ( Holden, 2006 ), and serves as a general guidance. Questions 
as to whether additional foods or beverages must  be avoided should be directed t o the Medical 
Monitor. 
Table 11:  Foods and Beverages to Avoida During Study Drug Administrationb 
Cheeses  Beverages  Meat, Poultry & Fish  Produce  Condiments  
Canadian or New 
York Cheddar  
Stilton  
Camembert  
Swiss  
Blue/Gorgonzola  Vermouth  
Tap beer  
Korean beer  Dry sausages (e.g., 
mortadella, salami)  
Chinese dried duck 
Aged chicken livers  
Smoked or pickled fish 
(e.g., lox)  
Pickled herring  
Caviar  
Soups, gravies, or sauces 
containing meat extracts 
(e.g., bouillon, beef broth)  Sauerkraut  
Fava beans and 
broad beans 
(Italian green 
beans)  
Banana peel  
Kimchi  
Miso soup, 
fermented soy 
bean/bean curd, 
tofu Soy sauce  
Concentrated yeast 
extract (Marmite®, 
Vegemite®) 
Thai or Vietnamese 
fish sauce  
a Similar aged, fermented, pickled, or sm oked foods or beverages not shown in this table (e.g., unlisted cheeses or 
alcoholic beverages) should be generally avoided or consumed rarely  with caution.  
b Foods that need to  be avoided from Day 1 until EOT   
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 99 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Appendix 3.  Restricted Medications  
Oxazolidinones are reversible, nonselective MAOIs; therefore, they have the potential for 
interaction with adrenergic and serotonergic agents  (Zyvox® Prescribing Information, 2018) . 
Exclusion Criterion 17 states that prior (within the past 2 weeks) or expected/required 
concomitant (from the start of the study drug to EOT) administration of systemic adrenergic or 
serotonergic medications are excl uded ( Section  4.2). Such agents include the following:  
Adrenergic Agents  
Adrenergic agents, including indirect -acting sympathomimetic agents, vasopressors, and 
dopaminergic agents, should be used with caution when administered concomitantly with 
oxazolidinones― patients  receiving concomitant linezolid may experience a reversible 
enhancement of the pressor response to such adrenergic agents  (Zyvox® Prescribing Information , 
2018) . Example s of s uch agents include:  
• Adrenergic receptor agonists ; examples include dobutamine, dopamine, epinephrine 
(adrenaline), norepinephrine, phenylpropanolamine, pseudoephedrine  
• Norepinephrine reuptake  inhibitors ; examples include b upropion and methylphenidate  
• Azapirones ; examples include b uspirone  and gepirone  
Serotonergic Agents  
Spontaneous reports of serotonin syndrome , including fatal cases , have been  reported  with the 
co-administration of linezolid  and serotonergic agents  (e.g.,  antidepressants such as SSR Is). 
Symptoms and signs of serotonin syndrome include hyperthermia, rigidity, myoclonus, 
autonomic instability, and mental status changes that include extreme agitation progressing to 
delirium and coma. In this study, study drug ( contezolid acefosamil  or linezolid)  should not be 
administered to patients taking any  of the following medications: 
• Serotonin re uptake  inhibitors (SSRIs) ; examples include paroxetine, sertraline, fluoxetine, 
fluvoxamine, and citalopram  
• Tricyclic antidepressants ; examples include cl omipramine and imipramine  
• Serotonin 5- HT1 receptor agonists  (triptans ); examples include almotriptan, eletriptan, 
frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 100 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Appendix 4.  Safety Laboratory Tests  
Hematology:  
• Hemoglobin  
• Hematocrit  
• Erythrocyte count  
• Leukocyte count ( WBCs ) 
• Neutrophils  
• Lymphocytes  
• Monocytes  
o Eosinophils  
o Basophils  
o Platelets  
 
Coagulation:  
• Prothrombin time/International normalized 
ratio (PT/INR) 
• Partial thromboplastin time  
• Activated partial thromboplastin time (aPTT)  
 
Urinalysis:  
• Specific gravity  
• pH 
• Protein  
• Glucose  
• Ketones 
• Bilirubin  
• Occult blood  
• Nitrites  
• Urobilinogen 
• Leukocyte esterase  
 
Urine Microscopy:a 
• WBCs 
• Red blood cells  
• Casts  
• Bacteria  
• Crystals  Chemistry (Serum Concentrations):  
• Glucose  
• Calcium  
• Albumin 
• Total protein  
• Sodium  
• Potassium  
• Bicarbonate  
• Chloride  
• Urea nitrogen  
• Creatinine  
• Alkaline phosphatase  
• Alanine aminotransferase  
• Aspartate aminotransferase  
• Total and direct bilirubin  
• Magnesium  
• Lactate dehydrogenase  
• Phosphorus  
• Uric Acid  
• Creatine kinase  
• Gamma -glutamyl transferase  
• Indirect bilirubin  
• Cholesterol  
• Triglycerides  
• β-Human chorionic gonadotropin for females  
• C-reactive protein (CRP)  
 
SCREENING/BASELINE  ONLY:  
• Creatinine clearance  
• Anti-HBcAg (anti -hepatitis B core antigen)  
• Anti-HBsAg (anti -hepatitis B surface antigen)  
• HBsAg (hepatitis B surface antigen)  
• HCV  Ab (hepatitis C antibody)  
• HIV Ab (human immunodeficiency virus 
antibody)  
a Performed if UA is positive for red blood cells, WBCs , or protein.  
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 101 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Appendix 5.  Instructions for Primary ABSSSI Site Measurement  
1. Measurements of erythema, edema, or induration, whichever is largest, should be done with a 
head -to-toe orientation by measuring the longest length  head -to-toe and then the widest width 
perpendicular  to that length. Note: the furthest edges of head -to-toe erythema, edema, and/or 
induration, whichever is largest should be the focus of the measurement. Note: in subject s 
with darker skin, the perimeter of erythema, edema, and/or induration may be difficult to 
delineate. Palpation may help delineate the perimeter of the inflammatory lesion.  
2. Measure in this manner and document the measurement in the source document  and eCRF . 
3. A surface area (cm2) will be calculated by the eCRF.  
Figure 3 : Primary ABSSSI Site Measurement – Example  
Longest length:  
 

Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 102 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Widest width perpendicular:  
 

Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 103 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Appendix 6.  Local Signs and Symptoms of  ABSSSI  
Local signs and symptoms will be assessed for the primary ABSSSI site.  
The Investigator is to provide a categorical assessment and comparison to baseline of the 
following pa rameters  using the scale below:  
Parameter Absent  Mild  Moderate  Severe 
Erythema  None  Pink Red Fiery red  
Swelling/edema  None  Swelling just apparent  
on casual inspection  
(up to 2 mm of pitting)  Marked swelling  
(≤ 4 mm of pitting)  Maximal swelling  
(> 4 mm of pitting)  
Localized warmth  None  Slightly warm  Warm  Hot 
Tenderness  on 
palpation  None  Slight or mild tolerable 
discomfort on palpitation  Uncomfortable with  
light palpitation or 
pressure  Intolerable by even a  
mild stimulus such as  
sheet touching  
Drainage  None  Serous  Seropurulent  Purulent  
Fluctuance  None  Present  Not applicable  Not applicable  
Induration  None  Present  Not applicable  Not applicable  
 
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 104 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
Appendix 7.  Recommended Instructions for Primary ABSSSI Site Digital Photography  
Digital photographs of the primary ABSSSI site will be taken with digital cameras provided by 
the S ponsor as described below .  (IMPORTANT NOTE: Depending upon the location of the 
infection site on a  subject’s face or body, a  digital image may include certain unique features that 
could reveal the subject’s identity. In order to protect and preserve patient privacy, please 
obscure or cover any unique features of the subject (such as eyes, nose or tattoos) prior to 
capturing the  digital image .) 
1. Drape area behind subject  with a white sheet.  
2. Place disposable ruler on the skin adjacent to the lesion. Define outer edge of erythema, 
edema, or induration, whichever is largest, with a marker at each visit. 
3. Using the ruler or another pie ce of paper, place identifying information (date, subject  
number, body part) adjacent to the lesion. 
4. Position camera approximately 2  feet (60  cm) from the lesion.  
5. Take a picture at a 90 -degree perpendicular angle from the lesion. 
6. Do not use any zoom settings.  
7. Turn the flash setting to “Off” if enough light is available from other sources. Otherwise, use 
the flash on auto exposure setting . 
8. Use rest of camera’s automatic settings for focus and lighting . 
9. Place a light source on each side of the subject  to help  prevent shadows.  
10. Capture at least a 4  to 6-inch border around the lesion to assess the status of skin surrounding 
the lesion. If the lesion wraps around a limb and cannot be fully seen in 1 photograph, take 
multiple perpendicular photographs to allow docu mentation of the entire lesion. If multiple 
photographs are required, mark the top and bottom of the lesion on the subject  to indicate the 
border of the viewing field of each photograph.  
11. After the digital photograph is taken, confirm on the camera screen that the picture is clear, in 
focus, and that all information on the ruler, including the ruler scale, is visible and legible 
(repeat if necessary).   
a. Please ensure the final image at each  visit is saved to the camera’s storage  card and the 
storage  card is maintained in the study files.   
b. Print the picture and include in the subject’s source documents.   
c. In order to protect and preserve patient privacy, please obscure or cover any unique 
features of the subject (such as eyes, nose or tattoos) that were not able to be covered 
prior to capturing the digital image.     
Clinical Protocol MRX4 -201  
 
 
MicuRx Pharmaceuti cals, Inc.  Page 105 of 105 
CONFIDENTIAL  Final, 19 Oct  2018  
d. After photographs are taken, discard the paper ruler per institutional guidelines.  
The Sponsor may request that digital images be sent to the Sponsor for review.  All images from 
all patients will also be collected on a memory  drive  or card  for storage.  Photographic data will 
be archived and may be analyzed at a later timepoint.    